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General Introduction
R. R. I. van Reij
CHAPTER 1
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1. Chronic postsurgical pain 
CPSP occurs in 5-85% of the patients depending on the type of surgery [1-3]. 
Chronic postsurgical pain (CPSP) has recently been classified under the 
International Classification of Diseases-11 (ICD-11) [1]. With that, classification 
the international association for the study of pain (IASP) defined CPSP as follows 
‘pain that develops or increases in intensity after a surgical procedure or a tissue injury 
and that persists beyond the healing process, i.e. at least 3 months after the initiating 
event’ [1]. Here it is important to note that with CPSP the pain persists beyond the 
healing process and thus lasts longer than might be expected. Furthermore, in the 
recent ICD-11 states that beside the general classification of CPSP there are sub-
diagnoses for specific surgeries that most commonly lead to CPSP e.g. 
hysterectomy, thoracotomy, breast surgery or amputation. The use of these sub-
diagnoses then optimally reflects the causes of the pain involved with specific 
surgeries [1]. Large surgeries like thoracotomy and breast surgery with a larger 
wound and in more nerve-innervated sites have a higher incidence of CPSP than 
eye surgery, which is characterized by its minimally invasive surgical procedures 
[1-3].  
CPSP has a high impact on the social, economic, and quality aspects of life of 
patients affected and their relatives [4-6]. Patients with severe CPSP report higher 
incidence of depressive symptoms, sleep disturbances, anxiety and other comorbid 
disorders [4, 7]. Furthermore, CPSP patients report an increased work and activity 
impairment, which worsens as pain increased. In total, the economic costs (direct 
and indirect) associated with CPSP per patient has been estimated to be $41.463,- 
per year in the United States of America (USA) alone whereby costs increase 
related to the severity of the pain [4]. 
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Acute pain after surgery is caused by tissue damage leading to stimulation of the 
peripheral nociceptors and nociception [8]. Peripheral nociceptors are located at 
the endings of the afferent nociceptive fibres. Tissue damage results in a local 
inflammatory process, which triggers the nociceptors and may result in peripheral 
sensitization. Peripheral sensitization is defined by IASP as ’Increased responsiveness 
and reduced threshold of nociceptive neurons in the periphery to the stimulation of their 
receptive fields’ [8, 9]. As a consequence more action potentials will be send, via the 
nociceptive afferents, to the spinal cord. Then the signal (action potentials) is 
transferred to the pain transmission neurons in the spinal cord. Upon continuous 
generation of action potentials, the communication between the nociceptive 
afferents and the pain transmission neurons in the spinal cord becomes sensitized. 
This sensitization is referred to as central sensitization, defined by the IASP as 
Increased responsiveness of nociceptive neurons in the central nervous system to their 
normal or subthreshold afferent input’. Central sensitization leads to an increase of 
action potential transmission from the spinal gate to supraspinal nociception 
related areas, where the perception and affective components will be combined 
into pain. The process of central sensitization and deregulated communication 
between nociceptive afferents and pain transmission neurons in the spinal cord, 
is considered to be fundamental in the chronification of pain. [8, 9]. The pain gate 
in the spinal cord plays an important role in this process of central sensitization. 
At the spinal pain gate, the nociceptive signal of the nociceptive afferent (C fibers) 
is transmitted to the projection neuron which transmits the signal to the brain 
[10-12]. At this level the nociceptive signal can be modulated by either innocuous 
stimulation (i.e. touch stimuli) or by descending inhibitory control modulated by 
three different neurotransmitters: serotonin, noradrenaline and dopamine [10-
13].  
While serotonin and noradrenaline are widely studied in the context of pain, 
dopamine is often overlooked in analgesic strategies [14]. Dopamine can inhibit 
the transmission of the nociceptive signal in the spinal cord by activation of the 
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D2 receptors and can facilitate central sensitization via the D1 receptors [14-16]. 
Dopaminergic neurotransmission, is most known for its involvement in reward, 
mood and locomotion [17-19]. DA provides the communication within the basal 
ganglia and connection to the locomotor networks in the brainstem as well as 
influences the central pattern generators in the ventral horn of the spinal cord [20, 
21]. Furthermore, DA is released in the VTA response to a drug or natural reward 
[22, 23]. As pain management strategies focussed on dopamine can affect these 
systems as well, targeting dopamine remains a challenge. 
The current perioperative pain management strategy is mainly focussed at the 
prevention or treatment of acute postoperative pain and remains suboptimal for 
prevention and treatment of CPSP [24, 25]. Multimodal analgesia is key in the 
acute postoperative pain management strategy where the first step consists of 
regional or local analgesia specific for the invasiveness of the surgery followed by 
non-opioidergic systemic analgesia and opioid medication, where the latter is used 
as a rescue medication [25, 26]. Nevertheless, the treatment remains suboptimal 
to prevent or treat CPSP leading to a high incidence of CPSP. Improving 
pharmacological interventions remains a challenge and the identification of new 
targets can aid in optimizing the treatment strategy [27]. Besides optimizing 
treatment strategies, it is important to identify the patients at risk of developing 
CPSP in order to prevent CPSP from occurring. Lack of knowledge on genetic 
risk factors and mechanism(s) underlying the development of CPSP inhibits 
accurate identification of patients at risk and development of new targets for 
pharmacological interventions and treatment. 
The aim of this thesis is to the study the genetic risk factors of CPSP and to identify 
the functional effects of genetic variation on nociception and chronic pain in both 
clinical and preclinical studies.  
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2.1. Prediction of CPSP 
Clinical, demographical, psychological and genetic risk factors of CPSP have been 
identified over the last years [2, 28-32]. Here, I will discuss current evidence on 
these risk factors. 
2.1.1. Clinical risk factors of CPSP 
Clinical risk factors associated with CPSP include the type of surgery (more 
invasive surgery, higher incidence), the duration of surgery as well as the level of 
intraoperative nerve damage [28, 30]. All these clinical risk factors indicate that 
the risk of developing CPSP is increased with major surgeries, as this is likely to 
be related to a higher degree of tissue damage [30]. 
2.1.2. Demographical risk factors of CPSP 
Patient related demographical risk factors for CPSP include age, biological sex and 
pre-operative pain. The most prominent demographical risk factor for CPSP is 
perioperative pain [28]. Both pre-operative pain and acute postoperative pain are 
important predictors for development of CPSP [2, 29-31]. It is possible that the 
pre-operative pain primes the nociceptive system leading to higher susceptibility 
to the development of chronic pain [30]. The severity of acute postsurgical pain 
(APSP) seems to be related to the clinical risk factors, as more invasive surgery is 
usually accompanied by more severe APSP [28]. Younger age and female 
biological sex have consistently been associated with a higher prevalence of CPSP 
[28-30]. The mechanism underlying pain has been shown to be different between 
the biological sexes due to both hormonal effects and differential immune 
response [33-36]. Interestingly, most of the research on pain intervention was 
conducted on males possibly explaining the higher prevalence in women [37-39]. 
Younger age is associated with a more severe pathology, which requires a more 
invasive approach and therefore leads to a higher prevalence of CPSP [31].  
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2.1.3. Psychological risk factors of CPSP 
Psychological risk factors associated with CPSP include pre-operative anxiety and 
pain catastrophizing [28, 32]. Pain catastrophizing is the tendency to describe a 
pain experience in more exaggerated terms than the average person, to ruminate 
on it more, and/or to feel more helpless about the experience [40]. Anxiety can be 
separated into state- and trait anxiety where state anxiety is a temporary condition 
experienced in a specific situation and trait-anxiety is a general tendency to 
perceive situation [32]. The central idea is that patients with psychological 
flexibility (more optimistic outlook on pain after surgery, and more confidence in 
the outcome of the procedure) will have a better outcome of the surgery compared 
to those who are inflexible [41]. This is summarized in the fear-avoidance model 
of pain whereby negative coping with the pain leads to a vicious cycle of pain 
while positive coping leads to recovery [42, 43]. Anxiety, both trait and state, leads 
to preventative strategies and avoidance behaviour which leads to disuse of the 
affected body parts and negatively influences the resolution of pain [44]. The fear-
avoidance model incorporates both pain catastrophizing and anxiety in a single 
model indicating that these are simultaneously affecting the outcome after surgery 
[42-44]. 
2.1.4. Genetic risk factors of CPSP 
Genetic risk factors of CPSP have been studied in a limited number of studies and 
only a restricted and selected number of genes and/or subset of genes have been 
studied up until now [45]. Despite the limited number of studies, an association 
was shown between several genes such as COMT, OPRM1, DRD2 and CACNG2 
and the development of CPSP [45]. However, a good understanding of the genetic 
risk factors and its putative role in CPSP is still lacking to date [2, 28]. Identifying 
the genetic risk factors of CPSP will aid in the prediction of CPSP as well as 
provide insight into the biological mechanisms [46, 47]. Most of the genes 
associated with CPSP can be classified as related to either inflammatory cytokines, 
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catecholamine signalling (e.g. dopamine and noradrenaline) or ion channels 
(calcium or potassium). Catecholamine signalling and especially dopaminergic 
neurotransmission are of interest as several components of the signalling pathway 
(GCH1 in dopamine-synthesis, DRD2 as a dopamine-receptor and COMT in 
dopamine-degradation) have been associated with CPSP. It is therefore important 
to focus on the genetic mutations related to dopaminergic neurotransmission in a 
context of CPSP and a good understanding of the relation and/or association is 
needed. 
Genetic studies employ either a gene-based approach where there is a focus on a 
subset of genes or a genome-wide approach where risk factors across the genome 
are associated with the phenotype [48]. In a GWAS study not all SNPs in the 
genome are genotyped but a fraction of them and most of the other SNPs are in 
high linkage disequilibrium with these SNPs so it can be assumed that if the 
genotyped SNP is present these other SNPs are as well [49]. Genome-wide 
association studies (GWAS) are able to validate the genes found by gene-targeted 
studies but also lead to new findings and thereby could elucidate new mechanisms 
underlying a disease [50]. A beautiful example of the use and implementation of 
GWAS analysis and the discovery of genetic risk factors has been shown in the 
field of migraine, which resulted in the identification of biological pathways 
involved [51]. In order to implement genetic risk factors in prediction of CPSP, 
large-scale GWAS studies in well-studied and diagnosed CPSP cohorts are needed 
to elucidate the genetic risk factors of CPSP and understand the underlying 
biology. In this thesis, the main cohort studied in relation to CPSP is a 
hysterectomy cohort, which has been extensively described, however, mainly 
related and restricted to clinical, psychological and demographical risk factors [29, 
52]. This hysterectomy cohort is exclusively female, and about 10% of the cohort 
develops CPSP [14]. Furthermore, a significant association between employment 
status, preoperative pain, postoperative pain, inflammation status and CPSP was 
reported and the implementation of these factors in a prediction explained of 78% 
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of the variation [52]. As peripheral blood samples were collected from the 
hysterectomy cohort (= discovery cohort) before the surgery this enabled further 
genetic analyses in conjunction to the already studied demographical, clinical and 
psychological risk factors [29]. It needs further emphasis that possible genetic 
associations found in the discovery cohort need to be replicated in other CPSP 
patient populations (or replication cohorts). Both replication and external 
validation are necessary to confirm that the findings are reproducible and to 
provide more conclusive statements on genetic risk factors and CPSP. 
2.2 The effect of genetic variations on biological functioning 
The link between genetic variation and CPSP is not direct, but rather through a 
complex mechanism whereby several steps have to take place before a genotype 
affects the phenotype [48, 53]. The following section will briefly introduce how 
genetic variation affects proteins and how this could affect the development of 
chronic pain. 
2.2.1 Mutations in the genome affect protein functioning 
On estimate there are about 19,000 genes coding for proteins in the human 
genome covering 1-2% of the DNA [54]. A protein-coding gene consists of an open 
reading frame which contains protein coding sequences (exons) and non-protein 
coding sequence (introns) which dictate splicing sites and this open reading frame 
is flanked by regulatory sites [55-57]. The regulatory sites can control the rate of 
transcription and determine the start site of transcription [58]. The DNA is 
converted into to protein in two steps. First, it is transcribed into mRNA 
(messenger RNA) by RNA polymerases and then translated into proteins by 
ribosome complexes [58, 59].  
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Genetic association studies such as genome-wide association studies (GWAS) and 
gene-targeted studies are intended to analyse variations in the DNA in relation to 
a phenotype. A mutation is defined as any alteration to the DNA sequence [60]. 
When mutations persist in the genome, they become single nucleotide 
polymorphisms (SNP). SNPs are single base-pair alterations, which are common 
in the population, meaning present in more than 1% of the population[60].  
SNPs located in coding regions can either lead to the same amino acid in the 
protein (synonymous) or result in transition and inclusion of a different amino 
acid in the protein (non-synonymous) which then most likely affects protein 
functioning (Figure 1) [61, 62]. Non-synonymous SNPs can be divided into 
missense and nonsense SNPs whereby missense SNPs can affect protein 
functioning (e.g. altered ligand binding, altered protein stability) and nonsense 
SNPs lead to a premature stop codon [62, 63]. One of the most well-known 
diseases associated with non-synonymous missense SNPs is sickle cell disease 
whereby the GAG codon is changed into a GTG codon causing a valine to be built 
into the protein instead of glutamic acid leading to a dysfunctional protein and 
eventually a dysfunctional red blood cell [60]. Synonymous SNPs lead to the same 
amino acid being translated from the mRNA and often the effect is considered 
neutral. However, there is a bias in codon usage and efficiency in the human cells 
which means that some codons used are translated more efficiently leading to a 
faster production of proteins thereby affecting the protein functioning [64, 65].  
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Figure 1: Illustration of the effects of different types of mutations. The codon sequence without mutation is 
displayed on the far left side under the header no mutation. The introduction of a synonymous mutation 
(middle left) in the codon leads to alterations on the level of the DNA and the mRNA but leads to the 
incorporation of the same amino acid in the protein. The introduction of a non-synonymous mutation in the 
codon leads to either a premature stop codon (middle right) also known as a nonsense mutation or to a 
missense mutation (far right) which introduces a different amino acid in the protein sequence. Adapted from 
Wikimedia commons Different Types of Mutations.png under a creative commons license 
A synonymous SNP within multi-drug resistance 1 (MDR-1)) has been associated 
with altered drug responsiveness in humans. The SNP causes a rare codon to be 
necessary for the translation into mRNA, which alters the post processing of the 
protein and thereby alters the substrate specificity [66]. Furthermore, different 
codons can affect the mRNA folding stability and thereby affect the folding of the 
protein, which could alter the accessibility of the ligand binding site of a protein 
[65]. SNPs located in intronic regions or the untranslated regions on both sides of 
the open reading frame do not affect protein functioning directly but can lead to 
major effects. Intronic SNPs can induce alternate splicing by adding, removing or 
altering splice sites and can affect the expression of a gene [67]. Two intronic SNPs 
within dopamine receptor DRD2 (rs2283265 and rs1076560) have been identified 
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which shifted the alternative splicing of this dopamine receptor from the short 
variant (expressed pre-synaptically) to the long variant (expressed mainly post-
synaptically). Hence, the effects of the DRD2 activation vary substantially between 
pre- and post-synapse and these SNPs have been associated with an altered 
cognitive performance [68]. 
Although GWAS analysis provides insights into association between SNPs and 
CPSP, it does not provide evidence on causality [69]. SNPs associated with disease 
phenotypes often exert their effect through altering target gene expression [69]. 
Gene expression is a quantitative trait, which is influenced by many factors among 
which SNPs contained in expression quantitative trait loci (eQTLs) [70]. eQTLs 
are regions of the genome containing SNPs which affect the expression of one or 
more genes [70]. eQTLs can be divided into cis- and trans-eQTLs whereby cis-
eQTLs affect nearby genes (within a few hundred kilo base-pairs of a gene) and 
trans-eQTLs affect distant genes often through diffusible factors such as 
transcription factors[70] (Figure 2). Most investigations study the variations 
surrounding the gene of interest and focus thereby on the cis-eQTLs [70, 71]. Most 
genes have multiple eQTLs and the interaction between the eQTLs affects the gene 
expression [71]. These interactions between eQTLs and gene expression are often 
tissue specific [69].  
All these different mechanisms contribute to development of disorders and CPSP. 
Each individual has a specific combination of SNPs and this could be used in 
clinical prediction modelling [47, 73, 74].  
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Figure 2: illustration of cis and trans expression quantitative trait loci. A) The transcription factor (TF) binds 
to the transcription site of gene A and gene B leading to their transcription and subsequent gene expression. 
B) Due to a mutation in the transcription site of gene A, the transcription factor cannot bind properly 
anymore leading to a decreased expression of gene A. this is a cis eQTL as the mutation altering the gene 
expression is located closely to the gene. C) There is a mutation in the gene encoding for the TF leading to a 
decreased binding at the transcription site of both gene A and B decreasing their expression. This is a trans-
eQTL as the mutation is located further away of the gene which expression is influenced. Reproduced with 
permission from Wolen et al., [72]. 
2.2.2 Common genetic risk factors for chronic pain syndromes 
As chronic pain conditions are known to follow a basic pattern in which an 
environmental factor (e.g. surgical trauma, infection, and injury) leads to an acute 
pain state which, if not resolved, can lead to a chronic pain syndrome [46, 75-77]. 
It is suggested that common biological pathways (e.g. inflammation or 
extracellular composition) underlie the different chronic pain syndromes [78, 79]. 
Common biological pathways underlying different disorders often entail 
common genetic risk factors. One genetic locus underlying two or more different 
phenotypic traits is called pleiotropy [80]. This means that a SNP can be involved 
in more than one distinct phenotype and could possibly underlie common factors 
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between the phenotypes [80, 81]. In order to study and explore the genetic 
pleiotropy between different chronic pain disorders analysis of polygenic risk 
scores (PRS) is possible and allows the detection and insights into possible 
common biological mechanisms across the disorders. PRS scores are the 
aggregated relative risk of developing a disorder based on summing SNPs 
associated with the disorder [82]. These mechanism-based insights might then 
result in targeting and development of new drugs for better treatment of CPSP. 
2.3 Genetics and new venues to pharmacological treatment of CPSP 
Genetic association studies have associated inflammatory cytokines, ion channels 
and catecholamines with the development of CPSP and this makes inflammatory 
cytokines as well as ion-channels or catecholamines excellent targets for 
pharmacological treatment of CPSP [45]. Inflammation is a risk factor for the 
development of CPSP and several preventive pharmacological strategies (such as 
corticosteroids and NSAIDs) are already employed peri-operatively and are part of 
the current multi-modal analgesic protocol [83]. Mutations in ion channels 
signalling (calcium and potassium) alter the conductivity of the nerves and 
thereby may affect the chronification process and thus the development of CPSP. 
Medication focussed on voltage-gated calcium signalling (for example 
gabapentinoids) are widely used in neuropathic pain and are increasingly used in 
treatment of acute postsurgical pain as well as CPSP management [83]. However, 
pharmacological treatments modulating very general process as for instance the 
role of calcium channels in neurotransmission may have large side-effects thereby 
making it difficult to find a balance between clinical benefits and aversive effects 
[83]. Catecholamine signalling includes various neurotransmitters like adrenaline, 
noradrenaline and dopamine, which are all synthetized and degraded via a 
common mechanism [84]. Drugs acting via the receptors involved in adrenaline 
neurotransmission (e.g. Clonidine as a 2-adrenergic receptor agonist) were 
proposed as treatment in both acute and chronic pain [83]. Clonidine has, 
21 | C h a p t e r  1  
however, also been associated with hemodynamic side effects due to it prominent 
role in the sympathetic nervous system and regulation of blood vessels dilatation 
and constriction [83]. Evidence of its efficacy in CPSP is currently not complete 
[83]. The recurrent associations with genes within the dopaminergic 
neurotransmission suggest catecholamines and more specific dopamine (see 3.2.1) 
as a likely target for developing pharmacological treatment of CPSP [45, 83, 85-
87]. 
In order to focus and boost the research on development of CPSP treatment 
related to dopaminergic neurotransmission, preclinical studies are needed and we 
aimed to develop a zebrafish model for a clinical genetic phenotype and test the 
effects on nociception in a validated assay [88]. This makes fast and reliable 
screening of functional effects of SNPs associated with pain phenotypes and new 
drugs possible which may modulate the various proteins involved like DRD2 
receptor.  
Research questions of the Thesis 
1. What is the role and impact of genetic variations related to dopaminergic 
neurotransmission in CPSP? 
2. What are the genome-wide risk factors of CPSP and the related functional 
mechanisms? 
3. What is the shared genetic aetiology between different chronic pain 
disorders including CPSP and does this provide insights into the common 
biological mechanisms underlying chronic pain? 
Outline of the Thesis 
Research question 1 is addressed in Chapter 2 and Chapter 6. Chapter 2 
summarizes the current literature regarding clinical and preclinical evidence on 
the genetic variations related to dopaminergic neurotransmission and its role in 
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chronic postsurgical pain. The genes most studied in association with CPSP are 
COMT, GCH1 and DRD2, which are all related to dopaminergic signalling. 
Therefore, a clinical phenotype of a decreased availability of the DRD2 receptor is 
modelled in an experimental zebrafish animal model and possible 
pharmacological treatment options were implemented in Chapter 6. In order to 
study the genetic risk factors of CPSP in an unbiased approach we formulated 
research question 2. A first genome-wide association study on CPSP is performed 
in a discovery cohort (hysterectomy patients and CPSP, Number NTR2702, Dutch 
Trial Register (http://www.trialregister.nl/trialreg/index.asp) and subsequently in 
a replication cohort (registry number NCT02002663 and NCT01989351, 
https://clinicaltrials.gov/ct2/home) (see Chapter 3). To gain further insight on the 
biological aspects of genetic risk factors and the functional mechanisms in the 
context of CPSP, Chapter 4 discusses the downstream biological effects of the 
identified SNPs on the transcriptome and protein expression in detail. Research 
question 3, is studied in Chapter 5 and analyses possible shared genetic aetiology 
between different chronic pain disorders (Rheumatoid Arthritis, Sciatica, Chronic 
widespread pain, Osteoarthritis). Finally, Chapter 7 will conclude, summarize and 
discuss the main findings of this thesis and its possible impact for prediction 
and/or treatment of CPSP.  
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Unstructured Summary 
Chronic postsurgical pain (CPSP) is a debilitating condition affecting 10-50% of 
surgical patients. The current treatment strategy for CPSP is not optimal and the 
identification of genetic variations in surgical patients might help to improve 
prediction as well as the treatment of CPSP. The neurotransmitter Dopamine 
(DA) is interesting in this aspect, as it has been associated with several chronic pain 
disorders. This review focusses at DA neurotransmission as a potential target in 
the treatment of CPSP. The current knowledge on genetic variations within DA 
neurotransmission and its role in CPSP susceptibility is reviewed. Three genes 
within DA neurotransmission (COMT, GCH1 and DRD2) have been associated 
with a variability in pain sensitivity, development of CPSP and analgesic 
requirement. The direction of the effect of the association is sometimes 
inconclusive due to contradictory results, but ample evidence suggests a 
modulatory role of DA. Due to this modulatory role, DA is an excellent 
pharmacological target in treatment of pain. Pharmacotherapy focussed at DA-
neurotransmission has a high potential in both the prevention (via D1LRs) and 
treatment (via D2LRs and DA reuptake inhibitors) of CPSP. The development of 
prediction models including genetic risk factors is needed to better identify the 
patients at risk. 
Key words: Chronic Post-Surgical Pain, Dopamine, Pain sensitivity, 
Pharmacology, Single Nucleotide Polymorphisms  
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Introduction 
Chronic postsurgical pain (CPSP) affects 10-50% of surgical patients, severely 
decreasing quality of life and socioeconomic status [1-3]. The risk factors for 
developing CPSP can be divided into psychological, demographical, clinical and 
genetic risk factors. The psychological risk factors consist of pre-surgical 
catastrophizing and anxiety amongst others, providing a clear link with the 
biopsychosocial model of pain. The demographical risk factors consist of young 
age, female sex and most importantly pre-surgical pain [4, 5]. Clinical risk factors 
consist of type and duration of surgery and intraoperative nerve damage. All of 
these factors affect the development of chronic pain phenotypes after surgery [4, 
5].  
The current perioperative pain management strategy is focussed on prevention or 
treatment of acute postoperative pain [6, 7]. Treatment of acute postoperative pain 
is provided using both opioid and non-opioid treatments, tailored to the specific 
surgery type and specific patient needs. Multimodal analgesia is the cornerstone 
of postsurgical pain management in order to reduce opioid requirements and 
minimize serious side effects of opioids, thereby facilitating early patient recovery 
[7, 8]. The first step consists of regional or local anaesthesia specific for the 
invasiveness of the surgery [7, 8]. The second step is non-opioid systemic 
analgesics, which provide initial analgesia and modulate stress [7, 8]. Opioids are 
then used as rescue medication or to cover regions of inadequate regional 
anaesthesia coverage [7, 8]. Multimodal techniques minimize opioid use as 
opioids have many and potentially dangerous side effects (including nausea, 
respiratory depression, tolerance, opioid induced hyperalgesia, and opioid 
withdrawal symptoms) and long-term use of opioids should be avoided when 
possible[6-8]. Nevertheless the current treatment strategy for CPSP remains 
suboptimal, which is possibly due to lack of new/optimal treatment targets [9].  
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Dopaminergic neurotransmission (DA-neurotransmission), most known for its 
involvement in psychological disorders, has been associated with chronic pain 
syndromes including CPSP and is often overlooked when it comes to analgesic 
treatment strategies [10-13]. This review will focus on the role of DA in 
chronification of pain, and its potential for optimizing treatment protocols of 
CPSP.A recent review showed that a number of genes involved in DA-
neurotransmission were reported to be associated with the prevalence and severity 
of chronic postsurgical [14]. This is in line with other studies that suggest an 
important role for DA-neurotransmission in chronification of pain [15, 16]. 
Hence, the understanding of DA-modulation in nociception and the role of 
genetics related to DA-neurotransmission is important and may result in better 
prediction models and in new treatment options for CPSP. 
The objective of this review is to discuss: (1) The effect of genetic variation within 
DA- neurotransmission on susceptibility to CPSP; and (2) The potential of DA-
neurotransmission modulation in prevention of chronification of postsurgical 
pain and treatment of CPSP. Since the evidence in certain areas concerning 
dopamine and CPSP is limited, we will review and extrapolate the evidence 
collected from other research fields in which pain is involved and where dopamine 
plays a critical role (e.g. pain in Parkinson’s disease).  
Dopaminergic Neurotransmission 
Dopamine (DA) is involved in locomotion, psychological processing and the 
reward system on supraspinal levels [17, 18]. Moreover, DA is involved in the 
modulation of nociception at the spinal dorsal horn. Nociception starts at the 
peripheral nociceptor, which is activated by a noxious stimulus, transmitting the 
signal to the dorsal horn. There, the primary afferent synapse onto the second 
order neuron, transmitting the signal to various brain regions involved in the 
processing of pain, like the somatosensory cortex, amygdala, periaqueductal grey 
and cingulate cortex [19]. Modulation of the incoming nociceptive information 
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in the spinal cord is possible via the descending pathways (serotonergic and/or 
noradrenergic fibers) which originate from supraspinal centres (including the 
rostroventral medulla and locus coeruleus) [19, 20]. DA can also modulate 
nociception at the level of the spinal cord as well as at various brain regions (e.g. 
PAG) [21-23]. In this review we will focus on the influence of DA at the spinal 
cord level. For supraspinal modulation, the reader is referred to reviews on this 
topic (e.g. by P.B. Wood 2008 or Mitsi and colleagues 2016) [11, 24].  
DA receptors are present throughout the spinal cord and are expressed both 
presynaptically (primary afferents) and postsynaptically (second order neuron) in 
the “pain-gate” with D2 receptors as the dominantly expressed receptor subtype 
[25-29]. Expression patterns of the DA receptor differ per subtype, D2 and D5 
receptors are expressed abundantly throughout the spinal cord, in both the ventral 
and dorsal horn. However, the D1, D3 and D4 receptor are more sparsely 
expressed and restricted to specific regions either in the dorsal horn or in the 
motor neurons in the ventral horn [27, 29]. There are two known variants of the 
D2 receptor; a long and short variant. The long variant is predominantly expressed 
postsynaptically and mediates the postsynaptic signalling via the PKA and AKT 
pathways while the short variant is expressed mainly presynaptically and regulates 
the phosphorylation of tyrosine hydroxylase (key enzyme in the production of 
DA, fig. 1) mediating the production of DA [30-32].  
DA binds to members of two families of G-protein coupled receptors: D1-like 
receptor (D1LR) family (including the D1 and D5 receptors) which are 
stimulatory, and the D2-like receptor (D2LR) family (consisting of the D2, D3 and 
D4 receptors) which are inhibitory [26]. DA binding directly facilitates (D1LRs) 
or inhibits (D2LRs) nociceptive signal transduction (Figure 1) [12, 13, 21, 33, 34]. 
The different subtypes of receptors can group together and form heteromers, 
which have a distinct working mechanism in which both receptors are needed to 
elicit their effect. Due to their specialized composition, heteromers are unique 
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pharmacological targets [31, 35]. At spinal cord level, it has been shown that D1-
D3 heteromers are present throughout the grey matter, with their expression 
under influence of DA concentration. Co-activation of this heteromer leads to 
antagonistic interaction with adenylyl cyclase (AC) [35]. 
Dopamine is synthetized in the A11 descending neuron and released into the 
synaptic cleft where it binds to either the D2-like or the D1-like receptors to inhibit 
or activate the downstream signalling cascade mediated by AC [26, 27, 36, 37]. It 
is proposed that the noradrenaline transporter (NET) removes the dopamine from 
the synaptic cleft as it has been reported that there is no dopamine transporter in 
the spinal cord and COMT presence has been confirmed in the primary afferent 
(Figure 1) [36-40].  
The effect of DA in the spinal cord is determined by the concentration of DA 
combined with the difference in affinity for the D1 receptor and D2 receptors. DA 
has a slightly higher affinity for the D2 receptor than the D1 receptor resulting in 
a preferential activation of D2 receptor at low concentration and inhibition of the 
signal transduction [41-43]. Furthermore, D2 receptor are more abundantly 
present in the spinal cord compared to D1 receptor but the D1 receptor have a 
more direct effect which leads to the following effects: (1) A low spinal DA 
concentration (±1μM) results in inhibition of nociceptive signal transduction as it 
activates the D2 receptor, (2) a medium spinal DA-concentration (10-50μM) 
results in activation of nociceptive signal transduction as it activates the D1 
receptor as well for which DA has a slightly lower affinity and (3) a high spinal 
DA concentration (>100μM) will inhibit nociceptive signal transduction through 
the abundance of D2 receptor [41, 43-46]. It has been demonstrated that there is a 
sexual dimorphism in the expression of D1 and D5 receptors leading to a higher 
expression in males than in females. Furthermore, both receptors are involved in 
maintaining chronic pain states, where the D1 receptor is more involved in 
females and the D5 receptor in males [47]. 
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Figure 1: Genetic variations and dopaminergic neuromodulation in spinal cord nociceptive network. This 
figure illustrates DA-neurotransmission between primary afferents, descending neurons and the second order 
pain transmission neurons in the spinal dorsal horn. SNPs in DA-neurotransmission are shown as rs 
numbers. Rs841 is located in GCH1 and decreases expression of GCH1 affecting the production of dopamine. 
Rs6277 is located in DRD2 (D2 receptor) and decreases the stability of the mRNA thereby decreasing the 
expression of the D2 receptor. Rs4680 and rs165774 are both located in COMT and both decrease the 
enzymatic activity of COMT. Each of these variations are located at key points in the dopaminergic 
neurotransmission and influence the effect of dopamine on nociception by altering the signalling cascade.  
Abbreviations: 3MT = 3-methoxytyramine, AC = adenylyl cyclase, AMPA = α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid, AADC = Aromatic L-amino acid decarboxylase, cAMP = cyclic adenosine monophosphate, BH4 
= Tetrahydrobiopterin, COMT = catechol-O-methyltransferase, D1 = Dopamine 1-like receptor , D2 = Dopamine 2-like 
receptor , DARPP-32 = dopamine- and cAMP-regulated neuronal phosphoprotein, DA = Dopamine, DOPAC = 3,4-
Dihydroxyphenylacetic acid, GCH1 = GTP cyclohydrolase 1, GTP = guanosine triphosphate, HVA = HomoVanillic Acid, 
K+ = Potassium channel, L-DOPA = levodopa, MAO = MonoAmine oxidase, Na+ = Sodium channel, NET = 
Norepinephrine transporter, NMDA = N-Methyl-D-aspartic acid, PKA = Protein Kinase A, PP1 = Protein Phosphatase 1, 
rs# = reference SNP number, SNP = Single Nucleotide polymorphism, TH = Tyrosine Hydroxylase, VMAT2 = vesicular 
monoamine transporter 2.  
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Search strategy 
An extensive PubMed search was conducted to find literature related to 
Dopamine, Pain or Chronic postsurgical pain, genetics and modulation of 
dopamine. The search term was as follows: ((("Dopamine"[Mesh] OR "Receptors, 
Dopamine"[Mesh] OR Dopamine) AND (Nociception OR Analgesia OR 
“Pain”[Mesh] OR “Chronic Pain”[Mesh] OR “persistent pain” OR “postoperative 
pain”) AND (genetic)) OR (((COMT AND Nociception) OR (COMT AND Pain)) 
AND (genetic)) OR (((GCH1 AND Nociception) OR (GCH1 AND Pain)) AND 
(genetic))))) OR ( Genetic AND dopamine AND Chronic Pain) OR ( Genetic 
AND dopamine AND Postoperative Pain) OR (polymorphism AND "Dopamine" 
and "receptor")). Special attention was given to include different aspects of pain 
(e.g. chronic pain, nociception) and the combination with different genes 
involved in DA-neurotransmission. The search resulted in 2897 hits, of which 
titles and abstracts were screened for relevance. Articles were selected if their focus 
was on either pain sensitivity, development of CPSP or analgesic requirements in 
human studies. To supplement this search, we used the Human Pain Genes 
Database (HPGD) to identify hits which were not noted by our search and checked 
the references of the articles which were included [48]. This resulted in a total of 
36 articles (see Table 1). 
Pathophysiology of CPSP 
Both tissue trauma (nerve transection) and inflammation resulting from incision 
and exposing tissues during surgery can lead to sensitization of the nociceptive 
system and consequently resulting in chronification and thus CPSP [1, 49]. The 
local inflammatory pain is mediated by cytokines released at surgical site and leads 
to peripheral sensitization [49, 50]. Especially during major surgeries, there is an 
increased chance of damage to the nerves which eventually results in a 
neuropathic pain phenotype, which is difficult to treat [1, 5, 49]. As it is shown 
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that nerve-sparing surgeries are not always preventive of CPSP, other processes, 
including neuroplasticity of the nociceptive system, might play an additional and 
important role in development of CPSP [51]. Peripheral and central sensitization 
mechanisms can lead to maladaptive neuroplasticity in the spinal cord and central 
nervous system including disinhibition and descending facilitation via 
monoamines, including DA [19, 20, 52]. The central sensitization process is 
primarily through the AMPA receptor but an injury or surgery causes a prolonged 
pain signal, which subsequently activates the NMDA receptor [19]. DA binding 
to the D1LR receptor modulates phosphorylation of the AMPA and NMDA 
receptor and thereby affects central sensitization (see Figure1) [20, 26].  
Genetic variations in DA and chronic postsurgical pain 
A Single Nucleotide Polymorphism (SNP) in the DNA is a sequence variation 
whereby a single nucleotide in the genome is different. A SNP can result in 
different effects on cellular processes. A missense SNP causes a different amino 
acid to be built into the protein affecting its function, a synonymous SNP could 
affect mRNA stability leading to an altered translation, SNPs in the promotor 
region could affects expression levels and even SNPs outside genes can have an 
effect on protein functioning. The mechanism through which a SNP is able to 
affect the gene expression level or protein functioning depends on the location of 
the SNP. A SNP in the promotor region is able to change the motif for the 
transcription factor to bind leading to a more enhanced or decreased binding of 
the transcription factor altering the transcription of DNA into RNA. A SNP may 
introduce a new methylation site at either the promotor or enhancer region 
altering the binding of the transcription factor as well. SNPs in the intronic region 
can affect the splicing of the mRNA causing a different composition of the protein 
[53]. Most of the SNPs studied in chronic pain research do not directly cause pain 
but can modulate pain sensitivity, susceptibility to chronic pain or analgesic 
requirements [54]. 
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Clinical and pre-clinical studies have demonstrated the importance of DA in 
nociception and the modulating effect of various SNPs within genes associated 
with DA-neurotransmission and their effect on (chronic) pain [14, 55, 56]. Three 
genes within the DA-neurotransmission (catechol-O-methyltransferase (COMT), 
GTP cyclohydrolase 1 (GCH1)), DA receptor 2 (DRD2)) have shown strongest 
associations with baseline pain sensitivity and CPSP and are interesting targets for 
pharmacological modulation. Table 1 provides an overview of current evidence 
on SNPs associated with DA-neurotransmission and pain sensitivity, development 
of CPSP and analgesic requirements.  
 
 
 
 
 
 
 
 
 
Table 1 (next page): Result of the individual association studies with pain sensitivity, CPSP and analgesic 
requirement. (next page) Dopaminergic neurotransmission and genetic variations: SNP’s and the direction 
of the effect of the minor alleles and the amount of positive, negative or neutral associations is visualized per 
gene of interest, and depicted as “0” (no significant association), “+” (an increase in this domain), “–“(a 
decrease in this domain) or “ø” (this variant was not tested within this domain). Missense variant: different 
base pair and a different amino acid in the protein, Synonymous variant: different base pair but same amino 
acid, intronic variant: different base pair but not expressed in protein.
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GENE SNP VARIANT 
PAIN 
SENSITIVITY 
DEVELOPMENT OF 
CPSP 
ANALGESIC 
REQUIREMENT 
REFERENCES 
CATECHOL-O-
METHYLTRANSFERASE 
rs737866 Intronic 0 ø 
0 
(2x0) 
60, 95 
(COMT) rs737865 Intronic 0 ø 0 60 
 rs1544325 Intronic 0 ø 0 60 
 rs8185002 Intronic 0 ø 0 60 
 rs174675 Intronic 0 ø 0 60 
 rs5993882 Intronic 0 ø 0 60 
 rs740603 Intronic 0 ø 
+ 
(1x+, 1x 0) 
60, 95 
 rs4646312 Intronic 0 0 0 60,100 
 rs4633 Synonymous 
0 
(2x 0) 
? 
(1x + , 1x - , 1x 0) 
? 
(1x + , 1x - , 3x 0) 
55,58, 60, 89, 92, 93, 96, 
98, 99, 104 
 rs2239393 Intronic 0 ø 
+ 
(1x+, 1x0) 
60, 95 
 rs4818 Synonymous 
+ 
(1x +,1x 0) 
+ 
(1x +, 3x 0) 
+ 
(3x+, 3x0) 
55, 58, 60, 89, 92, 93, 95, 
96, 98, 99, 104 
 rs4680 Missense 
+ 
(6x +, 5x 0) 
? 
(1x + , 1x - , 5x0) 
? 
(5x + , 5x - , 4x 0) 
55, 57, 58, 60, 62-68, 71, 
89-91, 93-98, 100, 102-
107 
 rs4646316 Intronic 
+ 
(1x +, 1x 0) 
ø 0 60,69 
 rs165774 Intronic 
- 
(2x -) 
ø 
0 
(2x 0) 
55, 59, 60 
 rs174696 Intronic 0 ø 
0 
(2x 0) 
55, 60 
 rs9306235 Intronic 0 ø 0 60 
 rs9332377 Intronic 0 ø 0 60 
 rs6269 Intronic 
? 
(1x + , 1x -) 
- 
(2x -, 3x 0) 
+ 
(2x +, 1x 0) 
58, 69, 89, 92, 93, 95, 96, 
99, 100, 104 
 rs2097903 Intronic 0 ø ø 58 
 rs7287550 Intronic ø ø 0 95 
 rs5746849 Intronic ø ø + 95 
GTP CYCLOHYDROLASE 1  rs3783641 Intronic - 
0 
(2x 0) 
+ 74, 92, 93, 100 
(GCH1) rs998259 Intronic ø 0 ø 100 
 rs8004445 Intronic ø 0 ø 100 
 rs12147422 Intronic ø 0 ø 100 
 rs9671371 Intronic ø 0 ø 100 
 rs4411417 Intronic - + ø 74, 100 
 rs752688 Intronic - + ø 74, 100 
DOPAMINE RECEPTOR D3 rs6280 Missense - ø ø 88 
(DRD3) rs3773679 Intronic + ø ø 81 
DOPAMINE RECEPTOR D2 rs2734837 Intronic ø 0 ø 100 
(DRD2) rs11608185 Intronic ø 0 ø 100 
 rs4936272 Intronic ø 0 ø 100 
 rs4648317 Intronic ø + ø 100 
 rs4322431 Intronic ø 0 ø 100 
 rs1076560 Intronic ø 0 ø 100 
 rs6277 Synonymous + 0 ø 87, 100 
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Variations in dopaminergic neurotransmission genes alter baseline pain 
sensitivity 
An often-reported gene associated with dopaminergic neurotransmission and pain 
sensitivity is COMT, a gene involved in degradation of DA and other 
catecholamines [57, 58] (see Figure 1). According to the HPGD, the COMT gene 
has been published most often in relation to pain, and in particular SNP rs4680 
[48]. Several studies have demonstrated the involvement of COMT in pain 
sensitivity with haplotypes that account for differences in individual pain 
perception and chronification of pain (Table 1) [16, 59-70]. Furthermore, 
individual SNPs within COMT, most notably the Val158Met polymorphism 
(rs4680) and the corresponding haplotype, affect both the enzyme’s biological 
activity, and the response to and requirements of opioids (Figure 1) [60, 63, 71-
73]. Another gene shown to be associated with dopaminergic neurotransmission 
and pain sensitivity is (GCH1) [64, 74, 75]. GCH1 is involved in the production 
BH4, a key molecule in the synthesis of DA. Several SNPs within GCH1 have been 
associated with a protective effect against various pain disorders [64, 76].  
The protective effect against pain disorders is most likely due a decreased function 
of GCH1 and consequentially decreased production of BH4 [74, 77]. Higher 
concentrations of BH4 have been associated with more pain through altered 
dopamine metabolism amongst other mechanisms [74, 77, 78]. Interestingly, 
gene-gene interaction between COMT and GCH1 has been demonstrated to 
mediate the effect of rs4680 within COMT on pain sensitivity, whereby the SNPs 
within GCH1, also involved in the function of dopamine in neurotransmission, 
provided a protective effect [64]. While the minor allele of the polymorphism 
affecting the enzyme activity (rs4680) is present in both the high pain sensitivity 
haplotype and the low pain sensitivity haplotype, this results in a different 
phenotype. A potential explanation could lie in the difference between 
membrane-bound COMT and soluble COMT. Both are transcribed from the same 
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genetic locus, but are regulated differently per tissue type. The composition of the 
haplotype around the rs4680 could modify this tissue specific regulation leading 
to a more pain sensitive haplotype or a pain protective haplotype [59, 60]. The 
exact role of COMT on pain sensitivity remains a matter of debate as it has been 
shown to be both protective factor as well as a risk factor, furthermore, 
psychological components could be involved as well [65-67, 79]. Recently, a study 
reported that the COMT polymorphism rs4680 was not associated with pain levels 
but with fear of pain, thus supporting a possible indirect psychological effect of 
COMT on pain [80]. 
Genetic variations in the receptor subtypes of the D2LRs have been shown to 
affect baseline pain sensitivity through functional alterations of the receptor [81-
87]. The synonymous SNP C957T (rs6277) within the D2 receptor decreases the 
stability of the D2 receptor, influences striatal and extra-striatal receptor 
availability, modulating the connectivity between brain structures [83-85, 88]. 
Furthermore, the D2 polymorphism rs6277 leads to increased baseline pain 
sensitivity and increased susceptibility to chronic pain [86]. Within the D3 
receptor, rs6280 was shown to be protective for acute pain crises in sickle cell 
disease, and the D3 rs3773679 was associated with response to nociceptive stimuli 
when under analgesia [81, 82].  
Genetic variations affect the susceptibility to CPSP 
Genetic variations between individuals could explain much of the variability in 
CPSP. SNPs within GCH1, COMT and DRD2, all involved in the dopaminergic 
pathway (Figure 1), have been studied in a context of pain sensitivity but also in 
relation and association to CPSP. Multiple SNPs within COMT, rs4680 
(Val158Met), rs4818, rs4633 and rs4633, are reported to be associated with lower 
incidence and intensity of CPSP and less opioid use in the acute phase after surgery 
(Table 1) [89-98]. Furthermore, the haplotype (rs4680 A, rs4633 C, rs4818 C, 
rs6269 G), was associated with a better clinical outcome and less pain one year 
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after surgery, whereas other studies found this haplotype to be associated with 
higher pain ratings and worse clinical outcome[60, 89, 99]. However, some studies 
did not report any association between SNPs or haplotypes within COMT and 
CPSP/analgesic requirement or an opposite effect [57, 62, 63, 72, 89, 90, 92-96, 98-
107]. The direction of the effect of the rs4680 allele does not seem to depend on 
the cohort of patients studied, as it has been associated with an increase and a 
decrease in analgesic requirement in different cohort of patients with cancer [72, 
94, 95, 106]. Interestingly, it has been shown that the combination of SNPs in 
COMT and psychological factors are also involved in the susceptibility to CPSP 
[108]. Especially with COMT, there is evidence for a bio-psychosocial interaction 
influencing the psychological risk factors of and susceptibility to CPSP.  
Most of the SNPs within GCH1 have been associated with protection against pain 
and this has been shown in CPSP as well [76, 100, 109]. Studies on discectomy, 
herniotomy and molar removal showed an association between the pain 
protective haplotype of GCH1 (rs3783641, rs8007267 and others) and less pain 
after surgery and faster recovery [92, 93, 110]. By contrast, studies on postoperative 
shoulder pain, mastectomy, hysterectomy, and hernia repair found no association 
with the individual SNPs or a higher risk of CPSP (Table 1) [92, 100, 111]. With 
postoperative shoulder pain, the effect of the SNP in GCH1 interacted with 
anxiety indicating that also GCH1 is involved in a bio-psycho-social interaction 
thereby affecting the susceptibility to CPSP. To our knowledge, the association of 
SNPs in the D1LR genes and CPSP has not been studied. A nominally significant 
association between SNPs in DRD2 (rs4648317 and rs12364283) and CPSP (after 
hernia repair, hysterectomy, and thoracotomy) has been reported [100]. 
Large-scale genetic studies are necessary to successfully identify which genetic 
variations are repeatedly associated with CPSP. Genome-wide association studies 
(GWAS) and next generation sequencing (NGS) could play an important role in 
elucidating which genetic variations within the DA-neurotransmission are 
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involved in different processes of CPSP. For this, vast sample sizes are necessary 
and replication in different cohorts is needed. 
Modulation of DA-neurotransmission in pain and new treatment 
possibilities in CPSP 
Due to its role in nociception, DA neurotransmission makes an interesting target 
for the pharmacological modulation of chronic pain, including prevention of 
chronification of postsurgical pain and with that treatment of CPSP (Figure 1). 
Several pre-clinical and clinical studies have investigated the therapeutic potential 
of modulating DA neurotransmission in the anti-nociceptive action of morphine, 
anti-psychotic, anti-depressant, and anti-asthma medication [13, 112-121]. As 
clinical research in other disorders has shown the potential of modulation of DA-
neurotransmission as a therapeutic for pain we include this in our review. Finally, 
we focus at implications for new treatments in CPSP. 
Direct modulation of DA-neurotransmission in pain 
Pharmacological intervention and modulation of DA-neurotransmission in 
chronic pain has primarily been shown by the use of the D1LR and D2LR (ant-) 
agonists. Pre-clinical studies show that application of D2LR agonist either 
intrathecally (i.t.) or via chronic subcutaneous infusion, provide an analgesic 
effect, and this is reversed by D2LR antagonist application [21, 46, 122]. D1LR 
agonist applied directly on the spinal cord induced sensitisation of C-fibres, which 
can be reversed by antagonists. Furthermore, D1LRs are involved in the protein 
synthesis phase of sensitisation and thereby modulate the chronification of pain 
[123]. In addition to direct binding and modulation of D2LR or D1LR, 
pharmacotherapy can be directed at the dopamine reuptake process (see Figure 1). 
Increasing the DA concentration by inhibiting the DA-reuptake can be established 
with administration of selective and non-selective monoamine reuptake inhibitors 
like bupropion, duloxetine or milnacipran [117, 119, 120]. The anti-nociceptive 
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effect of reuptake inhibitors applied intraperitoneally (i.p.) and i.t. on pain is 
partially mediated via DA as increasing the concentration of DA results in an 
inhibition of the nociceptive transmission [117, 119, 120]. Furthermore, i.t. 
application of D2LR antagonist Sulpiride counteracted the effect of the re-uptake 
inhibitors, further strengthening the role of DA [117, 119, 120]. Besides reuptake 
inhibitors, DA also (partially) mediates the anti-nociceptive properties of 
aripiprazole (partial DA agonist, anti-psychotic) and theophylline (alters DA 
release, anti-asthma medication) [115, 116, 124]. 
Clinical studies have shown bupropion to be an effective analgesic in neuropathic 
pain, but not in chronic low back pain without a neuropathic component [118, 
125, 126]. Clinical research in other disorders has shown the potential of 
modulation of DA-neurotransmission as a therapeutic for pain. In Restless Leg 
Syndrome (RLS) pain and lowered pain thresholds is often a comorbidity 
occurring with the unpleasant sensation in the legs and the urge to move [127, 
128]. Patients with RLS are often treated with DA agonist to alleviate their RLS 
symptoms long term treatment with DA agonist (L-DOPA, pramipexole (D2LR 
agonist) or cabergoline (D2 receptor agonist)) ameliorated their pain threshold, 
decreased hyperalgesia and improved their tactile sensations [129-133]. In 
Parkinson’s disease (PD), 30%-60% of the patients report pain in some form and 
therefore pain is considered a major non-motor symptom of PD [121, 134, 135]. 
The role of DA on pain in PD has been investigated and treatment with L-DOPA 
was shown to be effective [121, 136, 137]. Most patients with PD fluctuate between 
“on” condition (medication is at an effective dose) and “off” condition (PD 
symptoms re-emerge) [138]. Patients experience a lower pain threshold in the “off” 
condition compared to the “on” condition indicating the effect of dopaminergic 
medication on pain [121, 136, 137]. Nevertheless, genetic heterogeneity in PD 
patients, as there are different forms of PD with different clinical presentations, 
might affect the outcome of L-DOPA treatment on pain [139, 140]. The use and 
injection of a non-selective dopamine antagonist apo-morphine did not 
46 | C h a p t e r  2  
significantly modify pain thresholds in PD patients compared to controls [133, 
141].  
Indirect modulation of DA-neurotransmission in pain 
Indirect modulation of DA-neurotransmission is possible in various ways: a non-
DA receptor is activated, like for instance the opioid receptor, and this has an effect 
on the DA receptor functioning and thereby affects the nociception or the 
activation of the DA receptor has an effect on other receptors (e.g. the NMDA) 
and affects their neurotransmission and role in nociception. 
Morphine administration (i.p. or i.t.) leads to an increase in D2 receptor 
expression in the spinal cord, improved the interactions between opioid receptors 
and D2 receptors and it has been demonstrated that morphine-induced 
sensitisation can be reversed by blocking of the D2 receptor [112, 114]. 
Furthermore, a neuropathic pain condition leads to enhanced interaction between 
the DA receptors (D1LR (facilitatory in nociception) and D2 receptor (inhibitory 
in nociception)) and opioids [12, 13]. The D2 receptor co-localizes with the μ-
opioid receptors (MOR) in neuropathic pain, and the anti-nociceptive effect of the 
D2 receptor agonist (quinpirole) is counteracted by a subclinical dose of MOR 
antagonist CTOP. Moreover, the co-administration of a D2 receptor agonist 
(quinpirole) and a MOR agonist (DAMGO) provided effective analgesia at a 
subclinical dose [13]. This effect occurs due to co-localization of D2 receptors and 
MOR on the same excitatory neurons and activation of these receptors leads to 
similar downstream effects including as potassium channel opening, which then 
results in inhibition of the nociceptive signal transduction [13]. This clinically 
relevant finding suggests that modulation of DA neurotransmission affects 
morphine binding to MOR and this may result in further reduction of morphine 
dose for treatment of chronic neuropathic pain. 
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In neuropathic pain conditions, D1LRs have been reported to modulate central 
sensitisation (CS) processes via the NMDA receptor (Figure 1). Ablation of 
dopaminergic neurons showed involvement of D1LRs (facilitatory to 
nociception) in the initiation and maintenance of CS through modulation of the 
NMDA receptor and thereby facilitating a painful response to a subthreshold 
stimulus, D1LR antagonist (SCH 23390) can prevent this process [33, 142]. 
Furthermore, sustained D1LR activation, although initially anti-nociceptive, 
impairs opioid receptor functioning, which is then counteracted by D1LR 
antagonist SCH 23390[12, 34]. This effect occurs due to co-localization of D1LR 
and NMDA on the same excitatory neurons and juxta-localization of D1LR 
presynaptically and MOR postsynaptically. The postsynaptic D1LR is involved in 
phosphorylation of the NMDA receptor which potentiates the NMDA receptor 
(see Figure 1) [33]. Sustained presynaptic D1LR activation increases the release of 
met-encephalin and impairs the postsynaptic MOR due to prolonged activation 
[12]. The combination of these mechanisms results in a loss of inhibition as well 
as a potentiation of NMDA receptor and ultimately the facilitation of 
chronification of pain. 
In the spinal cord, DA modulates the GABAergic interneurons in neuropathic 
pain conditions. Chronic pain increases the expression of neuroligin 2, a synaptic 
adhesion molecule located within inhibitory synapses [143]. This neuroligin 2 
protein has a preference to form synapses between GABAergic and Dopaminergic 
neurons, causing mismatched synapses to be formed in chronic pain conditions. 
Inhibition of neuroligin 2 reverses the pain facilitation caused by D1LRs described 
above and restores the pronociceptive properties of a GABAA antagonist [47, 143]. 
The impairment of neuroligin 2 is likely to be a good target to treat both the 
disinhibition mediated by GABAergic interneurons as well as the maintenance of 
chronic pain states by D1LRs. 
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CPSP and modulation of DA-neurotransmission? 
Direct and indirect modulation of DA-neurotransmission have been shown to be 
involved in analgesia and chronification of pain and could therefore potentially 
be applied in CPSP. 
Prevention of CPSP 
The possibility to indirectly modulate the central sensitisation through D1LRs is 
especially relevant for the prevention of CPSP as current treatment strategies are 
relatively ineffective [33, 142, 144]. Research suggests that administration of D1LR 
antagonists (inhibiting facilitation of nociception) during surgery could prevent 
the initiation and maintenance of central sensitisation and could thereby prevent 
the chronification of the postsurgical pain [33, 142]. Activation of the D1LRs is 
required for the sensitisation process to occur. Without this activation, and 
antagonism by D1LR antagonist SCH 23390, the NMDA receptor will not be 
phosphorylated which is a crucial step in the central sensitisation process (Figure 
1) [33, 142]. 
Treatment of CPSP 
Direct modulation of DA-neurotransmission through D2LRs agonism (inhibition 
of nociception) and reuptake inhibitors (increasing DA concentration and 
preferential D2LR activation) are interesting options for the treatment of CPSP 
(Figure 1). D2LRs agonist quinpirole have been shown to reduce hyperalgesia in 
both acute pain and in chronic neuropathic pain in animal models [13, 21, 122]. 
DA agonists Pramipexole and cabergoline reduce comorbid pain symptoms in 
other disorders, and reuptake inhibitor bupropion has been shown effective in 
neuropathic pain [125, 131-133]. 
In the treatment of CPSP, the synergy between opioid receptors and D2LRs (both 
involved in the inhibition of nociception) form an interesting perspective. 
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Simultaneous administration of D2LR agonists and morphine have been shown 
to be effective at subclinical dosages in treatment of pain [13]. The use of 
subclinical dosages is clinically very relevant as it does result in a decrease in overall 
opioid use and opioid-related side effects such as opioid induced hyperalgesia and 
opioid withdrawal symptoms. 
Future Perspectives 
Clinical effectiveness of DA focussed pharmacological interventions has been 
shown in other disorders, but evidence of effectiveness in CPSP prevention and/or 
treatment is currently lacking and further research is needed [121, 129-133, 136, 
137]. Clinical studies on the genetics of DA-neurotransmission need to be 
replicated in follow-up GWAS and Next Generation Sequencing (NGS) studies on 
CPSP. Furthermore, new DA-related targets have to be identified and screened for 
their potential in analgesia. Newly developed nociceptive screening assays in 
zebrafish assays allow fast and quick screening of new pharmacological treatment 
strategies [145-148]. Additionally, zebrafish are excellent for testing the effect of 
genetic variations (e.g. identified in GWAS or NGS studies on CPSP) and could 
be used to determine the effect of genetic variations on effectiveness of different 
treatment strategies [145]. These pharmacogenomic strategies can subsequently be 
tested in rodents and translated to clinical practice [149]. 
Concluding remarks 
Dopamine-neurotransmission and variations within COMT-gene (risk factor), 
GCH1-gene (protective) and DRD2-gene (risk factor) have been reported to be 
associated with a variability in pain sensitivity, development of CPSP and 
analgesic requirement. Pharmacotherapy focussed at DA-neurotransmission has a 
high potential in prevention (via D1LRs) and treatment (via D2LRs and DA 
reuptake inhibitors) of CPSP. 
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The current evidence, as summarized here, provides ample evidence for the 
involvement of DA in the development of CPSP. Further research should focus 
on the translation of preclinical findings on DA and chronic postsurgical pain into 
clinical practice through two different approaches. Firstly, implementing the 
knowledge on genetic variation into currently existing prediction models, 
consisting of known risk factors, of CPSP which then may further improve the 
accuracy of the prediction. It has been shown that the addition of a single 
polymorphism (SNP rs4818 in COMT) to a prediction model of CPSP did 
enhance, although not significantly, the prediction power from 78% to 82% [150]. 
Lastly, studies assessing pharmacological interventions targeted at genetic 
variation are needed. Understanding the genetic risk factors of CPSP could 
optimize pharmacological treatment during the peri-operative period. 
Counteracting the biological effects of those SNPs involved in DA 
neurotransmission through peri-operative pharmacological intervention then 
may decrease the prevalence and chronification of postsurgical pain.  
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Summary 
Chronic Post-Surgical Pain (CPSP) is common and can have a negative impact on 
quality of life. Recent studies show that genetic risk factors are likely to play a role, 
although only gene targeted analysis has been used to date. This is the first 
Genome-Wide Association Study (GWAS) to identify Single Nucleotide 
Polymorphisms (SNPs) associated with the development of CPSP based on two 
independent cohorts. In a discovery cohort, 330 women scheduled for 
hysterectomy were genotyped. A case-control association analysis compared 
patients without CPSP and the thirty four who had severe CPSP three months 
after surgery. No SNPs reached genome-wide significance, but several showed 
suggestive associations with CPSP (P<1x10-5). SNPs with significance P<1x10-5 
were followed up in a replication cohort consisting of 203 men and women 
scheduled for orthopaedic or abdominal surgery. Ten of these patients developed 
severe CPSP. A SNP in NAV3 was significantly replicated with CPSP in the 
replication cohort (p=0.009) with a trend towards statistical significance for RSU1 
(p=0.07). Meta-analysis revealed that two loci (IQGAP1 and CRTC3) were 
significantly associated with CPSP at three months (IQGAP1 p=3.93x10-6 
=2.3863, CRTC3 p=2.26x10-6, =2.4209). The present GWAS provides initial 
evidence for genetic risk factors of CPSP and supports follow-up studies.  
Keywords: Chronic pain; genome-wide association study; risk factors 
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Introduction  
Moderate to severe Chronic Post-Surgical Pain (CPSP) is a debilitating condition 
affecting between 5 and 85% of patients undergoing surgery and has a large 
negative impact on the quality of life (QoL) and socioeconomic status [1-3]. It is 
defined as “pain developed or increased after a surgical procedure, which is present 
for at least three months, and affecting the QoL” [4, 5]. Furthermore, the pain is 
localized to the surgical field or projected innervation area of a nerve and other 
causes for the pain must have been excluded [4, 6]. Both clinical (e.g. type of 
surgery) and demographic (e.g. psychosocial status) risk factors have been 
described but these do not explain all the observed variance. So far, a good 
understanding of genetic risk factors for CPSP is still lacking [1, 7].  
The underlying biology of CPSP and genetic heritability is complex and not yet 
fully understood [8]. However, twin studies in pelvic and low back pain have 
indicated the importance of genetics in chronic pain phenotypes with an 
estimated heritability of 40% [9, 10]. Association studies focusing on candidate 
genes have suggested a possible role for COMT, GCH1, and KCNS1 among others 
[11-13], but a recent systematic review showed conflicting results for all the genes 
tested [14]. We tried to identify genetic polymorphisms in the human genome 
associated with CPSP three months after surgery by performing a genome-wide 
association study (GWAS) using a unique discovery CPSP cohort of patients 
undergoing hysterectomy [15]. The advantage of this cohort is the homogenous 
population consisting of only women (age 18-65, malignancies excluded) [16, 17]. 
Promising candidates were then further explored in a replication cohort of 
orthopaedic and abdominal surgeries to verify our findings. Combining different 
clinical cohorts leads to the identification of genetic risk factors associated with 
CPSP in general and each individual cohort gives information on surgery specific 
risk factors, as shown before in migraine research [18]. A meta-analysis of the 
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discovery and the replication cohort was conducted to investigate the combined 
effects of both studies. 
Methods 
This study was approved by our local Medical Ethical Committee (both discovery 
and replication study) and all participants gave written informed consent.  
An elaborate description of recruitment and data collection protocols for the 
discovery cohort has been published elsewhere [15]. In brief, a multicentre 
prospective cohort study was conducted, recruiting patients from four hospitals in 
the Netherlands. Patients undergoing hysterectomy for benign indications 
between September 2010 and January 2014 were included in the study. Inclusion 
criteria were: age between 18 and 65 y; fluency in the Dutch language; elective 
surgery; and total or subtotal hysterectomy with or without oophorectomy using 
all types of surgical approach. Exclusion criteria consisted of: illiteracy; history of 
cancer; and cognitive impairment. Furthermore, patients who reported a 
malignancy or underwent another surgical procedure during the first 
postoperative year were not analysed. Peripheral blood samples were collected 
before hysterectomy and genomic DNA was isolated at the clinical genetics 
department of Maastricht University Medical Center.  
For the replication study, two multicentre prospective cohort studies were 
conducted recruiting patients from three hospitals in Italy. In both studies, 
peripheral blood samples were collected during surgery and genomic DNA was 
isolated. Inclusion criteria of the orthopaedic cohort consisted of adult patients of 
all sexes undergoing total knee arthroplasty with ASA physical status 1–3. All 
patients enrolled had the same regional anaesthesia procedure in order to reduce 
any bias related to anaesthesia treatment and difference in intra-operative pain. 
Patients were excluded if there were contra-indications to regional anaesthesia, 
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unstable neurological diseases, diabetes or pre-surgical pain and if regional 
anaesthesia block was not effective.  
The protocol of the abdominal surgery trial has been already published [19]. 
Inclusion of the abdominal surgery cohort comprised adult patients of all sexes 
scheduled for major abdominal or urological surgery without regional 
anaesthesia, ASA physical status 1–3 and HIV negative. Exclusion criteria 
consisted of: previous regular use of opioids; history of alcohol/drug abuse; 
postoperative hospitalisation with sedation/ventilation; severe renal or hepatic 
impairment; cardiac, neurological and cognitive disorders; abnormal coagulation; 
low platelet count; BMI > 30 kg.m-2, allergy to the drugs studied, diabetes and pre-
surgical pain.  
Samples were genotyped at the Department of Genomics at the Life and Brain 
Center, University of Bonn using the Illumina PsychArray (Infinium PsychArray-
24 v1.2 Bead Chip, Illumina Inc., San Diego, (CA, USA)) which contains 
enrichment in genetic variants associated with psychiatric conditions. A strong 
psychological component is present in pain and several genes in psychiatric 
disorders have been associated with chronic postoperative pain as well as 
identified through the Pain Genes database (e.g. COMT and OPRM1) [20–22]. 
Psychological predictors are an important risk factor for chronic postoperative 
pain [15, 23, 24]. We believe this approach offers greater potential to identify 
genetic variants with phenotypic effects in chronic postoperative pain. The array 
includes 265,000 proven tag single-nucleotide polymorphisms (SNPs) found on 
the Infinium Core-24 Bead Chip, 245,000 markers from the Infinium Exome-24 
Bead Chip and 50,000 additional markers associated with common psychiatric 
disorders. 
Genotypes were called using BeadStudio (Genome Studio v2011.1, Illumina San 
Diego (CA, USA)). Basic quality control was done using Plink (Plink-1.9) [25, 26]. 
The quality control parameters consisted of: SNP call rate < 0.95; subject call rate 
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of < 0.95; deviation of Hardy–Weinberg equilibrium (p < 1x10-6); and removal of 
rare variants with a minor allele frequency < 0.01. Heterozygosity of the subjects 
was tested and outliers (± 3 SD from the mean heterozygosity rate) were removed 
(see also Supporting Information Fig. S1). No relatedness and sex inconsistencies 
were found within our cohort. After basic quality control, all AT or CG SNPs were 
removed from the SNP set. After these control steps, the SNPs were pruned to 
remove SNPs in linkage disequilibrium (R2 > 0.2), principal components analysis 
was performed using the Aberrant Package in R, and the first two principal 
components were analysed for outliers. Together with the principal component 
analysis, the ancestry and ethnicity of the subjects was determined using HapMap 
data (as described by ENIGMA) (Fig. 2) [27]. After quality control, the data were 
prepared for imputation by checking for flipped strands, allele assignments and 
position of SNPs and converted into variant call format files. 
Genotype imputation was performed using the imputation stepwise approach 
implemented in Minimac3 (https://genome.sph.umich.edu/wiki/Minimac3, 
University of Michigan, Ann Arbor, MI, USA) and Eagle2 
(https://data.broadinstitute.org/alkesgroup/Eagle, v2.3, Broad Institute, 
Cambridge, MA, USA) using default parameters with European HRC reference 
panel (http://www.haplotype-reference-consortium.org, version r1.1 2016) [28–
30]. Quality control on the imputed dataset was performed with the following 
parameters: genotype probability > 0.9, imputation accuracy > 0.5, INFO-score > 
0.4 and minor allele frequency and genotyping rate was checked again. Regional 
association plots were made to see the linkage disequilibrium of the significantly 
associated SNPs and their association with chronic postoperative pain using 
Locuszoom (http://locuszoom.org, University of Michigan, Ann Arbor, MI, USA) 
[31].  
The primary outcome measured in this cohort was the highest surgery-related pain 
score at rest during the last week at 3 months after surgery measured by the 
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numeric rating scale (NRS) [15]. Based on the primary outcome measure, patients 
were divided into a non-pain (NRS = 0) and a chronic postoperative pain (NRS > 
3) group to perform an extreme phenotype analysis to increase the power. Patients 
with mild pain (NRS between 1 and 3) score were not included in the genetic 
analysis. The gene dosages were tested for an association with chronic 
postoperative pain using an additive logistic regression model. To decrease false-
positives, the maximum threshold of  was set at 1.08 [32]. Genome-wide 
significance was set at p < 5x10-8 and the analysis was run using SNPTEST 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html, v2.5.4, 
Oxford University, Oxford, UK) [32, 33]. Single-nucleotide polymorphisms with 
a p value < 1x10-5 were selected as suggestive association SNPs for replication [34]. 
The same statistical tests were used for the discovery and the replication cohort. 
Next, the discovery and the replication cohort’s association SNP results were used 
to perform a random-effects meta-analysis in Plink. As the study design of the two 
cohorts was different, and some covariates (e.g. age) differed significantly between 
the cohorts, we chose to perform a random-effects meta-analysis. Bonferroni 
correction was applied to account for multiple testing. 
Power calculation for this study was conducted and based on the primary aim of 
the study and not for the genetic testing, which was a secondary aim. Therefore, 
this study is underpowered for a genome-wide analysis study and, as a 
consequence, there is a risk of a type-1 error which should be taken into account 
when interpreting the results [15]. 
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Figure 1 Patient inclusion in the discovery cohort .MUMC+, Maastricht University Medical Center+; CzE, 
Catharina Hospital Eindhoven; MMC, Maxima Medical Center Veldhoven; OMC, Orbis Medical Center 
Sittard Geleen; n, sample size.   
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Results 
Figure 1 shows the flow chart for inclusion, follow-up and genetic quality control, 
which is an extended version of the flow chart of our previous publication [15]. 
After quality control, samples from 330 patients were available for genetic analysis. 
Baseline pain and peri-operative characteristics can be found in Table 1. Out of the 
330 patients included in the analyses, 269 (81.5%) reported no pain (NRS = 0) 
related to the hysterectomy at the 3 month follow-up, 27 (8.1%) reported mild 
pain (NRS between 1 and 3) and 34 (10.3%) reported moderate to severe pain 
(NRS > 3).  
The replication cohort underwent a variety of orthopaedic and abdominal 
surgeries (pooled in this cohort). The total cohort consisted of 249 patients of 
which samples of 203 patients (67 men and 136 women) were available for genetic 
analysis. Out of these 203 patients, 157 received no intervention and 46 received 
an infusion of steroids (methylprednisolone) in the first 7 days. A total of 190 
patients were available for genetic analysis. It was decided to continue with the 
women without intervention leading to 106 women included in the study. After 
quality control, the results of 99 patients were available for genetic analysis. 
Baseline pain and peri-operative characteristics can be found in Table 1. Out of the 
99 patients included in the analyses, 39 (39.4%) reported no pain (NRS = 0) related 
to the hysterectomy at the 3-month follow-up, 37 (37.4%) reported mild pain 
(NRS between 1 and 3) and 11 (11.1%) reported moderate to severe pain (NRS > 
3). 
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Table 1: baseline and perioperative patient characteristics of all patients available for genetic analysis. 
Numbers represent mean (SD, Standard Deviation) or number (%). Missing data is reflected in the 
percentages.  
Abbreviations: NRS numeric rating scale, n sample size, PACU post-anaesthesia care unit 
# ASA scores only available for the patients who underwent abdominal or urological surgery (n=24) 
## Pain at PACU was measured at 1hr after surgery for discovery cohort, 0hr for the abdominal and urological surgeries 
and after 6 hours for orthopaedic surgery. 
  Discovery cohort (n = 330) Replication cohort (n=99) 
Gender     
Female 330 (100%) 99 (100%) 
Age  46.9 (7.2) 69.3 (9.6) 
Asa physical class     
I 179 (54.2%) 4 (16.6%) # 
Ii 135 (40.9%) 9 (37.5%) # 
Iii 4 (1.2%) 6 (25.0%) # 
Pre-surgical pain 
(surgical indication 
related) 
    
Nrs 0-3 161 (48.8%) 99 (100%) 
Nrs 4-10 169 (51.2%) Patients with pre-surgical pain excluded 
Pain at rest at pacu 
(acutely after surgery) ## 
    
Nrs 0-3 162 (49.1%) 64 (64.6%) 
Nrs 4-10 133 (40.3%) 31 (31.3%) 
Pain at postsurgical day 4 
(highest nrs last 24 hours) 
    
Nrs 0-3 179 (54.2%) 74 (74.7%) 
Nrs 4-10 111 (33.6%) 6 (6.06%) 
Pain at 3 months (highest 
nrs last week) 
    
Nrs 0-3 296 (89.7%) 76 (76.7%) 
Nrs 4-10 34  (10.3%) 11 (11.1%) 
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Figure 2 Ancestry plot based on the multidimension scaling method described by ENIGMA and population 
defined by HapMap. The discovery cohort (HYS) is plotted amongst the populations defined by HapMap. 
CEU, Utah residents with European ancestry; CHB, Han Chinese from Beijing, China; YRI, Yoruba from 
Ibadan, Nigeria; TSI, Italian from Tuscany, Italy; JPT, Japanese from Tokyo, Japan; CHD, Chinese from 
Denver, Colorado, USA; MEX, Mexican ancestry in Los Angeles, California, USA; GIH, Gujarati Indians 
from Houston, Texas; ASW, African ancestry from Southwest USA; LWK, Luhya from Webuye, Kenya; 
MKK, Maasai from Kinyawa, Kenya. 
Ethnicity of both cohorts was checked using the HapMap data and was 
determined to be of European background (Fig. 2). Subjects deviating from this 
background were not analysed during quality control (discovery cohorts n = 12, 
replication cohort n = 4).  
After quality control and imputation, 6,293,655 SNPs were included analysis. 
Overall association results are depicted in Fig. 3a. The QQ plot showed no 
apparent deviation from the null distribution of p values (Fig. 3b) and the 
genomic inflation factor (Fig. 3b, GC = 1.065) indicated only a slight inflation of 
the model without covariates. Although none of the SNPs tested reached the 
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threshold for genome-wide significance (p < 5x10-8, Fig 3a), several reached a 
suggestive level of association (107 SNPs with p < 1x10-5, Fig 3a) which were 
further analysed and labelled as ‘SNPs of interest’. Results of the top loci are shown 
in Table 2 and all SNPs were annotated using GRCh37.p13. A SNP cluster tagged 
by rs62281806 in FNDC3B was the most significant hit (p = 5.5x10-7). Other genes 
tagged by SNPs included EDNRA, NAV3, TLL2, RSU1, IQGAP1, TMEM63B, PJA2, 
CRTC3 and DLG2. None of these genes have been associated with chronic 
postoperative pain before, according to a recent systematic review [14]. The 
detailed results of the discovery cohort (SNPs p < 0.05) are available on request 
from the corresponding author. 
In the discovery cohort, no SNP reached the threshold for genome-wide 
significance. We decided to replicate only those SNPs in the replication cohort 
which showed a suggestive association (p < 1x10-5) with the phenotype to increase 
the power [34]. The SNPs (n = 107) showing suggestive association in the discovery 
cohort were further evaluated in an independent replication cohort. Results of the 
top replication loci are shown in Table 2 and the complete results in the 
Supporting Information Table S1. The SNP (rs118184265) in NAV3 showed 
nominal significance (p < 0.01) with chronic postoperative pain at 3 months and 
two SNPs within RSU1 (rs7894047, rs7893777) showed a trend towards statistical 
significance (p = 0.068). As the number of patients was limited, we decided to 
increase the cases by including all women with mild pain at 3 months (NRS > 0). 
The NAV3 SNP remained significant although somewhat decreased (p = 0.014) 
and the RSU1 SNPs became significant (p = 0.049) (see also Supporting 
Information Table S2). The direction of the effect in the replication study is 
reversed compared with the discovery cohort. 
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Figure 3: Manhattan plot and quantile-quantile plot representing the results of the genome-wide association 
analysis of the discovery cohort. (a) Manhattan plot representing the association between single-nucleotide 
polymorphism (SNP) genotype and chronic postoperative pain at 3 months after surgery in patients with a 
Caucasian ancestry. The negative log10 p values (y-axis) are plotted against their chromosomal positions (x-
axis). The red dotted line indicates the genome-wide significance level (p > 5.0x10-8), the blue dotted line 
indicates the SNPs of interest level (p > 1.0x10-5). (b) QQplot of genotyped and imputed SNPs. Observed p 
values are plotted against the expected p values. The lambda of 1.065 indicates a small genomic inflation 
corroborated by the near perfect correlation between the observed and expected p values. Figures were created 
using the quality control of GWAS data package in R. 
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The SNPs studied in both the discovery and the replication cohort (n = 96) were 
analysed in a random-effects meta-analysis to see the overall effects. Results of the 
top loci are shown in Table 2 and the complete results in the Supporting 
Information Table S3. The most significant SNP was rs117119665 in CRTC3 (p = 
2.26-6,  = 2.4209, adjusted p = 2.41-4). The second significant SNP was rs1145324 
in IQGAP1 (p = 3.93-6,  = 2.3863, adjusted p = 4.20-4). Several nominally significant 
associations were found (rs11655475 and rs4790802, p < 0.05) but these were not 
annotated to a gene. Both significant SNPs are located closely together on 
chromosome 15 within a region of low recombination (Fig. 4). To test whether 
the two SNPs (rs117119665 and rs1145324) are independent or part of the same 
locus, we performed a conditional analysis of each SNP with the other SNP as 
covariate. This analysis showed that the association with chronic postoperative 
pain disappeared (p > 0.1) and, thus, the SNPs are not independent. There is a 
possible involvement of rs4347600 in CRTC3 as well but this SNP was not tested 
in the replication cohort and could, therefore, not be entered into the meta-
analysis (Fig. 4). 
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Figure 4 Regional association plot for single-nucleotide polymorphism (SNPs) within CRTC3 and 
IQGAP1 and their association with chronic postoperative pain. The plot shows the chromosomal position of 
the SNPs (based on 1000 genomes Nov 2014 EUR) in the respective region against the -log10 P values. The 
SNP with the highest p value in the meta-analysis is represented as a purple diamond. The other SNPs are 
colour coded according to the extent of linkage disequilibrium with those specific SNPs 
Discussion 
One locus (NAV3) of the SNPs of interest was associated with chronic 
postoperative pain in the replication cohort. Two loci (CRTC3 and IQGAP1) were 
significantly associated with chronic postoperative pain in the meta-analysis of the 
discovery and replication cohort. Unfortunately, the sample size of the discovery 
cohort was too small and, thus, the study was underpowered. The replication 
cohort and meta-analysis partially overcome this problem but results should be 
interpreted cautiously. Nevertheless, the study provides an initial insight to 
genome-wide risk factors of chronic postoperative pain.  
The meta-analysis indicated two genes (CRTC3 and IQGAP1) as risk loci for the 
development of chronic postoperative pain. However, neither has been associated 
with pain before according to the Pain Genes Database and the Human Pain 
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Genetics Database [22, 35]. CREB-regulated transcription co-activator 3 (CRTC3) 
is expressed in a variety of tissues including the nervous system, is involved in 
regulation of CREB-dependent transcription of genes and inhibits adenylyl cyclase 
in response to catecholamine signalling [36, 37]. It has been associated with several 
abdominal disorders such as Crohn’s and inflammatory bowel disease and 
cognitive information processing [38–40]. IQ motif containing GTPase-activating 
protein 1 (IQGAP1) is expressed throughout the body including the nervous 
system, and is involved in cytoskeleton regulation, signalling molecules and cell 
motility [36]. It has been associated with immune system functioning and 
multiple sclerosis [41, 42]. Interestingly, two genome-wide association studies 
found both CRTC3 and IQGAP1 associated with their primary outcome measure 
(heel bone mineral density and neutrophil percentage of white cells, respectively) 
indicating a possible synergism or interaction between the two genes [42, 43]. In 
our study, the SNPs in both genes are in linkage disequilibrium with each other 
and influence the development of chronic postoperative pain together. Their 
involvement in the immune system is supportive of postoperative infection being 
a risk factor for the development of chronic postoperative pain, as previously 
shown [15]. 
In addition, a significant association of a SNP in NAV3 (neuron navigator 3) with 
chronic postoperative pain was noted in the replication cohort, which was part of 
the SNPs of interest in the discovery cohort. NAV3 is a gene predominantly 
expressed within the central and peripheral nervous systems, is involved in axonal 
growth and is upregulated 24 h after brain injury [44]. Another SNP in NAV3, 
found to be upregulated in degenerating Alzheimer’s disease [45], has been 
associated with brain development and neuronal differentiation [46]. 
Interestingly, the NAV3 gene has been associated with complex regional pain 
syndrome [47]. However, the direction of the effect of NAV3 differed between the 
discovery (protective effect) and replication cohort (risk effect) which could be 
due to several reasons. One of these could be that the effect of SNPs is subtype 
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specific as already shown in migraine [18]. The replication cohort consisted of a 
variety of surgeries, while the discovery cohort was focused on hysterectomy, 
although the hysterectomy approach did differ slightly between hospitals. 
Furthermore, the limited sample size could skew results to one side and large-scale 
follow-up and meta-analyses should further verify the direction and the size of the 
effect.  
Genetic studies and GWAS in particular, face several difficulties in the field of 
chronic postoperative pain. The first challenge is unifying the phenotype and the 
sub-phenotypes of chronic postoperative pain [3]. Several efforts have been made 
to improve the phenotyping of chronic postoperative pain [4, 6]. The most recent 
effort for the new International Classification of Diseases-11 made a further step 
by specifically defining the sub types of chronic postoperative pain with detailed 
symptoms per sub-phenotype [3]. Migraine research has done this sub-
classification before and a recent genome-wide association meta-analysis identified 
subtype-specific risk loci, which is a good example of the direction the field should 
pursue [18]. Combining various indications of chronic postoperative pain helps 
to identify which SNPs or loci are subtype specific and which are associated with 
chronic postoperative pain in general. The second challenge is acquiring an 
adequate sample size, which was rather small in this study. The sample size to find 
trustworthy results should be multiplied at least a 100-fold, which is not feasible 
for individual research groups. Instead, following the example of migraine [18], 
large consortia should be formed to make large sample sizes possible. Combining 
uniform and detailed (sub-)phenotypes of chronic postoperative pain with a 
sufficient sample size would make genome-wide association in chronic 
postoperative pain a success.  
Our study provides a foundation for follow-up genome-wide association studies 
on chronic postoperative pain. Our analysis only focused on the female sex, but 
data are available on men and women. Both the detailed information available on 
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both cohorts as well as the availability of both sexes makes this study an ideal 
starting point for follow-up research. Although none of the SNPs studied reach 
genome-wide significance, various suggestive signals were identified and 
replicated in an independent cohort. There are some differences between the 
discovery cohort and replication cohort, which could influence the results. Firstly, 
the replication cohort included men and women and approximately 20% received 
an intervention consisting of methylprednisolone infusion next to the standard 
postoperative medical regime, whereas the discovery cohort consisted of only 
women without extra interventions. Women have a higher chance of developing 
chronic postoperative pain than men [48, 49]. To overcome this difference, we 
decided to analyse only the women in the cohort who did not undergo 
methylprednisolone infusion. Secondly, there was a significant 20-year mean age 
difference between the discovery and the replication cohorts. Younger age is a risk 
factor for chronic postoperative pain and should be corrected for where possible 
[48]. To correct for age, a random-effects instead of a fixed effects meta-analysis 
was conducted as the study design and influential covariates differed between 
studies.  
Currently, a significant portion of the variance in the risk of developing chronic 
postoperative pain remains to be elucidated, despite the already comprehensively 
studied psychological, clinical and baseline characteristic risk factors [1, 17, 23]. 
The identification of genetic risk factors will be a key step towards identifying 
people at risk of chronic postoperative pain and devising new treatment strategies 
based on optimised prediction modelling. Although this genome-wide association 
study alone did not yield genome-wide significant SNPs, the meta-analysis 
indicated two risk loci for the development of chronic postoperative pain and the 
replication study provided additional evidence for two loci. Future studies in 
larger cohorts of patients with chronic postoperative pain will help to elucidate 
the underlying genetics. Expanding to other surgery types may uncover 
susceptibility factors for chronic postoperative pain independent of the surgery 
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intervention and possibly subtype-specific loci. Finally, characterisation of the 
pathways related to chronic postoperative pain has the potential for developing 
therapeutic approaches to prevent it. 
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mu 1; EDNRA, endothelin receptor type A; NAV3, neuron navigator 3; TLL2, tolloid-like protein 
2; RSU1, ras suppressor protein 1; TMEM63B, transmembrane protein 63B; PJA2, praja ring 
finger ubiquitin ligase 2; DLG2, discs large MAGUK scaffold protein 2; FNDC3B, fibronectin 
type-3 domain containing 3B; KCNS1, potassium voltage-gated channel modifier subfamily S 
member 1 
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included (NRS > 0) versus no pain group (NRS = 0). 
Table S3. Random effects meta-analysis results of discovery and replication cohort. 
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Abstract 
Chronic Post-Surgical Pain (CPSP), or pain developed or increased after a surgical 
procedure present for at least 3 months, affects between 5-85% of patients 
undergoing surgery. A recent GWAS study identified two potential risk loci in a 
small cohort. Although GWAS analysis provides insights into association between 
SNPs and CPSP, it does not provide evidence on causality. In the current study, 
expression quantitative trait loci (eQTLs) are used to further elucidate the genetic 
risk factors of CPSP and their working mechanisms. We conducted a large-scale 
meta-analysis across various CPSP cohorts and study the possible mechanisms via 
eQTLs and Mendelian randomization.  
The statistical analysis included a comparison of the severe CPSP (NRS>3) with 
the no-CPSP group (NRS=0) and continuous phenotype (NRS 0-10). Meta-
analysis of the different cohorts was conducted using METAL in a fixed approach 
weighted by standard errors. Transcriptome-wide Mendelian randomization 
(TWMR) approach was used to combine SNP association with CPSP and eQTLs 
in different tissues. 
Performing the meta-analysis on half of the cohorts led to the identification of the 
first genome-wide significant hit (rs17882261) for CPSP. The TWMR approach 
led to the identification of genes (SNAP29, RPA2) which potentially causally 
associated with CPSP in multiple tissues. 
Increasing the sample size of the initial GWAS study led to the identification of 
the first genome-wide significant locus for CPSP. TWMR analysis identified two 
genes with potential causally associated with CPSP in multiple tissues and 
expressed either in nervous tissues or immune cells. The present study provides a 
major step forward in genetic studies identifying genetic risk factors in CPSP. 
Key words: TWMR, GWAS, CPSP, SNP  
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Introduction 
Chronic Post-Surgical Pain (CPSP) is a debilitating condition affecting between 5 
and 85% of patients undergoing surgery. CPSP has a large negative impact on the 
quality of life (QoL) and socioeconomic status of the affected patients [1-3]. Both 
clinical (e.g. type of surgery) and demographic (e.g. psychosocial status) risk 
factors have been described to predispose to CPSP, but these do not explain all the 
observed variance. So far, a good understanding about genetic risk factors for 
CPSP is still lacking [1, 4]. The underlying biology of CPSP is complex and not 
yet fully understood and genetic heritability of CPSP is not yet known [5]. Studies 
in other chronic pain syndromes have shown that chronic pain is moderately 
heritable with estimates ranging from 30-70% with a median of 45% [5-9]. 
Candidate gene-based studies on CPSP have shown conflicting evidence [10-13]. 
Thus far, one genome-wide association study (GWAS) has been conducted which 
found one potential genetic risk locus after replication of the top hits [14]. 
Unfortunately, this study was underpowered for a GWAS and larger scale studies 
are necessary to identify risk loci for CPSP. 
Only a small fraction of the disease associated SNPs has been examined 
functionally and the mechanisms underlying the associations explored [15]. Most 
of the disease-associated SNPs identified in GWAS are located in non-protein-
coding regions (e.g. intronic or intergenic regions) and affect the phenotype 
through other mechanisms than altering the protein coding sequence [15]. One 
of the predominant mechanisms is altering gene expression [15]. Gene expression 
is a quantitative trait which is influenced by many factors among which SNPs 
contained in expression quantitative trait loci (eQTLs) [16]. Most genes have 
multiple eQTLs and the interaction between the eQTLs affects the gene expression 
[17].  
The effect of a SNP on gene expression (eQTL) is tissue-specific [18]. Recent 
studies have identified a clear link between neuro-inflammation and chronic pain 
93 | C h a p t e r  4  
[14, 19, 20]. Therefore, not only neuronal tissues are interesting in the context of 
CPSP but also whole blood as a marker for the immune system [21].Combining 
CPSP GWAS summary results with cell-type specific eQTL data can suggest 
credible candidate loci for the prioritization of functional studies [22]. 
Mendelian randomization (MR) is a statistical approach whereby the causal 
relation between an instrument (SNP) in combination with a biological trait 
(eQTL) is explored on an outcome (e.g. CPSP) [23]. This technique can identify 
potentially causal SNPs to follow up in further functional assays. MR has three 
assumption about the instruments that need to be met: 1) sizable association with 
the exposure, 2) no association with any confounder of the relationship between 
exposure and outcome and 3) should only be associated with the outcome through 
the exposure [22]. A recent study has led to the development of transcriptome-
wide Mendelian randomization (TWMR) which meets the assumptions of MR 
better than previous efforts [22].  
The aim of this study was to identify genetic factors associated with the severity of 
CPSP. To do so, we first performed a meta-analysis of three independent surgical 
cohorts, which combined sample size (n=954) increased power to detect risk loci. 
Then, we hypothesized that risk for CPSP was partly conferred in a cell-specific 
fashion via transcriptional mechanisms. We used the transcriptome-wide 
Mendelian randomization approach (TWMR) to screen the entirety of the meta-
analysis results for prioritization of functional SNP using eQTL. 
Methods 
The protocol for this study was reviewed and approved by the local Medical 
Ethical Committees of each independent cohort and all participants gave written 
informed consent. The discovery cohort was registered at the Dutch trial registry 
under the number NTR2702 (http://www.trialregister.nl/trialreg/index.asp). The 
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replication cohort was registered at the Clinical Trials registry under the number 
NCT02002663 and NCT01989351 (https://clinicaltrials.gov/ct2/home). 
Patient enrolment 
An elaborate description of patient recruitment, sample and data collection 
protocols for the three cohorts has been published previously [14, 24-26]. In brief, 
a multicentre cohort study was conducted in four hospitals in the Netherlands 
(hysterectomies, Hys), three hospitals in Italy (abdominal surgeries and knee 
replacements, AbKnee) and one hospital in Pittsburgh USA (mastectomies, 
PMPS). DNA-samples were genotyped at the Department of Genomics at the Life 
and Brain Center, University of Bonn using the Illumina PsychArray (Infinium 
PsychArray-24 v1.2 Bead Chip, Illumina Inc., USA) for the Hys and AbKnee 
cohorts. The PMPS cohort was genotyped using the UK Biobank Axiom platform 
on samples derived from lymph node tissue, blood or saliva at the Genome center 
at McGill University.  
Genotyping and GWAS analysis 
Genotypes were called using BeadStudio (Genome Studio v2011.1, Illumina). 
Basic quality control was done using Plink (Plink-1.9) [27, 28]. The quality control 
parameters consisted of: SNP call rate < 0.95, subject call rate of < 0.95, and 
deviation of Hardy-Weinberg equilibrium (P<1x10-6) and removal of rare variants 
with a minor allele frequency (MAF) <0.05. Heterozygosity of the subjects was 
tested and outliers (±3 SD from the mean heterozygosity rate) were removed. 
Genotype imputation for the all cohorts was performed using the stepwise 
imputation approach implemented in Minimac3 
(https://genome.sph.umich.edu/wiki/Minimac3; University of Michigan, Ann 
Arbor, USA) and Eagle2 (https://data.broadinstitute.org/alkesgroup/Eagle/; Broad 
Institute, Cambridge, USA v2.3) using default parameter settings and a European 
HRC reference panel (http://www.haplotype-reference-consortium.org/; version 
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r1.1 2016 ) [29-31]. Genome-wide association analysis was carried out using Plink 
(Plink-1.9) [27, 28]. The primary outcome measured in the Dutch and USA 
cohorts was the highest surgery-related pain score measured by the Numeric 
Rating Scale (NRS), recorded at rest during the last week, three months post- 
surgery [14, 24]. The primary outcome measured in the Italian cohorts was the 
average surgery-related pain score measured by the Numeric Rating Scale (NRS), 
recorded at rest during the last week, three months post-surgery [14]. The primary 
outcome measure was assessed on a continuous scale. 
Meta-analysis 
Meta-analysis of the three cohorts was conducted using METAL software [32]. A 
fixed-effects standard error weighted meta-analysis was conducted with 
Bonferroni correction applied to account for multiple testing. Before meta-
analysis all datasets and effects were aligned to the 500k UK biobank release to 
ensure matching effect alleles and direction of effects.  
Transcriptome-wide Mendelian randomization 
For the TWMR analysis, four different eQTL datasets were used: Whole blood, 
cervical spinal cord, and cortex datasets from GTEx V7 and DRG dataset described 
by Parisien et al., [33, 34]. The TWMR approach was adapted from Porcu et al., 
[22]. Briefly, SNPs were assigned to genes if they were within 100kb of that gene. 
Next, the eQTLs were identified per tissue and per gene and checked whether they 
were eQTLs for other genes as well. Followed by pruning of the selected eQTLs 
based on an r2 threshold of 0.1, the remaining SNPs were introduced into the 
TWMR script as provided by the manuscript [22]. During pruning, the SNP with 
the highest association to CPSP in the meta-analysis was kept in the analysis. Cell-
type and Tissue specific Protein expression of the genes significantly associated 
with CPSP in the TWMR was assessed using data from the protein abundance 
database [35]. The following human databases were assessed: B cells, CD4 T cells, 
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CD8 T cells, NK cells, Monocytes, Plasma, Platelet, Spinal Cord, Frontal Cortex, 
Cerebral Cortex and Whole brain. If proteins were expressed in B cells, CD4 T 
cells, CD8 T cells, NK cells, Monocytes, Plasma or Platelet database it was 
determined as present in immune cells. Protein expression in Frontal Cortex and 
Cerebral Cortex was determined as present in cortex. Protein expression in Spinal 
Cord, Frontal Cortex, Cerebral Cortex and Whole Brain was determined as 
present in neuronal tissue. 
Results 
In total, genetic data was available on 841 patients after quality controls spread 
across the three cohorts (Hysterectomy cohort n= 303, Abdominal and Knee 
replacement cohorts n= 77, PMPS cohorts n = 461). Out of the 841 patient 
included in the analysis, 204 developed moderate to severe CPSP (NRS >3, 24%) 
and 637 controls minor to no CPSP (NRS <4, 76%).  
Ethnicity of all cohorts was checked using HapMap data and subject deviating 
from Caucasian background were excluded. After quality control, imputation, 
and datasets alignment, roughly 5 million SNPs per cohort were included in the 
meta-analysis. Overall association results are depicted in figure 1a. The QQ plot 
shows no apparent deviation from the null hypothesis of the p values distribution 
(figure 1 b, lambda=1.02). One locus reached the genome-wide significance 
threshold (p = 2.83e-8,  = -1.46, se = 0.26, rs17882261) with the closest located gene 
being SFTPA2 (surfactant protein 2A) (table 1). This locus was associated in two 
of three cohorts (Hys and AbKnee) but the allelic frequency was too low in the 
PMPS cohort to be tested. Other possible risk loci were identified but these did 
not reach genome-wide significance (table 1). 
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Figure 1: Manhattan plot and quantile-quantile plot 
representing the results of the genome-wide association 
studies meta-analysis. (a) Manhattan plot representing 
the association between SNP and the severity of CPSP. 
The negative log10 p values (y-axis) are plotted against 
the chromosomal positions of the SNPs. The red dotted 
line indicates the level of genome-wide significance (p< 
5.0x10-8). (b) QQ plot of genotyped and imputed SNPs. 
Observed p values are plotted against the expected p 
vales. The lambda of 1.015688 indicates are minor 
genomic inflation corroborated by the near perfect 
A 
B 
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MARKER 
NAME 
Β SE P-
VALUE 
DIRECTION HETPVAL GENE 1 GENE 
2 
rs17882261 -1.46 0.26 2.83E-8 --? 0.01 SFTPA2 - 
rs146170439 2.38 0.44 6.82E-8 ?+? 1 - - 
rs11062375 1.08 0.21 2.56E-07 +++ 0.22 ITFG2 - 
rs1795902 0.64 0.12 3.33E-07 ++? 0.26 SLC16A7 - 
rs1693614 -0.64 0.12 3.33E-07 --? 0.26 SLC16A7 - 
rs4760299 0.64 0.12 3.33E-07 ++? 0.26 SLC16A7 - 
rs1693616 0.63 0.12 3.90E-07 ++? 0.25 SLC16A7 - 
rs80036206 2.53 0.50 4.19E-07 ??+ 1 SLC38A8 - 
rs58672943 -1.19 0.24 5.53E-07 --? 0.10 - - 
rs75714914 1.74 0.35 5.73E-07 ?+? 1 LOC105374715 - 
rs1693622 -0.61 0.12 8.78E-07 --? 0.18 SLC16A7 - 
rs17834697 0.99 0.20 9.41E-07 +++ 0.55 NRIP2 ITFG2 
rs79107778 -1.58 0.32 1.13E-06 -?? 1 XKR6 - 
rs7035861 -0.65 0.13 1.18E-06 --- 0.05 - - 
rs72712948 1.10 0.23 1.36E-06 ++? 0.53 - - 
rs10810872 -0.70 0.15 1.52E-06 --- 0.13 - - 
rs11062371 -0.98 0.20 1.67E-06 --- 0.58 NRIP2 ITFG2 
rs13380582 -2.35 0.49 1.69E-06 ??- 1 SLC38A8 - 
rs56155031 -1.08 0.23 2.07E-06 --? 0.46 - - 
rs1871553 1.86 0.39 2.16E-06 ?+? 1 SSPN - 
rs2046066 -1.86 0.39 2.16E-06 ?-? 1 SSPN - 
rs7304527 1.86 0.39 2.16E-06 ?+? 1 SSPN - 
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Table 1 (previous page): Results of the meta-analysis on the summary statistics of three independent chronic 
postsurgical pain cohorts. Results are shown per SNP including the direction of the SNP in the various 
cohorts, heterozygosity across the cohorts and associated genes. The order in the direction column is Hys cohort, 
AbKnee cohort and PMPS cohort. SE = standard error, HetPval = p-value of the heterogeneity of minor allele 
frequencies, + = minor allele is associated with an increased severity of CPSP, - minor allele is associated with 
a decrease severity of CPSP and ? = minor allele was not tested in that cohort. HUGO gene symbols are: 
integrin alpha FG-GAP repeat containing 2, ITFG2; solute carrier family 16, member 7, SLC16A7; 
Surfactant protein 2A, SFTPA2; nuclear receptor interacting protein 2, NRIP2; solute carrier family 38 
member 8, SLC38A8; X Kell Blood Group Precursor-Related Family, Member 6, XKR6. 
To assess the potential causal relationship between SNPs associated with severity 
of CPSP we employed TWMR. In this approach the summary statistics of the 
meta-analysis were used as instrument variables, the association of those same 
SNPs and gene-expression in the four tissues studied was set as exposure variable 
and the severity of CPSP as outcome. The TWMR approach meets most of the 
assumptions of Mendelian randomization as it takes into account both the 
association between SNPs and gene-expression per tissue and clusters the SNPs 
and gene-expression data which is related to overcome pleiotropy.  
In total, 1,391 unique potential causative genes were associated significantly with 
CPSP, 5 were significantly associated in all for tissue expression sets and 21 genes 
were significant in all the neuronal tissues (supplementary table 1, 2 and 3). In 
whole blood 250 potential causative genes were associated with CPSP, 579 in the 
cortex, 392 in the spinal cord and 423 in the DRG (figure 2 a-d, figure 3). The 5 
genes significantly associated with CPSP in the TWMR analysis across all 4 tissues 
were DFNA5, NTPCR, HEATR3, NSA2 and SFXN4 (table 2). All the genes show 
significant association levels in all four tissues. Rs6883420 (NSA2) is the only SNP 
involved in all the eQTL blocks across the tissues. The 21 genes significantly 
associated with CPSP in the TWMR analysis across all 4 tissues were DFNA5, 
NTPCR, HEATR3, NSA2, SFXN4, SNAP29, EPCAM, C9orf89, PITRM1, VPS8, 
DCXR, SLC2A8, STYXL1, ATP5G2, SLC25A34, RPA2, ULK4, NKAIN4, PEX5, 
TMPRSS5 and EPHX2 (table 3). Rs113768745 (SNAP29), rs4744176 (C9orf89), 
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rs62289500 (VSP8), rs41301427 (STYXL1) and rs6883420 (NSA2) were SNPs 
involved in all the eQTL blocks in the neuronal tissues (table 3). 
Table 2: TWMR analysis results of the genes significantly associated with CPSP in all tissues. Results of the 
TWMR analysis are given per tissues including the SNPs forming the eQTL block entered into the analysis. 
eQTL = expression quantitative trait loci, HUGO ID =human genome organisation id, SNP = single 
nucleotide polymorphism, DRG = dorsal root ganglion, SC = spinal cord. 
HUGO 
ID 
Blood p-
value 
eQTL SNPs 
blood 
DRG p-
value 
eQTL SNPs 
in the DRG 
SC p-
value 
eQTL SNPs 
in the SCc 
Cortex p-
value 
eQTL SNPs 
in the cortex 
DFNA5 2.78E-07 rs2721777, 
rs17208431, 
rs1476521 
9.90E-
65 
rs2074142, 
rs7809654, 
rs34081711 
1.84E-
06 
rs2721777 2.42E-09 rs2074142, 
rs79724368, 
rs10270198, 
rs2721806 
SFXN4 1.31E-08 rs11198804, 
rs12774592, 
rs12414175, 
rs11198805 
6.33E-
12 
rs7923486 1.13E-
09 
rs7923486 7.32E-12 rs11198804, 
rs11198805 
NTPCR 3.71E-07 rs743196, 
rs72759978, 
rs16858464, 
rs6676972 
2.57E-
11 
rs743196 1.75E-
21 
rs17355525 4.65E-20 rs743196, 
rs72759978 
HEATR3 2.35E-08 rs35098361 1.41E-
08 
rs71138029 5.53E-
16 
rs35098361 7.47E-16 rs35098361 
NSA2 5.37E-09 rs6883420, 
rs3968877 
3.90E-
08 
rs6883420 1.29E-
07 
rs6883420 6.67E-08 rs6883420 
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Figure 2: Volcano plots of the TWMR analysis results per tissue. (a) TWMR analysis results in whole blood. 
–log10 TWMR association p-value plotted on y-axis against the effect size alpha on the x-axis. Top 15 genes 
are annotated and all genes are identified based on protein expression in either neuronal tissue, immune 
cells, both or other. (b) TWMR analysis results in the dorsal root ganglion. –log10 TWMR association p-value 
plotted on y-axis against the effect size alpha on the x-axis. Top 17 genes are annotated and all genes are 
identified based on the protein expression in the cortex. (c) TWMR analysis results in the Spinal cord. –log10 
TWMR association p-value plotted on y-axis against the effect size alpha on the x-axis. Top 22 genes are 
annotated and all genes are identified based on the protein expression in the spinal cord. (d) TWMR analysis 
results in the cortex. –log10 TWMR association p-value plotted on y-axis against the effect size alpha on the 
x-axis. Top 20 genes are annotated and all genes are identified based on the protein expression in either 
neuronal tissue, immune cells, both or other.  
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Figure 3: Venn diagram showing the number of overlapping genes across the four eQTL datasets tested in the 
TWMR analysis. Four distinct eQTL datasets were used in the analysis (Blood, DRG, Spinal cord and 
Cortex). The number under each category indicates the number of significant genes per category whereas the 
numbers in the Venn diagram indicates the overlap across the tissues. 
Table 3 (next page): TWMR analysis results of the genes significantly associated with CPSP in neuronal 
tissue. Results of the TWMR analysis are given per tissues including the SNPs forming the eQTL block entered 
into the analysis. eQTL = expression quantitative trait loci, ENSG ID = Ensembl ID, HUGO ID =human 
genome organisation id, SNP = single nucleotide polymorphism, DRG = dorsal root ganglion, SC = spinal 
cord. 
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HUGO ID DRG p-
value 
eQTL SNPs in 
the DRG 
SC p-
value 
eQTL SNPs in 
the SCc 
Cortex p-
value 
eQTL SNPs 
in the cortex 
DFNA5 9.90E-65 rs2074142, 
rs7809654, 
rs34081711 
1.84E-06 rs2721777 2.42E-09 rs2074142, 
rs79724368, 
rs10270198, 
rs2721806 
SNAP29 8.77E-50 rs113768745, 
rs178068 
7.19E-30 rs113768745 1.40E-32 rs113768745 
EPCAM 1.35E-32 rs4953495, 
rs7581007 
2.45E-19 rs77131614 4.32E-19 rs77131614 
C9ORF89 2.87E-26 rs4744176, 
rs13286624 
1.09E-31 rs4744176, 
rs2027585 
3.30E-12 rs4744176, 
rs2027585 
PITRM1 6.70E-21 rs7898754 5.94E-07 rs9423505 2.12E-29 rs11251754, 
rs76496015, 
rs7898754, 
rs7903088 
VPS8 9.01E-21 rs62289500 1.18E-18 rs62286934 6.82E-14 rs62286934, 
rs7640976 
DCXR 7.88E-20 rs72861756 3.54E-17 rs56001523 1.20E-06 rs56001523 
SLC2A8 1.43E-15 rs10987643 1.28E-11 rs1138740 1.60E-06 rs1138740, 
rs17464948 
STYXL1 1.68E-15 rs41301427 1.45E-10 rs41301427 5.04E-09 rs41301427, 
rs3779419 
ATP5G2 2.44E-15 rs7312853 2.69E-10 rs11170643 3.51E-11 rs11170643 
SFXN4 6.33E-12 rs7923486 1.13E-09 rs7923486 7.32E-12 rs11198804, 
rs11198805 
NTPCR 2.57E-11 rs743196 1.75E-21 rs17355525 4.65E-20 rs743196, 
rs72759978 
SLC25A34 2.78E-11 rs937592 1.48E-10 rs35365738 3.01E-13 rs35365738 
RPA2 1.11E-10 rs28904914 4.60E-56 rs17185052 1.23E-65 rs17185052 
ULK4 3.40E-10 rs7652369 4.41E-12 rs145684897 3.88E-11 rs145684897, 
rs994439 
HEATR3 1.41E-08 rs71138029 5.53E-16 rs35098361 7.47E-16 rs35098361 
NKAIN4 2.66E-08 rs6011700 2.83E-10 rs147378830 6.17E-08 rs58229940, 
rs2281566 
NSA2 3.90E-08 rs6883420 1.29E-07 rs6883420 6.67E-08 rs6883420 
PEX5 9.53E-08 rs7975045 7.61E-08 rs1450962 6.37E-07 rs1450962 
TMPRSS5 1.45E-07 rs4938050 3.15E-07 rs4938050 3.84E-11 rs7103478 
EPHX2 2.04E-06 rs4149259 5.25E-07 rs1126452 2.52E-09 rs7816586, 
rs28368998 
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Discussion 
The results of this study present the first genome-wide significant risk locus for 
chronic postsurgical pain in a meta-analysis of three different cohorts. 
Furthermore, the TWMR analysis has shown tissue-specific potential causal genes 
to be significantly associated with CPSP. Five genes showed a significant 
association across all tissues (whole blood, cortex, spinal cord and DRG) and 21 
genes showed a significant association in all neuronal tissue (cortex, spinal cord 
and DRG).  
A fixed effect meta-analysis weighted by the standard error was performed on the 
summary statistics of GWAS data of three independent cohorts (Hys, AbKnee and 
PMPS). The findings indicate a possible risk locus for CPSP centred on rs17882261 
with the nearest gene being surfactant protein 2A (SFTPA2). This SNP has not 
been associated before in any GWAS or study on pain [36, 37].  
The TWMR analysis with multiple instruments and multiple exposures identified 
potential causal genes associated with CPSP. The power of the TWMR analysis is 
the possibility to identify tissue specific associated genes by focusing on single 
tissue results as well as identifying trends across tissues. In this study, two tissue 
sets (Whole blood focusing on immune cells and neuronal tissue comprised of 
DRG, spinal cord and cortex tissue) were used to prioritize potential causal genes 
associated with CPSP. 5 genes were associated with CPSP in the TWMR analysis 
in both tissue sets (DFNA5, SFXN4, NTPCR, HEATR3 and NSA2). Rs6883420 in 
NSA2 is a potential candidate as it was in the eQTL block for each tissue. In the 
neuronal tissue, 21 genes were identified who were associated with CPSP in the 
TWMR analysis. Of these genes, rs113768745 (SNAP29), rs4744176 (C9orf89), 
rs62289500 (VSP8), rs41301427 (STYXL1) and rs6883420 (NSA2) were SNPs 
involved in all the eQTL blocks in the neuronal tissues. Rs62289500 (VPS8) is an 
intronic variant within Vacuolar Protein Sorting-Associated Protein 8 Homolog 
and this gene has been associated the immune system, brain morphology and 
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cognitive performance [36]. Rs113768745 (SNAP29) is an intronic variant within 
synaptosome associated protein 29 and members of this gene family have been 
associated with fibromyalgia [37, 38]. Loss of SNAP29 has been associated with a 
decrease in endocytic recycling within the cell and a decrease in cell motility. This 
led to a dysfunctional wound healing and neurological abnormalities [39, 40]. 
Furthermore, SNAP29 is involved in synaptic vesicle trafficking, specifically 
inhibiting synaptic transmission in an activity dependent manner and involved in 
mast cell phagocytosis [41, 42]. This combined evidence indicates a modulatory 
role for fine-tuning cellular growth and immune cell functioning and alterations 
to the expression of this gene could affect repair mechanisms contributing to the 
development of chronic pain. The other genes have not been associated in any 
GWAS or study on pain [36, 37]. These findings suggest a potential role for both 
the immune system and nervous system in the pathophysiology of CPSP. 
The findings of this study could be utilised in clinical practice in risk prediction 
modelling. Polygenic risk scores (PRS) are computed by the sum of risk alleles for 
a given phenotype weighted by the effect size estimate provided by a GWAS and 
it indicates an increased or decreased likelihood in developing a phenotype [43]. 
PRSs have been successfully applied in prediction and response to medication of 
both psychological disorders and migraine [44-48]. Research in diabetes and 
oncology have shown that PRSs could have a higher predictive accuracy than 
currently available prediction models [49]. Combining the clinical and genetic 
risk predictions could lead to an additive effect whereby both influence each other. 
A recent clinical prediction model on CPSP showed an increase in predictive 
power by adding a single SNP to the model [50]. Although this increase was not 
significant, including a complete PRS would definitively lead to a significantly 
improved prediction model [50]. 
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The potential causative genes for CPSP identified in this study are not definitive 
yet. More efforts are necessary to shed light on the biological mechanisms of these 
association [15]. However, these results do function as a prioritized list of SNPs 
and genes to follow-up upon. Experimental studies in in vitro models (i.e. cell 
cultures) and in vivo models (e.g. zebrafish or mice) are necessary to understand 
the biological effects of altered gene-expression both on cellular level and on the 
whole organism [51]. Recent techniques, including CRISPR-Cas9, have made it 
possible to introduce specific mutations and study there effects. As these 
techniques mature, their specificity and effectiveness will increase further [51-53]. 
Furthermore, larger sample size is necessary in both the GWAS studies on CPSP 
and the eQTL datasets. Larger sample sizes will lead to better estimate of 
association, effects sizes and in the case of eQTL datasets better inventory of 
possible pleiotropic effects [22]. This will lead to a better prioritization and more 
accurate results.  
In conclusion, this study has identified the first genome-wide significant locus 
associated with the severity of CPSP and both tissue specific as well as combined 
tissue set specific potential causative genes. The identified locus and genes are in 
need of further functional follow-up studies to identify underlying biological 
mechanisms and confirm the potential causal relationship. Larger sample sizes 
and follow-up studies are necessary to further increase the accuracy and efficiency 
of the techniques employed in this study. 
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Abstract 
Chronic Post-Surgical Pain (CPSP) is a debilitating chronic pain condition that has a 
substantial effect on quality of life. CPSP shows considerable clinical overlap with 
different chronic peripheral pain syndromes which suggests a shared aetiology. However, 
why some patients develop CPSP whereas others do not, and the nature of underlying 
molecular processes that contribute to chronic pain, are incompletely understood. This 
study aims to assess whether different chronic pain syndromes show genetic overlap with 
CPSP and to provide relevant biological context for potential chromic pain markers of 
CPSP.  
To analyse the genetic overlap between CPSP and chronic peripheral pain syndromes, 
recent GWAS studies were combined for polygenic risk scores (PRS) analysis, using 
patients who developed CPSP and those who did not as a starting point. Biological 
contextualisation of shared genetic markers overlap between CPSP and chronic pain 
syndromes was assessed using Gene Ontology (GO) and Pathway Scoring Algorithm 
(PASCAL). 
A significant genetic overlap was found between 3 of CPSP and chronic pain disorders: 
Sciatica (p value threshold = 0.00025, R2 = 0.03, p = 0.045), Chronic widespread pain (p 
value threshold = 0.003, R2 0.06, p = 0.003) and Rheumatoid arthritis (p value threshold = 
0.0177, R2 = 0.04, p = 0.017). No significant genetic overlap was found with osteoarthritis, 
cluster headache and migraine. The GO analyses suggested an aetiological involvement of 
genetic markers that control neurological signalling (specifically sodium channels) and 
inflammatory response. 
In conclusion, this study is the first to report genetic overlap between regulatory processes 
implicated in CPSP and chronic peripheral pain syndromes. The genes involved in the 
genetic overlap are related to the regulation of neurological signalling and inflammatory 
responses. Enhanced understanding of mechanisms underlying chronification of pain will 
aid the development of new preventative therapeutic strategies for CPSP.  
Key words: PRS, chronic pain, CPSP, SNP  
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Introduction 
Chronic Post-Surgical Pain (CPSP) is a debilitating chronic pain condition that 
affects patients who underwent surgery and has a substantial effect on the quality 
of life (QoL) and socioeconomic status [1-3]. CPSP is defined as “pain developed or 
increased after a surgical procedure, which is present for at least three months, and 
affecting the QoL” [4, 5]. Depending on the type of surgery, 5-85% of the patients 
may experience pain localized to the surgical field or the projected innervation 
area of a nerve [4, 6]. Clinical (e.g. type/duration of surgery), demographical (e.g. 
age, biological sex) and psychological (e.g. anxiety) risk factors of CPSP can 
account for 78% of the variance in the development of CPSP [7, 8]. Although 
recent evidence (both GWAS and gene-targeted studies) defines a potential role 
for genetic risk factors in CPSP, the limited CPSP sample size in comparison to 
studies of other chronic pain syndromes has thus far not provided clear candidate 
genes for CPSP [9-12]. While increasing sample size for GWAS analyses holds the 
potential for unambiguous identification of genetic risk factors, genetic 
mechanisms underlying CPSP may be probed indirectly by determination of 
common genetic factors with other pain syndromes. Polygenic risk scores (PRS) 
allow testing for genetic correlation (i.e. overlap) between different phenotypes 
[13, 14]. Establishing the intersection and/or overlap of genetic networks between 
various chronic pain syndromes may help define common mechanisms in chronic 
pain and provide starting points for functional and intervention studies. 
CPSP shows considerable overlap with different chronic peripheral pain 
syndromes (CPPs), among which sciatic pain, chronic widespread pain, 
osteoarthritis and rheumatoid arthritis with regard to demographical and 
psychological risk factors: chronic pain occurs most often in women, is associated 
with age and with psychological syndromes [15-17].  
Although such observational studies suggest a shared aetiology between CPSP and 
chronic peripheral pain syndromes, the identity and interplay of underlying 
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genetic causes and molecular processes that contribute to chronic pain, are 
incompletely understood [15-17]. Therefore, this study aims to assess whether 
different chronic pain syndromes show genetic overlap with CPSP and to provide 
relevant biological context for potential genetic risk factors. Ultimately, 
identification of novel targets is expected to pave the way for a better 
understanding of cellular and molecular mechanisms in CPSP and provide 
therapeutic opportunities.  
Methods 
To assess whether chronic pain syndrome show genetic overlap with CPSP, we 
assessed several available datasets against a discovery and replication cohort of 
CPSP patients. The protocol for this study was reviewed and approved by the local 
Medical Ethical Committees (both discovery and replication study); all 
participants have provided written informed consent. The discovery cohort was 
registered at the Dutch trial registry under the number NTR2702 
(http://www.trialregister.nl/trialreg/index.asp). The replication cohort was 
registered at the Clinical Trials registry under the number NCT02002663 and 
NCT01989351 (https://clinicaltrials.gov/ct2/home). 
Genome-wide association analysis  
An elaborate description of patient recruitment, sample and data collection 
protocols for the discovery and replication cohorts has been published elsewhere 
[8, 9, 18]. In brief, a multicentre cohort study was conducted in four hospitals in 
the Netherlands (discovery cohort, n = 303) and three hospitals in Italy (replication 
cohort, n = 77). DNA-samples were genotyped at the Department of Genomics at 
the Life and Brain Center, University of Bonn using the Illumina PsychArray 
(Infinium PsychArray-24 v1.2 Bead Chip, Illumina Inc., USA). Genotypes were 
called using BeadStudio (Genome Studio v2011.1, Illumina). Basic quality control 
was done using Plink (Plink-1.9) [19, 20].  
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The quality control parameters consisted of: SNP call rate < 0.95, subject call rate 
of < 0.95, deviation of Hardy-Weinberg equilibrium (P<1x10-6) and removal of rare 
variants with a minor allele frequency <0.01. Heterozygosity of the subjects was 
tested and outliers (±3 SD from the mean heterozygosity rate) were removed. 
Genotype imputation was performed using the stepwise imputation approach 
implemented in Minimac3 (https://genome.sph.umich.edu/wiki/Minimac3; 
University of Michigan, Ann Arbor, USA) and Eagle2 
(https://data.broadinstitute.org/alkesgroup/Eagle/; Broad Institute, Cambridge, 
USA v2.3) using default parameter settings and a European HRC reference panel 
(http://www.haplotype-reference-consortium.org/; version r1.1 2016 ) [21-23]. 
GWAS was carried out using SNPTEST v2.5.4 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html; Oxford 
University, Oxford, United Kingdom) [24, 25]. The primary outcome measured in 
the discovery cohort was the highest surgery-related pain score measured by a 
Numeric Rating Scale (NRS), recorded at rest during the last week, three months 
post- surgery [8, 9]. Based on the primary outcome measure, patients were divided 
into a non-CPSP (NRS=0) and a CPSP (NRS >3) group. 
Cohort selection for polygenic risk score calculation 
To analyse the genetic overlap between CPSP and chronic peripheral pain 
syndromes, recent GWAS studies were used to form PRS scores in order to 
differentiate between patients who developed CPSP and those who did not. Using 
PubMed, we identified 6 GWAS reports on chronic pain syndromes (sciatic pain, 
migraine, chronic widespread pain, osteoarthritis, rheumatoid arthritis and cluster 
headache) meeting the inclusion criteria [11, 12, 26-30]: The headache related 
disorders (migraine and cluster headache) were selected as negative control due to 
a different pathophysiology [31, 32]. 7,208 SNPs were reported as summary 
statistics in migraine, of which 214 were present after pruning in the discovery 
cohort and 207 after pruning in the replication cohort [11]. 14,167 SNPs were 
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reported as summary statistics in cluster headache, of which 6,906 were present 
after pruning in the discovery cohort and 7,438 after pruning in the replication 
cohort [28]. 89 SNPs were reported as summary statistics in chronic widespread 
pain, of which 34 were present after pruning in the discovery cohort and 35 after 
pruning in the replication cohort [26]. 129 SNPs were reported as summary 
statistics in osteoarthritis, of which 74 were present after pruning in the discovery 
cohort and 76 after pruning in the replication cohort [27]. 297,081 SNPs were 
reported as summary statistics in rheumatoid arthritis, of which 50,294 were 
present after pruning in the discovery cohort and 51,834 after pruning in the 
replication cohort [29]. 380,066 SNPs were reported as summary statistics in 
sciatica, of which 20,744 were present after pruning in the discovery cohort and 
19,053 after pruning in the replication cohort [12]. All SNPs included in the 
analysis per study per cohort can be found in supplementary file 1. 
Table 1 Articles included in the PRS analysis 
AUTHOR YEAR CONDITION POPULATION SEX SAMPLE SIZE 
(CASES – CONTROLS) 
SNPS 
REPORTED 
van Reij et al., 2019 Chronic Post-
Surgical Pain 
European 
Ancestry 
Women 439 
(45 – 394) 
6,241,991 
Gormley et al., 2016 Migraine European 
ancestry 
Men & 
Women 
375,752 
(59,674-316,078) 
7,208 
Bacchelli et al., 2016 Cluster 
Headache 
Italian Men & 
Women 
458 
(99 – 359) 
14,167 
Peters et al., 2013 Chronic 
widespread 
pain 
European 
ancestry 
Women 16,568 
(2,788–13,780) 
89 
Zeggini et al., 2012 Osteoarthritis European 
ancestry 
Men & 
Women 
50,411 
(7,473 – 42,938) 
129 
Plenge et al., 2007 Rheumatoid 
arthritis 
North America 
and Sweden 
Men & 
Women 
3,372 
(1522 – 1850) 
297,081 
Lemmela et al., 2016 Sciatica Finnish Men & 
Women 
3,961 
(291 – 3,671) 
380,066 
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Shared genetic background analysis 
The polygenic risk score analysis tool PRSice, was used to determine genetic 
overlap between chronic pain syndromes and CPSP [33]. Summary statistics of 
published studies on chronic pain syndromes were used as ‘reference dataset and 
the data of the discovery and replication cohorts after quality control (described 
in the original publication) as ‘target phenotype’ sample [9, 11, 12, 26-29]. The 
target phenotype was considered a dichotomous variable, defined as presence of 
CPSP (yes or no) and the base phenotypes were used to differentiate between 
presence and absence of CPSP.  
PRS analysis settings comprised pruning based on linkage disequilibrium (r2 >0.1) 
within a 250 kb window and incrementally increasing summary statistic p-value 
threshold starting at p<0.0001 (increasing with increments of 0.00005) [34]. This 
determines optimal SNPs fit with regard to predicting polygenic risk score. 
Identical parameters were used for the discovery and replication cohorts. 
Pathway analysis 
Biological context for potential genetic overlap between CPSP and chronic pain 
syndromes was assessed using Pathway Scoring Algorithm (PASCAL) [35]. The 
input data consisted of all SNPs of significant PRSs for both the discovery cohort 
and the replication cohort using p-values reported in the original publications [12, 
26, 29]. Pathway scoring was done using the biological processes (BPGO), 
molecular function (MFGO) and cell component (CCGO) databases of the gene 
ontology resource (GO) [36, 37]. Pathway enrichment was assessed by comparing 
enrichment score of the provided gene-sets with a random sampling permutation-
based distribution per pathway. To correct for multiple testing the empirical p-
values of the PASCAL enrichment were corrected using the p.adjust function with 
false discovery rate (FDR) in R [38, 39]. Clustering of GO terms were visualized 
using REVIGO based on GO id’s and PASCAL p-values with similarity set to 
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small, similarity measure to SimRel and using the uniport database as a reference 
[40]. 
Statistics 
GWAS data was analysed using logistic regression and the p-values were corrected 
for the number of SNPs analysed using Bonferroni correction. PRSice was used to 
determine polygenic risk scores of SNPs obtained from analysis of the base dataset 
weighted by their respective effect sizes [34]. The PRS scores were calculated 
assuming an additive model with the following equation: 
 
Where S denotes the summary statistics for the effective allele of SNP i, G denotes 
the number of effective alleles observed for individual j for SNP i and M denotes 
the number of alleles included in the PRS of the individual j. Significance was set 
at p ≤ 0.05. All graphs were visualized using R [39]. 
Results 
Analysis of genetic overlap between chronic pain syndromes and CPSP discovery cohort 
PRS was used to assess genetic overlap between the chronic pain phenotypes and 
the discovery cohort of CPSP. A significant genetic overlap was found between 3 
of CPSP and chronic pain disorders: Sciatica (p value threshold = 0.00025, R2 = 
0.03, p = 0.045), Chronic widespread pain (p value threshold = 0.003, R2 0.06, p = 
0.003) and Rheumatoid arthritis (p value threshold = 0.0177, R2 = 0.04, p = 0.017). 
No significant genetic overlap was found with osteoarthritis, cluster headache and 
migraine (Figure 1, supplementary table 1). This finding suggested significant 
genetic overlap between sciatica, chronic widespread pain and rheumatoid 
arthritis and CPSP but no genetic overlap between cluster headache, migraine and 
osteoarthritis and CPSP. 
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Figure 1: graphic representation of the genetic overlap between different chronic pain syndromes and CPSP 
discovery cohort. Y axis depicts variance explained by the polygenic risk score, x axis depicts the different 
phenotypes and the numbers indicate the p-values of the polygenic risk scores. Mi = migraine, Sc = sciatica, 
CWP = chronic widespread pain, RA = rheumatoid arthritis, OA = osteoarthritis. 
Validation of genetic overlap in CPSP replication cohort 
To validate the discovery cohort-based findings on genetic overlap between CPSP 
and chronic pain syndromes, the PRS analysis was independently repeated in the 
replication cohort. Consistent with the outcome of the discovery cohort, a 
significant genetic overlap was observed with four of the chronic pain disorders 
and CPSP: Sciatica (p value threshold = 0.00385, R2 = 0.08, p = 0.045), Chronic 
widespread pain (p value threshold = 0.141, R2 0.21, p = 0.0003), Rheumatoid 
arthritis (p value threshold = 0.3549, R2 = 0.23, p = 0.002) and Osteoarthritis (p 
value threshold = 0.0001, R2 = 0.11, p = 0.022) (Figure 2, supplementary table 2). 
No significant genetic overlap was found between cluster headache and migraine 
and CPSP.  
123 | C h a p t e r  5  
Figure 2: graphic representation of the genetic overlap between three chronic pain syndromes and CPSP 
replication cohort. Y axis depicts variance explained by the polygenic risk score, x axis depicts the different 
phenotypes and the numbers indicate the p-values of the polygenic risk scores. Mi = migraine, Sc = sciatica, 
CWS = chronic widespread pain, RA = rheumatoid arthritis, OA = osteoarthritis. 
Pathway analysis of genes associated with significant polygenic risk scores 
To assess the biological context defined by common genetic markers of chronic 
pain disorders and CPSP an exploratory pathway analysis was performed cohorts 
using Pathway Scoring Algorithm (PASCAL) [35]. In agreement with published 
instruction, pathway analysis was limited to SNPs that showed significant genetic 
overlap in both the discovery and replication cohorts [35]. The findings of the 
PASCAL analysis were clustered using REVIGO [40]. BPGO revealed enrichment 
for 3 terms at FDR <1%, 17 terms at FDR <= 5%, 9 terms at FDR <= 10% and 26 
terms at FDR <= 15% (figure 3a, supplemental table 3). These terms clustered into 
4 main clusters: Protein phosphorylation, Positive regulation of signalling, Response to 
cytokine and Cation transport (supplemental figure 1). CCGO revealed enrichment 
for 1 term at FDR <1%, and 1 term at FDR <5% (figure 3b, supplemental table 4). 
The terms associated with cellular components clustered into 3 main clusters: 
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Endoplasmatic reticulum, Sodium channel complex, intrinsic component of plasma 
membrane (supplemental figure 2). MFGO revealed enrichment for 3 terms at FDR 
< 10% (figure 3c, supplementary table 5). The terms associated with molecular 
functions clustered into 5 main clusters: Identical protein binding, Phosphoric ester 
hydrolase activity, Metal ion transmembrane transporter activity, Phosphatidylinositol 
binding and Sodium channel regulator activity (supplemental figure 3). Taken 
together, the clusters identified by the GO analyses suggested an aetiological 
involvement of genetic markers that control neurological signalling and 
inflammatory response. 
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Figure 3: graphic representation of GO analyses on genetic factors with significant PRS scores. Lollipop plots 
represent the top 20 associations of GO terms with the respective GO databases. Dotted lines represent FDRs 
of 15% (black), 10% (yellow), 5% (orange) and 1 % (red), respectively. 
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Discussion 
The present report is the first to study genetic overlap between different chronic 
peripheral pain syndromes (CPPs) and CPSP based on polygenic risk score (PRS) 
analysis. We hypothesized that CPSP shares biological mechanisms and hence 
genetic factors with some of the known chronic pain syndromes (sciatic pain, 
chronic widespread pain, osteoarthritis and rheumatoid arthritis). Polygenic risk 
score analyses show significant genetic overlap between CPSP and CPPs (sciatica, 
chronic widespread pain and rheumatoid arthritis) but not with osteoarthritis or 
common headache phenotypes (migraine or cluster headache). Functional 
enrichment analysis using PASCAL and REVIGO implicate the genes identified 
in the genetic overlap to be involved in regulation of neurological signalling and 
inflammatory response.  
Shared mechanisms in CPSP and peripheral pain syndromes 
The three CPP subtypes that showed genetic overlap with CPSP in both cohorts 
are known to affect peripheral nerves directly [16, 17, 41]. Sciatica involves nerve 
compression such as intervertebral disc rupture (the most common cause of 
sciatica) and other non-spinal causes of sciatica (e.g. gynaecologic causes or 
traumatic injury) [16]. In chronic widespread pain, both central and peripheral 
sensitization play a role, involving peripheral acid-sensing ion channels, decreased 
density of epidermal nerve fibres and pro-inflammatory cytokines [41, 42]. 
Rheumatoid arthritis (RA) originates in the immune system: pain originates from 
the affected joints, where inflammatory cytokines sensitize peripheral nociceptors 
or modify receptor activation thresholds [17]. All the processes underlying the 
above mentioned chronic peripheral pain syndromes have been associated with 
the chronification of postsurgical pain as well [43].  
Chronic headache disorders (migraine and cluster headache) show a different 
pathophysiology. In these disorders there is a clear involvement of the vasculature 
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and part of the pathophysiology seems to stem from an asynchrony in cortical 
processing [31, 32]. Migraine occurs mostly in women and pain develops by an 
interplay between vasculature, nerve innervation of both dura and skull and 
central nervous processing [31]. Cluster headaches (CH) classifies as a severe 
headache disorder occurring mostly in men, where the pathophysiology is 
thought to comprise synchronised abnormal activity in the hypothalamus, 
trigeminal vasculature and central nervous processing [32]. CGRP is a key player 
in both cluster headaches and migraine pathophysiology which is a potent 
vasodilator but was also shown to modulate activity of trigeminal neurons [31, 
32]. Our genetic analyses suggest CPSP is aetiologically distinct from CH and 
migraine; the link between vasculature and nervous systems may explain these 
differences. 
Consistent with the results in our study, comparative twin studies report only a 
low phenotypic correlation between CWP and migraine indicating them to be 
aetiologically distinct subgroups. However, a high correlation between CWP and 
low back pain was found indicative of an overlap between two different CPPs and 
more closely related aetiologically [44, 45]. This provides further evidences for the 
lack of genetic overlap between CPSP and headache related disorders.  
Comparison and genetic overlap between CPSP and Osteoarthritis (OA) resulted 
in ambiguous outcome, as it showed no consistent genetic overlap with the CPSP 
cohorts used. OA, is caused by a degenerative articular cartilage condition and also 
involves the immune system, matrix proteins and metalloproteinases [46, 47]. The 
pathophysiology of the disease is diverse and complex, and frequently involves 
increased innervation and vascularization in the diseased joint [47]. The discovery 
cohort consists solely of patients who underwent a hysterectomy whereas the 
replication cohort is a mixture of knee and abdominal surgeries [46]. Since the 
knee is often affected in osteoarthritis, it could be that the genetic overlap is due 
to the location of the surgery indicating more of a genetic overlap between the 
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indication for the surgery and OA than CPSP and OA [46]. Secondly, the 
inconsistency could be due to a difference in sample size between cohorts: the 
sample size of the replication cohort is roughly 1/3 of the size of the discovery 
cohort. The size of the target sample (the discovery and replication cohorts in this 
study) is correlated with the reliability of the variance explained [48]. This 
indicates that genetic overlap found with the discovery cohort is a better estimate 
for the true genetic overlap. Therefore, pathway analysis was conducted without 
inclusion of the SNPs underlying the significant genetic overlap between OA and 
CPSP. 
GO analysis on the genetic overlap of CPSP with CPP subtypes (RA, CWP, 
sciatica) resulted in the identification of 4 common biological processes clusters, 3 
cellular components clusters and 5 molecular functions clusters that could provide 
insight in shared aetiology [35, 40]. Pathway analysis of the SNPs underlying the 
genetic overlap between peripheral pain syndromes and CPSP indicated 
involvement of neuronal processes: nervous system process, neuron part sodium 
channel activity, and of inflammatory response: response to cytokine, response to 
wounding, regulation of immune system process. These findings are consistent with 
published reports on the interaction of the neuronal and inflammatory reaction 
in the aetiology of chronic pain [49-53]. In CPPs the communication between 
neurons and the immune system has been well documented [49-53]. This is 
consistent with what is known about the pathophysiology of CPPs and CPSP. 
Both in CPSP and CPPs, neuroinflammation (via glial cells) plays a key role in the 
maintenance of central sensitization [54-58]. The communication between 
nociceptive afferents and glial cells is bidirectional, whereby by both can release 
cytokines and chemokines that modulate the response of the other [56]. When 
activated, nociceptive afferents release fractalkine which binds to glial cells [54, 
58]. Consequently the glial cells release IL1  which leads to increased sodium 
channel activity and subsequent hyperalgesia and allodynia [54, 56, 58]. Central 
sensitization is a fundamental process in the chronification of pain and both 
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neuronal signalling and inflammatory response play a key role in this process [59, 
60]. Central sensitisation occurs due to increased and continuous action potentials 
coming from the nociceptive afferents most often caused by a combination of 
local inflammatory processes and tissue or nerve damage [59, 60].  
The genetic overlap across CPPs may ultimately be translated to clinical practice. 
Polygenic risk scores have been used in migraine cohorts to not only identify 
patients likely to develop migraine but also to identify sub clusters of patients who 
respond to certain classes of medication [61]. This same approach was tried in 
psychological disorders where they combined major depression disorders and 
neuroticism to predict efficacy of antidepressant drugs and although not 
significant they showed that a greater genetic load for MDD and neuroticism was 
associated with a less favourable response to antidepressants [62]. Secondly, the 
PRS can be integrated into currently available clinical prediction models. In 
diabetes and prostate cancer, the predictive accuracy is higher than the currently 
available clinical models [63]. A recent clinical prediction model on CPSP 
increased the predictive power of by including a single SNP into the prediction 
model [7]. This increase in predictive power was not significant but including a 
complete PRS into the prediction model would significantly improve the clinical 
prediction modelling [52, 54, 62, 64] 
Limitations 
This is the first study that combines published GWAS datasets to study genetic 
overlap across chronic pain phenotypes and CPSP. A limitation is the fact that the 
number of SNPs included in published GWAS analyses does vary substantially 
between studies. Ideally, the input-set of SNPs for PRS analysis is the entire GWAS 
dataset, as more SNPs can lead to a better PRS score: a PRS has more predictive 
power if more causal SNPs are included in the combined score [33, 48]. Some 
studies were omitted from the current study as only the top hits were reported [65-
67]. This complicates and limits accurate PRS assessment as the technique requires 
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genome-wide input [68]. The recommendation to include all summary statistics 
(preferably raw data) as part of publications will enhance transparency and 
robustness of analyses and interpretation. A second limitation of this study is the 
sample size of the various studies included in the analyses. As for accurate 
measurements sample sizes of above 2000 people are preferred, small sample size 
will lead to an inflation of the explained variance [48]. For the current analysis, 
two small studies (Table 1) were underpowered [9, 28]; the other studies were 
sufficiently powered for the analyses. To overcome the small sample size in the 
discovery cohort, the analysis was repeated in an independent replication cohort.  
The herein presented pathway analysis provides a starting point for functional 
studies on pathways and mechanisms involved in CPSP to substantiate the 
potentially shared aetiology of CPSP and CPP syndromes. Future research aimed 
at understanding the impact of genetic variations on the development of CPSP 
should include functional aspects of genetic networks and corresponding 
regulatory processes in chronic pain. Functional aspects of both coding and non-
coding SNPs should be elucidated to fully understand the impact of genetic 
variation on the development of chronic pain. Studies on the effects of genetic 
variation on protein function, cell signalling and cell and organismal physiology 
should further clarify their mechanistic connection to chronic peripheral pain 
syndromes, among which CPSP. 
Conclusion 
In conclusion, this study is the first to report genetic overlap between regulatory 
processes implicated in CPSP and chronic peripheral pain syndromes (CPP). The 
genes identified in the genetic overlap and the factors involved in chronification 
of postoperative pain are related to the regulation of neurological signalling and 
inflammatory responses. Enhanced understanding of mechanisms underlying 
chronification of pain will aid the development of new preventative therapeutic 
strategies for CPSP.   
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Supplementary Table 1: optimal p-value results PRS scores for CPSP prediction in discovery cohort based on 
pain phenotypes 
Supplementary Table 2: optimal p-value results PRS scores for CPSP prediction in replication cohort based 
on pain phenotypes 
Abbreviations: PRS = polygenic risk score, Num_SNP = number of SNPs included in the significant 
polygenic risk score. 
Phenotype Threshold PRS_r2 Coefficient Standar
d error 
Pvalue Num snps 
Cluster headache 0.0226 0.014247 94.313 63.8321 0.14 3429 
Migraine 0.0001 0.003774 132.164 174.162 0.448 214 
Sciatica 0.00025 0.026629 -42.692 21.3395 0.045 267 
Chronic 
widespread pain 
0.0875 0.0294922 0.033183 23.0474 10.8211 6 
Rheumatoid 
arthritis 
0.0177 0.03742 348.111 146.096 0.017 2771 
Osteoarthritis 0.0001 0.007937 -31.5548 28.6297 0.27 74 
Phenotype Threshold PRS_r2 Coefficient Standar
d error 
Pvalue Num snps 
Cluster headache 0.02865 0.020731 110.979 110.166 0.314 4557 
Migraine 0.0001 0.016748 245.526 272.742 0.368 207 
Sciatica 0.00385 0.0847342 293.388 146.183 0.04475
06 
2149 
Chronic 
widespread pain 
0.141 0.213118 -95.548 31.8452 0.00269
638 
12 
Rheumatoid 
arthritis 
0.3549 0.232604 -4111.97 1334.35 0.00205
877 
28117 
Osteoarthritis 0.0001 0.113215 -105.29 45.9319 0.022 76 
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Abstract  
Dopamine (DA) is an important modulator in nociception and analgesia. Spinal 
DA receptors are involved in descending modulation of the nociceptive 
transmission. Genetic variations within DA neurotransmission have been 
associated with altered pain sensitivity and development of chronic pain 
syndromes. The variant rs6277 in dopamine receptor 2 a (drd2a) has been 
associated with a decreased D2 receptor availability and increased nociception. 
The aim of this study is to further characterize the role of DA neurotransmission 
in nociception and the anti-nociceptive function of drd2a. The phenotype caused 
by rs6277 was modelled in zebrafish larvae using morpholino’s and the effect on 
nociception was tested using a validated behavioural assay. The anti-nociceptive 
role of drd2a was tested using pharmacological intervention of D2 agonist 
Quinpirole. The experiments demonstrate that a decrease in drd2a expression 
results in a pro-nociceptive behavioural phenotype (p = 0.016) after a heat 
stimulus. Furthermore, agonism of drd2a with agonist Quinpirole (0.2μM) results 
in dose-dependent anti-nociception (p = 0.035) after a heat stimulus. From these 
results it is concluded that the dopamine receptor drd2a is involved in anti-
nociceptive behaviour in zebrafish. The model allows further screening and 
testing of genetic variation and treatment involved in nociception. 
Keywords 
DRD2, danio rerio, morpholino, quinpirole, pharmacology, pain 
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Introduction 
Worldwide, 1 in 5 people suffer from chronic pain [1]. The treatment of pain 
remains a major clinical challenge, partly due to a lack of knowledge on the 
involvement of different neurotransmitter systems in nociception. The 
neurotransmitter Dopamine (DA) seems an important modulator in analgesic 
processes, acute and chronic pain both at spinal and supraspinal levels [2-9]. 
Several genes in the DA-neurotransmission have been associated with the 
chronification of pain [10-12]. Hence, it is important to understand the exact 
mechanism by which DA-neurotransmission affects nociception and the 
involvement of genetic variation herein. 
The external development of zebrafish larvae it is possible to easily manipulate the 
development and genetics of the organism [13, 14]. Moreover, as the zebrafish is 
an organism with a fully sequenced genome, it is an ideal model to study the effect 
of genetic variation on nociception in a time and cost-effective manner [13, 15, 
16]. The zebrafish sensory nervous system has shown to have many similarities 
with vertebrates including descending modulation of nociception [17-21]. The 
zebrafish model allows a direct high-throughput approach. Furthermore, it was 
recently shown that zebrafish could also be used as a model for assessing 
nociceptive processes [22, 23].  
DA receptors are present throughout the spinal cord in humans and are expressed 
both in pre- and post-synaptic neurons. There are two classes of DA receptors, the 
D1 receptor family and D2 receptor family. The D1 receptor family is excitatory 
whereas the D2 receptor family is inhibitory [24] with D2 receptors as the 
dominantly expressed receptor subtype [24, 25]. As zebrafish underwent an 
evolutionary genome duplication event, the vast majority of genes is present in 
duplicate [26]. The drd2a, drd2b genes are the zebrafish orthologues of human 
DRD2 whereby drd2b is more abundantly expressed in the brain of the zebrafish 
and drd2a is preferentially expressed in the spinal cord [27]. 
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The single nucleotide polymorphism (SNP) rs6277 which is a non-protein-altering 
genetic variant, is one of the most studied genetic variants in DRD2 in humans 
[28, 29]. SNP rs6277 accelerates mRNA decay and has been associated with a 
decreased DA D2 receptor availability in the brain [30, 31]. A decrease in DA D2 
receptor availability has been associated with nociception and chronic pain [32-
34]. Hence, a link between genetic variants altering the availability of DA D2 
receptors and an augmented pain response in humans is suggested. 
The aim of this study is to further characterize the anti-nociceptive role of DA-
neurotransmission in nociception via modulation of the drd2a receptor in a 
zebrafish model. This will be modelled via gene knockdown of drd2a in larval 
zebrafish using established morpholino oligomers and pharmacological 
intervention [35]. Behavioural parameters will be used to quantify the effects of 
drd2a mediated neurotransmission on nociception in zebrafish. It is hypothesized 
that the activation of the drd2a receptor will be anti-nociceptive whereas as a 
decrease in drd2a receptors will result in a pro-nociceptive response. 
Methods 
Zebrafish husbandry 
Zebrafish (Danio rerio) were housed and raised at Maastricht University. Zebrafish 
were maintained at a 14/10h light/dark cycle, water temperature was set at 27°C 
and adults were fed twice a day [15]. For mating, the males and females were 
separated by a divider the day prior to collection. At the day of collection in the 
morning during the light cycle, the animals were placed in the same compartment 
to allow mating to take place. Eggs were collected using a fine-meshed strainer 
and transferred to petri dishes containing E3 medium [36]. 
The zebrafish line dat:EGFP was developed and characterized by Xi and colleagues 
[37]. In this line, the promotor of the dopamine transporter (dat) gene drives GFP 
expression. As a consequence, DA neurons in the brain are tagged with a 
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fluorescent mark in vivo. Experimenters (RvR and MS) were blinded for the 
conditions during the experiments until analysis. 
Morpholino experiments 
Expression of the drd2a gene was suppressed using a previously described 
translation block drd2a antisense morpholino [35]. Antisense and control 
(mismatch) morpholino were ordered with the following sequences: drd2a 
morpholino 5’-AGG CAT ACG CTG TGA AGA CTT CCA T-3’; mismatch drd2a 
5’-AGC CAT AGG GTG TGA ACA GTT CCA T-5’ (Gene Tools, LLC, Philomath, 
OR, USA). The complimentary sequence of the ATG start site is underlined in 
each sequence. For injection, the morpholino’s were diluted in 1x Danieau and 
1:10 dilution of rhodamine. Each 1-2 cell stage embryo was injected with 2nl of 
morpholino solution. 
At 24h after injection, the injection success rate and survival rate was assessed 
under the fluorescent microscope (DMI 4000B, Leica, Wetzlar, Germany). At 72h 
after injection the morphology of the developing embryos was checked using a 
dissection microscope as a quality control measure. 
Zebrabox experiments 
To quantify nociception in the zebrafish we measured temperature sensitivity and 
in particular noxious heat induced locomotion on the fifth day after fertilization 
(5dpf). This was assessed with an add-on, developed in-house, to the ZebraBox 
system (Viewpoint, Lyon, France and Maastricht Instruments BV., Maastricht, the 
Netherlands) [15]. We used the same set-up and parameters as described and 
validated earlier [15]. Briefly, animals were placed in 48 wells plate containing 500 
μl E3 medium in the water compartment and allowed to adapt to their 
surroundings for 30 min in the dark. This period was followed by 10 minutes 
baseline measurement followed by the experimental phase with the temperature 
increase. Baseline temperature was set at 28.5°C and was increased in the 
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experimental phase to 41°C. The temperature increase difference between the 
arena containing the water and the wells containing the fish is ±1°C. During 
experiments, conditions were rotated over the 48 wells plate to reduce location 
bias. The ZebraBox software uses contrast differences between water and the 
zebrafish larvae to detect the size of the larvae. A camera records movement of the 
larvae and the activity of the larvae is determined by the amount pixels that change 
from one frame to the next. 
Pharmacological experiments 
To determine the effect of drd2a on nociception we used the DRD2 agonist 
Quinpirole (QP). (-)-quinpirole hydrochloride (QP) was purchased from Sigma 
Aldrich (St. Louis, MO USA).The drug was dissolved in milli-Q and diluted in E3 
medium to reach the final concentration within the range of 0.2-8μM based on 
previous literature [38]. The optimal dose was determined in a series of pilot 
experiments. During the pharmacological experiments, the fish were incubated 10 
min prior to the start of the adaptation phase of the experiment. This period was 
chosen as longer periods of incubation could lead to motor effects which we 
wanted to avoid [38]. QP was also diluted to the same concentration in the 48 
wells plate as during the incubation period. Thus, the animals were exposed to QP 
during the experiments. E3 medium was used as vehicle control. During 
experiments conditions were rotated over the 48 wells plate to reduce location 
bias. 
Statistics 
R was used to carry out the statistical analyses. For the comparison of different 
morphologies during the optimisation of the morpholino experiments, a two-
sample t-test was used. For the behavioural experiments, the timeline was divided 
in different sets: acclimatisation phase (0-30 min), baseline phase (30-40 min), 
experimental phase (40-60 min). The peak activity time (45-50 min) was analysed 
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to detect differences in nociception. Activity of the fish was standardized per fish 
to account for the variability between different individual larvae. 
Analysis of behavioural data was done using a linear mixed effect (lme) model in 
the nlme (nlme: Linear and Nonlinear Mixed Effects Models) package [39]. Activity was 
determined in a linear regression model by group and time assuming a random 
intercept for each individual fish. Data were considered to be significant when the 
calculated p-value <0.05. All data are presented as average ±standard error of the 
mean (SEM). 
Results 
Optimization of the drd2a Morpholino  
Before we can determine the effect of the drd2a knockdown on temperature 
sensitivity with our assay, the dosage of the drd2a morpholino had to be 
optimised. To determine the optimal dose of the morpholino, the morphologies 
of the fish had to be consistent with the literature describing this morpholino 
and have a significantly higher proportion of affected fish compared to the non-
injected (NI) controls [35]. The two morphologies described in the literature 
were heart oedema and growth retardation. 
A range of 2 ng until 10 ng was tested and morphology was assessed at 3dpf. All 
the doses tested had a proportion of fish with the described phenotype (Figure1). 
The 10ng drd2a morpholino had a significantly higher fraction of affected 
zebrafish compared to the NI control (p=0.037, t=3.16, 95% CI 1.42-27.20). None 
of the other dosages of drd2a or mismatch morpholino’s had a significantly higher 
fraction of affected zebrafish (p>0.05). 
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Figure 1: The proportion of phenotypes after morpholino injection are depicted in percentages affected per 
condition. N2ng 2a = 159, N2ng MM = 225, N4ng 2a = 366, N4ng MM = 128, N6ng 2a = 230, N6ng MM = 145, N10ng 2a 
= 176, N10ngMMa = 160, NNI = 1376. NI = non-injected controls, 2A = drd2a morpholino, MM = mismatched 
morpholino, dose is presented before the type of morpholino. * = P<0.05 
Morpholino behavioural experiments 
A dose of 10ng (5ng/nl) was determined to be the optimal dose and used in the 
behavioural experiments. The behavioural response of the zebrafish larvae (5dpf) 
to the temperature change was assessed in the zebrafish exhibiting the normal 
phenotype to minimise the effect of morphology on the behavioural read-out. All 
three groups responded with an increase of their activity in response to the 
temperature increase (Figure 2). 
At baseline (30-40 minutes) no significant differences in activity between the three 
conditions is observed. During the peak activity phase of the experimental period 
(45-50 min) a significant increase in activity in the drd2a morpholino group is 
noted as compared to the non-injected control group (figure 2, p = 0.016, t= 2.45, 
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=1294.036). No difference in activity between control morpholino and the non-
injected control (p=0.947, t=-0.07,  = -36.335) is observed. As reported in earlier 
studies the activity of the larvae gradually declined after reaching a maximum [15]. 
 
Figure 2: Effect drd2a and control of morpholino’s on noxious heat induced activity. At 5dpf, larvae injected 
with drd2a or mismatch morpholino were exposed to an increase in water temperature. This resulted in a 
significant higher activity of the zebrafish larvae injected with the drd2a morpholino. No significant 
differences were observed between the mismatch control and the non-injected control. Ndrd2a morpholino=32, 
nmismatch morpholino = 29, nnon-injected control = 32 divided over three different experiments. 
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Drd2a agonist concentration optimization 
Next, to study the effect of activation of the drd2a receptor on nociception an 
agonist is used. To determine the optimal concentration a range of concentrations 
(0.2μM – 8μM) of QP was tested based on the available literature [38]. To be 
considered for follow-up experiments the concentrations should not lead to motor 
effects visible in a significantly different baseline and should have a significant 
effect on activity during the peak effect phase. This was tested using a two-sample 
t-test between experimental concentrations and control group. 
There were significant differences in average baseline activity compared to control 
for the concentrations 4μM (p = 1.88-13) and 8μM (p = 5.4-16) (Figure 3 left side). 
There was no significant difference between control and 0.2μM (p = 0.18) and 
1μM (p = 0.074). No significant effect on average peak activity was found for the 
concentrations 4μM (p = 0.86) and 8μM (p = 0.86). There was a significant decrease 
in average peak activity for the concentration of 0.2μM (p = 1.4-5) and 1μM (p = 
0.021) (figure 3 right hand side). 
 
 
148 | C h a p t e r  6  
Figure 3 (previous page): comparison of average baseline and peak activity of zebrafish larvae at 5dpf exposed 
to quinpirole and control condition. A significant difference in baseline activity was observed in the 
concentrations 4 and 8μM (p<0.0001) compared to control. No significant change was observed in the 
baseline activity of 0.2 and 1μM (p=0.18) compared to control. There was a significant decrease in the 
average peak activity of larvae exposed to 0.2μM (p<0.05). No significant differences compared to control 
were found for the other concentrations. * p <0.05, **** p<0.0001. n0.2μM=40, n1μM=47, n4μM=31, n8μM = 29, 
ncontrol = 71. 
Pharmacological behavioural experiments 
The concentration of 0.2μM QP was determined to be optimal and used in the 
behavioural experiments. The behavioural response of the zebrafish larvae (5dpf) 
to the temperature change was assessed in the zebrafish exhibiting the normal 
phenotype to minimise the effect of morphology on the behavioural read-out. 
Both groups responded with an increase of their activity in response to the 
temperature increase (Figure 4). 
At baseline (30-40 minutes) there were no significant differences in activity 
between the two conditions. However, during the peak activity phase of the 
experimental phase (45-50min) a significant decrease in activity is noted in the QP 
group as compared to the control group (figure 4, p = 0.035, t= -2.13, =-958.178). 
As observed in earlier studies the activity of the larvae gradually declined after 
reaching a maximum [15]. 
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Figure 4: Effect of Quinpirole on noxious heat induced activity increased. At 5dpf, larvae were exposed to 
either quinpirole or control E3 medium followed by an increase in water temperature. This resulted in a 
significantly lower activity of the zebrafish larvae exposed to Quinpirole. No significant differences were 
observed between the mismatch control and the non-injected control. nquinpirole = 70, ncontrol = 74. 
Discussion 
The aim of this study was to further characterize the anti-nociceptive function of 
dopamine receptor 2 a (drd2a). The results of our experiments indicate that 
knockdown of the inhibitory drd2a gene leads to pro-nociceptive behaviour in 
zebrafish. Furthermore, the activation of the drd2a receptor via application of 
agonist QP leads to anti-nociceptive behaviour. From this, we conclude that the 
drd2a is involved in modulation of nociception in zebrafish providing further 
insight in the role of the DA receptor 2 in pain in humans. 
Pharmacological modulation of the D2 receptor in rodents clearly demonstrated 
a role for DA in nociception and specifically the anti-nociceptive effects of the D2 
receptor [40-42]. Furthermore, genetic variants have been associated with a 
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decrease in D2 receptor availability and pain phenotypes [30-34]. The present 
study is the first to show a causative link between a decrease in D2 receptor 
expression and pro-nociceptive behaviour. The present findings not only validate 
prior studies but also provides a framework for future genetic screening in 
zebrafish. Several techniques are available (incl. morpholino’s, CRISPR and 
mRNA overexpression) to test the functional effects of known and unknown 
variants associated with pain phenotypes [28, 42-44]. In this study, we modelled 
the phenotype associated with a variant with known functional effects to proof 
the causation between variant and behaviour.  
It has been shown that dopamine plays an important role in pain and nociception 
in different clinical phenotypes [8, 45]. This study provides further evidence for 
the role of a dopamine receptor expression and a pharmacological intervention on 
nociception. Pharmacological intervention using QP is an interesting option in 
the clinical phenotypes which show an altered nociceptive threshold due to an 
aberrant dopaminergic neurotransmission (e.g. pain in Parkinson’s disease) [10, 
46, 47]. Specifically QP could provide relief in “OFF” periods when administered 
in subclinical dosages to counteract the decreased nociceptive threshold and 
central pain symptoms associated with the decrease in dopamine levels [47]. 
However, patients carrying the SNP rs6277 would most likely not benefit from 
QP, as the decrease in receptor availability could prevent the QP from exerting its 
effects on the dopaminergic neurotransmission [48]. 
The zebrafish is an excellent model to assess the functional effects of genetic 
variations. In the pain field, a zebrafish model of small-fibre neuropathy (SFN) in 
which the pathogenicity of certain known pathological variants was tested, has 
recently been described [15]. In the present study, an established antisense 
morpholino is used to downregulate the expression of the DA receptor 2A [35]. 
This knockdown of the DA receptor 2A leads to decreased expression of DA 
receptor 2A, and models the human phenotype of genetic variation based on SNP 
151 | C h a p t e r  6  
rs6277. In humans, this SNP results in a decrease in DA 2 receptor availability and 
is associated with chronic pain disorders [30-34].  
An important aspect in this study is the modelling of nociception in zebrafish. 
Zebrafish have a functional nociceptive sensory system from 16 hpf onwards [19, 
21]. In addition, zebrafish possess a functional opioid system, nociceptors, 
descending neuronal control and brain structures to process and respond to 
potentially noxious external stimuli [19, 49-51]. So far, zebrafish have been shown 
to respond to thermal and chemical nociceptive signals, as well as analgesics [15, 
18, 19, 22, 52-55].  
These approaches can be beneficial to research pipelines as they provide easy and 
fast screening and are easily translated to other model organisms or humans. This 
robust response of zebrafish larvae to nociceptive stimuli and attenuation of the 
effect in response to pharmacological intervention indicates the validity of 
zebrafish as model for nociception. The customized zebrafish behavioural testing 
system Zebrabox has been extensively validated for thermal nociception as 
described by Eijkenboom and colleagues [15]. It is important to note that in this 
zebrafish nociception model, the altered activity of the zebrafish larvae in response 
to an increase in temperature is robust, providing a decent window to see effects. 
Therefore, the Zebrabox is the ideal method to assess thermal nociception in 
zebrafish.  
When comparing human dopamine receptor families to their zebrafish 
counterparts, a sequence homology of ±70% is observed whereby the 
transmembrane segments are conserved [27]. The zebrafish genome is duplicated 
in comparison to the human genome leading to a duplication of the genes 
available. While some of these duplications have been lost in evolution, other 
orthologues developed new functionality [26]. The zebrafish genome contains two 
genes for the dopamine D2 receptor (drd2a and drd2b).The expression of drd2a 
and drd2b differs with respect to both location and developmental stage of 
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expression in the zebrafish CNS [56]. The expression of drd2a in zebrafish has 
been shown to be detectable from 8 hours post fertilisation (hpf) onwards, while 
spinal cord shows expression of drd2a at 36 hpf [57, 58]. Drd2b receptor is 
detectable from 24 hpf and mainly expressed in tectum, tegmentum and 
telencephalon [57]. Large similarity has been reported between zebrafish drd2a 
and drd2b expression patterns and mammalian D2 receptors [56]. This makes the 
zebrafish an excellent model to study the effect of DA neurotransmission on 
different processes, including nociception. The differential distribution and 
targeting of drd2a and drd2b allows to investigate the effect of DA in specific CNS 
structures. 
During development, the DA system in zebrafish larvae is sensitive to external 
influences. With respect to the use of drd2a morpholino it is important to note 
that growth retardation and heart oedema have been described [35]. With our 
morphological examinations, we observed both growth retardation and heart 
oedema phenotypes developing in the zebrafish larvae (see Figure 1). At the 
optimal morpholino concentration of 10ng (5ng/nl) the proportion of fish with 
these phenotypes was significantly higher than in the control groups as seen 
previously (see Figure 1). This confirms that we have the same phenotype in the 
zebrafish as the phenotypes mentioned in the study where the morpholino was 
originally described [35].  
In addition, studies have shown that (ant)agonism of the dopaminergic receptors 
can specifically affect locomotion [38, 57-59]. The effect of DA on locomotion is a 
crucial aspect as the behavioural assay in this study is based on locomotion of the 
zebrafish larvae and it could interfere with the effect on nociception. In our study 
we noted a significant increase in baseline locomotion (at 40-50 min of exposure) 
during exposure to the intermediate dosages of 4μM and 8μM, as reported 
previously [38]. No effect of the lower dosages (0.2μM and 1μM) on baseline 
locomotion was noted. Therefore, we conclude that the results of QP on 
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nociception in the temperature nociception assay are not confounded by a 
locomotion effect of QP.  
There are some limitations to this study. The first issue is the indirect modelling 
of the functional effects of rs6277. This SNP normally promotes mRNA decay 
leading to a decreased expression of the receptor. Overexpressing mRNA with 
rs6277 in zebrafish would therefore not lead to the matching phenotype as more 
DA receptor mRNA is present next to the already transcribed drd2 mRNA. 
Therefore, the morpholino approach was chosen to model the clinical phenotype 
as closely as possible. Although there is significant overlap between the human 
and the zebrafish genome, there are differences between zebrafish and human 
genomes including two different orthologues of the D2 receptor [27, 60]. Drd2a is 
the gene mostly expressed in the spinal cord here is the first modulation relay 
station in the transduction of the nociceptive signal (the spinal pain-gate)[61]. The 
nociceptive system and spinal pain-gate seems well conserved between fish and 
vertebrates [17, 21, 51, 62]. The spinal pain-gate modulates the nociceptive signal 
transduction, making spinally expressed drd2a the best candidate to study in 
nociception [27, 56]. Second issue is the large variability seen in the behaviour of 
the zebrafish. Zebrafish are outbred animals, which already indicates genetic 
variability, and they respond differently to the conditions in the experiments. To 
account for this variability all experiments were executed using multiple runs. 
In conclusion, we report a causative link between D2 receptor expression and 
nociception in zebrafish. With these experiments the genetic variants in humans 
phenotype and DA neurotransmission characterized by SNP rs6277 was modelled 
in vivo in a zebrafish using a morpholino targeted at drd2a. Future studies could 
use this established zebrafish nociception assay to functionally asses the effect of 
genetic variations on morphology, behaviour and pharmacological intervention 
screening. 
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The aim of this thesis was to study the genetic risk factors of chronic post-surgical 
pain (CPSP) and to identify functional effects of genetic variation on nociception 
and chronic pain in both clinical and preclinical studies (see Chapter 1 
Introduction page 11). Related to this aim various RQ’s were formulated and then 
investigated in Chapters 2-6. In this General Discussion the RQ’s and related 
findings will be discussed in a more general context and moreover the possible 
implications of the findings, critical considerations and future perspectives will be 
evaluated  
Research question 1: What is the role and impact of genetic variations 
related to dopaminergic neurotransmission in CPSP? 
Dopaminergic (DA) neurotransmission, most known for its involvement in 
reward, mood and locomotion, has been associated with nociception and chronic 
pain syndromes including CPSP but is often overlooked when it comes to 
analgesic treatment strategies [1-6]. DA is known to be important in stimulating 
as well as inhibiting nociception at the level of the spinal cord dorsal horn [7]. As 
DA has an important role in pain and is often overlooked in analgesia, we 
conducted a review of the available literature (see Chapter 2) and performed a 
preclinical study to model the effect of DA genetic variation on nociception (see 
Chapter 6).  
From the literature review, we present a tri-phasic effect of DA concentration in 
the spinal cord due to differential affinity Of DA for either the D1-like or the D2-
like receptors (Chapter 2, Figure 1 page 36) [8-10]. In short, both a low and a high 
concentration of DA leads to inhibition of nociception of whereas a medium 
concentration tends to be excitatory [8, 10-13]. The modulation of nociception in 
the spinal cord via DA receptors can either be direct (inhibition of the nociceptive 
transmission by D2 receptors or via sensitization of C-fibres by the D1 receptors) 
or indirect (synergy with opioid receptors of D2 receptors or synergy with NMDA 
receptors by D1 receptors) as seen in Figure 1, Chapter 2 [3, 4, 13-21].  
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Central sensitization (as explained in Chapter 1, page 10) is a process of 
deregulated communication between nociceptive afferent and pain transmission 
neurons [22, 23]. DA neurotransmission affects this process both in an inhibitory 
(D2 receptors) and facilitatory (D1 receptors) manner [7, 24]. D2 receptors can 
modulate the opioid receptor involved in inhibition of the pain transmission 
thereby preventing central sensitization [4]. However, activation of the D1 
receptors potentiates the NMDA receptors leading to facilitation of central 
sensitization [25, 26]. 
Genetic variations within the DA-neurotransmission, specifically in COMT gene 
(risk factor), GCH1 gene (protective factor) and DRD2 gene (risk factor), have been 
associated with a variability in pain sensitivity, development of CPSP and 
analgesic requirement [24, 27-29]. Although there is still some ambiguity in the 
results between studies, fluctuations in either DA concentration, altered 
production due to SNPs in GCH1 or altered breakdown due to SNPs in COMT, 
or DA receptor availability, SNPs in DA receptors, affects nociception and the 
development of chronic pain [24, 27-29]. Therefore, studying DA-metabolism and 
neurotransmission could lead to new therapeutic options for treatment of chronic 
pain conditions including CPSP. One key aspect in the administration of drugs 
targeting the DA receptors are possible side effects on locomotion and mood or 
reward [5, 6]. DA is for instance inherently linked to locomotion in all vertebrates 
[5]. In view of this, combining DA-focussed interventions with other interventions 
targeted at synergistically linked pathways might be an approach to decrease the 
optimal dosage to a subclinical dosage whereby locomotor and other side-effects 
are absent [4]. For instance, mu-opioid receptors and D2 receptors are functionally 
linked and co-administration of D2 agonist and morphine could decrease the dose 
necessary for an effect of both administered drugs thereby reducing side effects, as 
shown before [4]. 
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To further examine the impact and role of genetic variations related to 
dopaminergic neurotransmission in CPSP, we modelled a clinical phenotype of 
decreased dopamine D2 receptor expression in zebrafish. The findings as in 
Chapter 6 show a pivotal role of D2 receptors in nociception. A decrease in D2 
receptor expression led to pro-nociceptive behaviour in response to a noxious heat 
stimulus while application of Quinpirole, a D2 receptor agonist, resulted in an 
anti-nociceptive response (see Chapter 6 pages 145-149). With this a causal link 
between a decrease in D2 receptor expression and pro-nociceptive behaviour is 
shown. Clearly the results in Chapter 6 not only validate prior studies 
(Eijkenboom et al.,) but also provides a framework for future genetic screening 
and testing of drugs in zebrafish [30]. Several techniques in zebrafish are available 
(incl. morpholino’s, CRISPR and mRNA overexpression) which allows to further 
test the functional effects of known and unknown variants associated with pain 
phenotypes [31, 32]. 
Critical considerations should be taken into account when interpreting the results 
of the zebrafish study in a context of analgesia and peri-operative pain. Zebrafish 
are an excellent model to study the effect of genetic variations and pharmacology 
on behavioural and morphological outcome parameters related to acute pain 
conditions. Unfortunately, as of yet, no studies on chronic pain conditions in 
zebrafish have been published. Chronic effect studies in zebrafish that have been 
presented deal with effects and toxicology of exposure to different compounds 
related to ethanol-induced effects or chronic hyperglycaemia [33, 34]. Hence, a 
direct link between studying genetic variants in zebrafish and their effect in CPSP 
is currently lacking. Studying chronic disorders in zebrafish is challenging as 
zebrafish have a potent regenerative capacity and they recover within weeks from 
myocardial infarctions (i.e. heart attacks) and spinal cord injury [35-37]. Therefore, 
testing how genetic variants affect the development of chronic pain after surgery 
or peripheral nerve injury is not possible. On the other hand the effect on nerve 
sprouting and regeneration in a context of acute pain can be studied in zebrafish, 
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which might yield interesting perspectives and therapeutic strategies [36-38]. 
Variants within the D2 receptor which are associated with altered baseline 
sensitivity are also associated with the development of chronic pain indicating that 
zebrafish can be used a high-throughput screening model for the effects on 
nociception in the acute phase [39]. These results then need to be tested in models 
of chronic postsurgical pain in rodents (e.g. thoracotomy and skin/muscle incision 
and retraction model (SMIR)) for effects on chronic pain, before clinical trials can 
commence [40, 41].  
Translational use of zebrafish models for screening of pharmacological 
interventions has been shown in various research areas and drug responses were 
identical across species [42]. One area of pharmacological research for which 
zebrafish might be particularly interesting is drug repurposing. In this field, drugs, 
which are currently available for humans, are tested for other indications than 
originally intended. In the context of dopamine and pain, it might be interesting 
to look at drugs developed for Parkinson’s disease as this disorder is characterized 
by a DA pathophysiology [43, 44]. Recent studies have shown promising results 
in drug repurposing and combined with the interspecies validity shown in other 
studies, this might be a valuable application of zebrafish models [45-47]. 
The association on Dopamine and CPSP is based on gene-targeted studies on 
CPSP which chooses targets a priori. As explained in the introduction Chapter 1 
(page 14), GWAS studies test a wide array of SNPs across the genome and are able 
to validate gene-targeted studies (e.g. the studies on DA and CPSP) but also lead 
to new findings and elucidate new mechanisms underlying a disease [48, 49]. 
Furthermore, a GWAS study has a higher resolution to detect variants with a 
modest effect on the phenotype and it genotypes variants outside of the coding 
regions of the genes [49]. 
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Research question 2: What are the genome-wide risk factors of CPSP and 
the related functional mechanisms?  
Our GWAS (Chapter 3) on genetic risk factors of CPSP (Chapter 3) gave an initial 
insight into the genome-wide risk factors of CPSP and identified the first potential 
risk locus [50]. The potential risk locus contains two genes (IQGAP1 and CRTC3) 
which were both associated with CPSP. CRTC3 is expressed in many tissues 
including neuronal tissue, is downstream of the catecholamine (e.g. dopamine) 
signalling and associated with both inflammatory disorders and neurological traits 
[51-55]. IQGAP1 is also expressed throughout the body including neuronal tissue, 
involved in signalling molecules and cell motility and associated with immune 
system functioning and multiple sclerosis [54, 56, 57]. In our study, the SNPs in 
both genes are in linkage disequilibrium (LD) with each other and influence the 
development of CPSP together. Their involvement in the immune system is 
supportive of postsurgical infection being a risk factor for the development of 
CPSP, as previously shown [58]. 
One of the disadvantages of a GWAS is the need for large sample sizes. Sufficiently 
large sample sizes are necessary to find smaller effects, especially if the minor allele 
frequency or effect size decreases [49, 59, 60]. The second challenge in GWAS 
studies and CPSP research in particular is the homogeneity in the phenotype. The 
incidence of CPSP varies across surgeries, ranging from 5% to 85% [61, 62]. The 
type of surgery is one of the risk factors of developing CPSP and explains the large 
variation in incidence [61, 63, 64]. Surgeries in areas with more nerve innervation 
have larger risk of nerve damage leading to neuropathic symptoms as do surgeries 
requiring larger incisions and a longer duration [61, 63, 64]. On the other hand, 
not everybody exposed to a major surgery with a long duration and large incision 
develops CPSP, indicating a differential susceptibility to chronification of pain 
after nerve damage which might be explained by genetics. Depending on the 
surgery, different genes might be involved in the development of CPSP.  
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As explained in the introduction Chapter 1 (page 10) central sensitization is a 
central process in the development of CPSP [22, 23]. Central sensitisation occurs 
due to increased and continuous action potentials coming from the nociceptive 
afferents most often caused by a combination of local inflammatory processes and 
tissue or nerve damage [22, 23]. As, both inflammation and tissue damage are key 
components of CPSP, the composition of inflammatory processes and tissue/nerve 
damage underlying the CPSP could differ per surgery [61]. It is to be expected that 
this will be reflected in the genetic risk factors for different types of surgeries. 
GWAS studies in migraine have shown that it is feasible to identify general genetic 
risk factors for all migraine subtypes combined and specific risk factors for 
migraine subtypes [65]. This only becomes feasible as soon as the sample size in 
each subtype is sufficiently large enough to have enough power on its own and if 
the combined sample is large enough to detect subtle effects in the general cohort 
[60]. Future GWAS studies on CPSP should thus be able to identify general 
genetic risk factors for CPSP as well as surgery specific risk factors. 
Currently, the sample size in our first GWAS study on CPSP (Chapter 3) is not 
large enough to be able to differentiate between subtypes. Moreover, the results of 
a GWAS are merely associations and the associated SNPs need not be the causal 
variant associated with the phenotype [66]. For most complex diseases such as 
pain, associated SNPs are primarily found in non-coding areas making it difficult 
to assess possible causal relationships [66-68]. Further validation studies are 
necessary to identify potential causal SNPs and genes [66].Here we anticipated and 
in collaboration with Radboud University Medical Center and UniKlinikum 
Muenster initiated and started a larger scale follow-up (GWAS) study including 
all elective surgery patients. 
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In order to relate the GWAS data and potential risk loci associated with CPSP to 
possible functional mechanisms, we used transcriptome-wide Mendelian 
randomization (TWMR) which combines GWAS and eQTL data (see Chapter 4). 
Combining the GWAS data (Chapter 3) with tissue specific eQTL data and 
TWMR led to the identification of tissues specific associations as well as genes 
associated with CPSP across multiple tissues. The findings suggest a potential 
causal relation of 5 genes with CPSP across all tissues studied (whole blood, DRG, 
cortex and spinal cord) and 21 genes with CPSP across neuronal tissues (see 
Chapter 4). Using the Pax protein expression database we were able to identify 
two genes (Synaptosome Associated Protein 29 (SNAP29) and Vacuolar Protein 
Sorting-Associated Protein 8 (VPS8)) [69]. VPS8 has been associated with the 
immune system functioning, brain morphology and cognitive performance [70]. 
SNAP29 and members of this gene family have been associated with fibromyalgia 
[71, 72]. Loss of SNAP29 has been associated with a decrease in endocytic recycling 
within the cell and a decrease in cell motility. This has shown to result in 
dysfunctional wound healing and neurological abnormalities [73, 74]. 
Furthermore, SNAP29 is involved in synaptic vesicle trafficking, specifically 
inhibiting synaptic transmission in an activity dependent manner and involved in 
mast cell phagocytosis [75, 76]. This combined evidence related to SNAP29 
strongly suggests this protein plays a modulatory role in fine-tuning of cellular 
growth and immune cell functioning. Therefore, alterations in the expression of 
the gene coding for SNAP29 may affect repair mechanisms involved in and related 
to the development of chronic pain. 
Future genetic studies on CPSP should take into account the complex biology 
underlying the phenotype. Increasing sample sizes is only part of the solution, also 
the eQTL datasets should be increased and further specified to incorporate 
different and more specific tissues. For example, studies on major psychiatric 
disorders have found tissue specific gene-expression effects and uncovered novel 
biological mechanisms using eQTLs [77-79]. Furthermore the associations found 
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in a GWAS do not indicate causality while the TWMR approach does identify 
putative causal relations. Therefore, future functional studies are necessary to a 
clear overview of which SNPs and genes are causally involved in CPSP. Next to 
increasing sample sizes, also different ethnic populations should be taken into 
account. Complex phenotypes have a varying distribution across ethnic 
populations which is partly due to differences in allele frequencies, effect sizes and 
genetic architecture due to differential evolution [80-82]. Almost all of the GWAS-
data published to date have focussed on individuals of Caucasian descent [82]. As 
there are known differences across ethnicities it should be taken into account that 
this likely will affect possible associations in GWAS and eQTL studies [82, 83]. 
Studies on the genetic risk factor in psychiatric disorders have innovated the 
research field of neuro-genetics and led to new developments in application of 
functional genetics related to understanding underlying biological mechanisms 
[84-87]. This innovation was partly possible due to studying the shared genetic 
aetiology existing between the psychiatric disorders. There is a considerable 
amount of overlap in pain characteristics among chronic pain conditions: 
prevalence is higher in women, age is a risk factor, central sensitization plays a 
major role in all phenotypes and chronic pain conditions co-occur with 
psychological syndromes [88-90]. This overlap suggests a possible shared genetic 
aetiology between CPSP and different chronic pain disorders.  
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Research question 3: What is the shared genetic aetiology between different 
chronic pain disorders including CPSP and does this provide insights into 
the common biological mechanisms underlying chronic pain? 
Our analysis of the shared genetic aetiology of chronic pain syndromes (see 
Chapter 6) revealed a (possible) shared aetiology between CPSP and chronic 
peripheral pain syndromes (CPPs) but not with headache/migraine related pain 
syndromes. Pathway analysis indicated involvement of neuronal signalling and 
inflammatory response.  
Gene ontology (GO) analysis on the genetic overlap of CPSP with chronic 
peripheral pain (CPP) subtypes (rheumatoid arthritis (RA), chronic widespread 
pain (CWP), sciatica) resulted in the identification of 4 common biological processes 
clusters, 3 cellular components clusters and 5 molecular functions clusters that could 
provide insight in a shared aetiology [91, 92]. Pathway analysis of the SNPs 
associated with the genetic overlap between CPP syndromes and CPSP strongly 
suggest involvement of neuronal processes: nervous system process, neuron part 
sodium channel activity, and of inflammatory response: response to cytokine, response 
to wounding, regulation of immune system process. These findings are consistent with 
published reports on the interaction of the neuronal and inflammatory reaction 
in the aetiology of chronic pain [93-97]. Both in CPPs and RA the communication 
between neurons and the immune system has been very well documented [93-97]. 
This is consistent with what is known about the pathophysiology of CPPs and 
CPSP. The three CPP subtypes that showed genetic overlap with CPSP in both 
cohorts are known to affect peripheral nerves directly [88, 90, 98]. As discussed in 
the introduction (Chapter 1), nerve damage is one of the phenomena underlying 
peripheral and central sensitisation in CPSP [22, 23]. 
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Unfortunately, the GO terms associated with the inflammatory response did not 
indicate any specific process or cell component to be involved in the genetic 
overlap between CPPs and CPSP. Future studies and larger sample sizes should 
be able to further establish the genetic overlap and may then eventually identify a 
specific component of the inflammatory response to be involved in both CPSP 
and CPPs. The GO terms associated with neuronal signalling, point to the 
involvement of sodium channels (e.g. sodium channel complex cluster in cellular 
components GO terms and sodium channel regulator activity cluster in molecular 
functions). Sodium channels are very heavily involved in pain as the sodium 
channels conduct the action potentials and thus the nociceptive signal from the 
periphery towards the brain [99]. The most well-known example of the relation 
between pain and sodium channels is congenital insensitivity to pain which is 
caused by a mutation within the sodium channel 1.7 (Nav1.7) [100]. Genetic 
variations within sodium channels have been associated with multiple chronic 
pain conditions such as small fiber neuropathy, painful diabetic polyneuropathy 
and peripheral neuropathies [101-105]. However, genetic variations in the genes 
encoding for sodium channels have not (yet) been significantly associated with 
CPSP and only one study investigated the sodium channel gene SCN9 in relation 
to CPSP [29]. Although much effort has been put in development of drugs to 
modulate identified sodium channels (as related to specific clinical indications 
like small fiber neuropathy) this use and implementation has been hampered by 
significant side-effects [100, 106-108]. Non-selective sodium channel inhibitors 
can lead to an array of side effects due to the widespread use of sodium channels 
throughout the body [108]. Hence, the development of isoform specific sodium 
channel inhibitors might be the next step in personalized and precision medicine 
[100, 108]. Zebrafish might play a role in this development as sodium channel 
mutations introduced in the zebrafish mimic the clinical phenotype [30]. 
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Future research, incorporating larger sample sizes can utilise polygenic risk scores 
(PRS) can identify individual genes and genetic variation in clinical practice. This 
approach has been successful in migraine where the PRS identified patients likely 
to develop migraine as well as sub clusters of patients who respond to certain 
classes of medication [109]. A similar approach was used in psychological 
disorders for efficacy of antidepressants [84]. The combined use of PRS and larger 
GWAS studies as applied in migraine and psychological disorders may guide 
future research in CPSP and drug development. 
Chapter 5 is the first study combining published GWAS datasets on pain to study 
genetic overlap across pain phenotypes and CPSP. A major limitation is the 
variability in the number of SNPs reported by the various GWAS studies. The 
input set of SNPs for a PRS analysis is often the complete GWAS data and more 
potentially causal SNPs in a PRS lead to more predictive power [110, 111]. 
Including only the top hit SNPs complicates and limits accurate PRS assessment 
and some studies were omitted from the current study for only reporting top SNPs 
[112]. The recommendation to include all summary statistics (preferably raw data) 
as part of publications may enhance transparency and robustness of analyses and 
interpretation. A second limitation of is the sample size of the various studies 
included in our analyses. Sample sizes larger than 2000 are preferred for the PRS 
analysis as lower sample sizes lead to an inflation of the explained variance [110]. 
To overcome the small sample size, a replication approach was chosen.  
The herein presented pathway analysis (Chapter 5) provides a starting point for 
studies on mechanisms and pathways involved in CPSP and the potential shared 
aetiology of CPSP and CPP syndromes. Future research aimed at understanding 
the impact of genetic variations on the development of CPSP should include 
functional aspects of genetic networks and corresponding regulatory processes in 
chronic pain. Functional aspects of both coding and non-coding SNPs should be 
elucidated to fully understand the impact of genetic variation on the development 
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of CPSP. Detailed studies on the effects of genetic variation on protein function, 
cell signalling and cell and organismal physiology are needed and then should 
further clarify their mechanistic connection to CPSP and CPP’s. 
Framework for developing new treatment strategies and personalized 
medicine in CPSP  
Both clinical and preclinical studies are necessary to validate and functionally 
annotate the findings reported in this thesis. The future perspectives in the field 
of prediction and treatment of CPSP are discussed in the context of the 
translational framework. The starting point of this translational framework 
(figure1) is the clinical phenotype as described extensively in the introduction 
(Chapter 1) and throughout this dissertation. 
Figure 1: Framework for developing new therapeutic strategies and personalized medicine in CPSP. By 
starting from the clinical phenotypes (Green arrow) using a genomic and multi-omic (e.g. transcriptomics, 
ribosomal footprint profiling) approach (Yellow arrow), we hope to prioritize candidates for genetic screening 
in zebrafish and screening of pharmacological interventions tailored to the possible genetic risk factors (Blue 
arrows). These findings have to be tested in postsurgical animal models (Pink arrow) before translating those 
findings back to the clinical practice. 
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GWAS analysis of CPSP 
As explained in Chapter 3 (Page 66), most of the genetic studies on CPSP have 
been gene-targeted studies focussed on a small subset of genes. Performing 
GWASs on CPSP cohort will lead to the identification of genome-wide genetic 
risk factors of CPSP. Although, the first genome-wide significant risk locus for 
CPSP has been identified (rs17882261, SFTPA2) in Chapter 4, the current CPSP-
cohorts are not large enough to accurately identify multiple genome-wide 
significant SNPs and the current findings need to be replicated. A major focus 
should be on increasing the sample sizes of the CPSP-GWAS cohorts and thereby 
increasing the power of genetic studies. Large scale studies on migraine and on 
psychiatric disorders provide excellent examples of the possibilities of GWAS 
analysis in neuroscience leading to new insights and treatment options [65, 113, 
114]. To continue this, large scale collaborations are necessary to enlarge the 
sample sizes, leading to in depth identification of genetic risk factors, 
identification of subtype specific risk factors and prioritization of biological 
mechanisms [65, 113, 114]. Several initiatives have recently been started to form 
collaborations capable of collecting data on large cohorts of patients undergoing 
surgery (e.g. Horizon 2020 grant proposal PostOpOmics, Pain Predict Genetics 
project together with Radboud University and Muenster University, International 
collaboration with the Human Pain genetics lab at McGill University). The first 
results of the latter collaboration are reported in Chapter 4 which has already 
identified the first genome wide significant association with CPSP.  
Part of the findings in GWAS studies can already be implemented in the clinic via 
integration into clinical CPSP prediction models Current clinical CPSP 
prediction models have shown to allow prediction of 78% of the variance in CPSP 
[115]. Up until recently, costs for clinical genetic testing were excessive and thus 
implementation into clinical practice not possible [116]. As genetic testing has 
become cheaper over the last years, cost-benefit increases and from now it is 
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feasible to integrate genetic testing and implementation of the results into clinical 
prediction modelling. Furthermore, a systematic review on integration of SNPs in 
prediction models related to complex diseases recently showed an increase in the 
predictive accuracy [117]. Integration of one SNP into a clinical prediction model 
of CPSP also resulted into a led to an improvement in prediction accuracy from 
78 to 81% [115]. Although promising it should be taken into consideration that 
the additional value of the integration of genetic analysis into prediction models 
depends on factors such as the genetic architecture of the disease [117]. 
Multi-omic profiling of CPSP 
Although GWAS analysis provides insights into association between SNPs and 
CPSP, it does not provide evidence on causality [69]. SNPs associated with disease 
phenotypes often exert their effect through altering target gene expression [69]. A 
strong focus should be directed towards prioritization of potential causal variants 
associated with CPSP. Two techniques that could provide further insight in the 
relation between SNPs, biological mechanisms and CPSP are RNA-seq studies 
identifying eQTLs and ribosomal footprint profiling [118, 119]. eQTL studies 
allow identification of SNPs which are associated with the differential gene-
expression of a specific gene [66, 118, 120]. The altered gene-expression could then 
lead to an altered protein expression which may affect several biological processes 
for pharmacological targeting [66, 118, 120]. On the other hand increased gene-
expression does not necessarily equal increased protein expression as the 
translation of mRNA to protein can is dependent on several factors including 
ribosomal activity [119, 121, 122]. By combining ribosomal footprint profiling of 
the immune cells in the blood sample or biopsies of patients the level of mRNA 
can be assessed as well as how much of the mRNA is being translated into protein 
to gain further functional insights [119]. The use of these techniques will allow to 
prioritize likely candidates in the development of CPSP to be studied further in 
preclinical studies. Furthermore, this then could point towards biological 
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mechanisms that subsequently are targeted by pharmacological interventions. The 
prioritized candidates identified by these approaches need to be tested in 
preclinical models to assess the functional effects and biological mechanisms. 
Genetic screening in zebrafish 
One of the largest challenges in genetic studies is the lack of functional 
annotations of all the SNPs that have been associated with a phenotype [66]. As 
discussed earlier, zebrafish are an excellent model for screening and this could also 
be applied to study the functionality of SNPs by reverse genetics using 
CRISPR/CAS9 [123]. The advantage of zebrafish over cell culture are that 
zebrafish are fully functional organisms and not a specific mix of cultured cells. 
This makes it possible to test effects of a genetic variation on the whole 
(nociceptive) system. The lack of complexity of cell cultures have been partially 
overcome by development of brain organoids and their main advantage is that it 
allows to culture the patient’s own cells including its DNA profile [124, 125]. To 
study the functional effects of SNPs on neuronal functioning, it is important to 
be able to include physiological responses at a cellular/neuronal level. A 
combination of both calcium imaging and electrophysiology is technically 
possible in zebrafish and has been described in literature [126-128]. From this, it 
is expected that genetic screening in zebrafish combined with studies in human 
organoids will probably form the future fundament for analysis of studies on 
genetic risk factors in prediction and treatment of CPSP.  
Pharmacology screening in zebrafish 
Functional annotations found in zebrafish are targets for pharmacological 
screening. As discussed in Chapter 6 we showed that pharmacological 
intervention of a genetic phenotype is possible. In addition, it has been shown that 
most pharmacological intervention applied to zebrafish show similar effects as in 
humans [42]. The next step in this process is pharmacological intervention to 
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counteract the functional effects of a genetic risk factor [129]. By applying a 
pharmacological intervention to genetically modulated zebrafish, the altered 
behavioural, morphological and/or physiological outcomes caused by the genetic 
risk factor can be treated. These findings need to be applied in a translational 
model of CPSP to test the findings before translating them back to the clinic. 
Chronic postsurgical rodent model 
As discussed above, zebrafish are not the optimal model to study chronic pain as 
their recovery trajectory is different from mammals [35-37]. Therefore, findings in 
zebrafish need to be translated to rodent models which mimic human surgeries. 
The thoracotomy model in rats, for example, leads to CPSP in 50% of the rats 
which is comparable to the human incidence [40, 61, 130, 131]. This and other 
surgeries (i.e. hind paw incision and SMIR) can be used to test the efficacy of 
pharmacological interventions in prevention and treatment of CPSP [132-134]. 
Mice have long been the preferred laboratory animal for studies on genetics due 
to the shorter reproductive cycle and genome editing techniques have been 
available since the 1980’s [135, 136]. Thoracotomies have been performed in mice 
but not tested in the context of CPSP [137, 138]. To be able to study the effects of 
a pharmacological intervention in combination with genetics risk factors in 
rodents, the CPSP models in rats first need to be validated in mice. The alternative 
is genetic editing of rat strains, which has been done but is still developing and 
relatively expensive [139]. The next step is translating these findings back to the 
clinic. As discussed earlier (page 166), repurposing of drugs related to prevention 
or treatment of CPSP has great potential.  
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Concluding remarks 
This dissertation aimed to study the role of genetics in prediction and treatment 
of chronic postsurgical pain. In view of this, we started genetic screening and 
provided a genome-wide insight into the genetics of CPSP. This initial step 
identified the first potential risk loci and candidates for follow up studies. 
Furthermore, we have shown the important role of genetic variations related to 
dopaminergic neurotransmission in CPSP and preformed first steps in genetic and 
pharmacological screening in a zebrafish nociception model. With this 
dissertation a framework is provided for future studies and a combined and 
focussed clinical /pre-clinical approach aimed to develop personalized medicine 
in treatment of CPSP. 
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Summary 
Chronic Postsurgical Pain (CPSP) remains a major clinical problem affecting on 
average 20% of all patients undergoing surgery. CPSP has a major impact on the 
quality of life of both the patients affected and their relatives, and leads to an 
increase in health care consumption and associated costs. Although clinical, 
psychological and demographical risk factors of CPSP have been identified, a good 
understanding of the genetic risk factors and its putative role in CPSP is still 
lacking to date. The aim of this thesis was to the study the genetic risk factors of 
CPSP and to identify the functional effects of genetic variation on nociception 
and chronic pain in both clinical and preclinical studies. 
A systematic review on the genetic risk factors of CPSP revealed that SNPs 
associated with the dopaminergic neurotransmission might be involved in CPSP. 
To further identify the involvement of genetic variations within the dopaminergic 
neurotransmission in the development of CPSP, the current literature regarding 
clinical and preclinical is summarized in Chapter 2. Three genes (COMT, GCH1, 
DRD2) within the dopaminergic neurotransmission have been studied extensively 
in relation to CPSP, pain sensitivity and analgesic requirement. Although the 
direction of the effect (inhibitory or excitatory) is unclear due to conflicting 
results, ample evidence suggests a modulatory role for dopamine in the pain 
transmission. Due to its modulatory role, the dopaminergic neurotransmission 
system is an excellent pharmacological target in the treatment of (chronic) pain. 
Interestingly, pharmacological modulation of the dopaminergic 
neurotransmission system can aid both prevention (via D1 receptors) and 
treatment (via D2 receptors) of chronic pain.  
Delving deeper into the genetics of CPSP, the first genome-wide association study 
(GWAS) on CPSP in two independent cohorts is reported in Chapter 3. A case-
control GWAS study in both a discovery (a well-studied and previously 
characterised cohort of hysterectomy patients, n=330) and replication (cohort 
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consisting of patients undergoing abdominal surgeries or knee replacements, 
n=203) cohort comparing patients with and without CPSP did not reach genome-
wide significance. However, the meta-analysis did reveal a potential risk locus for 
CPSP (IQGAP1 and CRTC3, p=2.26x10-6). The genes within this locus (IQGAP1 
and CRTC3), both have been associated with the immune system and neurological 
processes. This study provides initial evidence on genome-wide risk factor of 
CPSP, and gives suggestions for future research. 
Chapter 4 describes the functional effects of single nucleotide polymorphisms 
(SNPs), a type of genetic variation, on gene expression and potential causal effects 
on CPSP. Meta-analysis of the different cohorts in the analysis indicated the first 
genome-wide significant locus (rs17882261) associated with CPSP. 
Transcriptome-wide mendelian randomization (TWMR) analysis identified two 
genes (SNAP29 and VSP8) to be potentially causally associated with CPSP in 
multiple tissues. Both genes are associated with immune system and neuronal 
morphology. This shows that the TWMR approach allows to identify both tissue-
specific and global potential causal genes associated with CPSP. The identified loci 
and genes are in need of further functional follow-up studies to identify 
underlying biological mechanisms and confirm the potential causal relationship. 
Establishing the intersection and/or overlap of genetic networks between various 
chronic pain syndromes may help define common mechanisms in chronic pain 
and provide starting points for functional and intervention studies. Polygenic risk 
scores (PRS) allow testing for genetic correlation (i.e. overlap) between different 
phenotypes. The genetic overlap between different chronic peripheral pain 
syndromes and CPSP is described in Chapter 5. Using polygenic risk scores, we 
identified a genetic overlap between sciatic pain, chronic widespread pain, 
rheumatoid arthritis and CPSP. Based on the gene ontology analysis the genetic 
overlap was suggested to involve neuronal signalling, specifically sodium channel 
functioning, and inflammatory response. In conclusion, this study is the first to 
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report genetic overlap between regulatory processes implicated in CPSP and 
chronic peripheral pain syndromes. The genes involved in the genetic overlap are 
related to the regulation of neurological signalling and inflammatory responses. 
Enhanced understanding of mechanisms underlying chronification of pain will 
aid the development of new preventative therapeutic strategies for CPSP. 
To further examine the impact and role of genetic variations related to 
dopaminergic neurotransmission in CPSP, we modelled a clinical phenotype of 
decreased dopamine D2 receptor expression in zebrafish in Chapter 6 and the 
effects of a pharmacological intervention targeting dopamine receptor 2 was 
tested. The experiments showed that a decrease in drd2a receptor expression is 
associated with increased locomotion in response to a thermal nociceptive 
stimulus, indicative of an increased pain response. To verify the anti-nociceptive 
role of drd2a, a pharmacological intervention using agonist Quinpirole was tested. 
Agonism of the drd2a showed dose-dependent anti-nociceptive properties during 
a heat stimulus. The established model allows for further screening and testing of 
genetic variation and treatment involved in nociception and pain. 
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Samenvatting 
Chronische Post Operatieve Pijn (CPOP) blijft een groot klinisch probleem en 
treft gemiddeld 20% van de patiënten die een operatie ondergaan. CPOP heeft een 
grote impact op de levenskwaliteit van zowel de getroffen patiënten en hun 
naasten. Het leid tot een toename in zorgverbruik en de daarbij horende kosten. 
Alhoewel klinische, psychologische en demografische risicofactoren van CPOP 
bekend zijn, is er nog een gebrek aan kennis over genetische risicofactoren en hun 
mogelijke rol in CPOP. Het doel van deze thesis was om de genetische 
risicofactoren te onderzoeken die betrokken zijn bij CPOP en mogelijke 
functionele effecten te ontdekken van de genetische variatie op nociceptie en 
chronische pijn in zowel klinische als preklinische studies. 
Een samenvatting van de huidige literatuur aangaande klinisch en preklinisch 
onderzoek in relatie tot genetische variatie in de dopaminerge neurotransmissie 
wordt gegeven in Hoofdstuk 2. Drie genen (COMT, GCH1, DRD2) binnen de 
dopaminerge neurotransmissie zijn uitgebreid bestudeerd in relatie met CPOP, 
pijngevoeligheid en pijnstilling. Het precieze effect (inhiberend of exciterend) van 
genetische variatie binnen deze genen is momenteel nog niet volkomen duidelijk 
vanwege tegenstrijdige resultaten. Echter, er is voldoende bewijs om te stellen dat 
dopamine een modulerende werking op pijn heeft. Vanwege de modulerende 
werking is de dopaminerge neurotransmissie een uitstekend farmacologisch 
doelwit in de behandeling van (chronische) pijn. Interessant is dat de 
dopaminerge neurotransmissie kan helpen bij zowel de preventieve behandeling 
(via de D1 receptoren) alsook in (chronische) pijnbestrijding (via de D2 
receptoren). 
Diepgaander onderzoek naar de genetica van CPOP leidde tot de eerste genoom-
wijde associatie studie (GWAS) naar CPOP in twee onafhankelijke cohorten, 
gerapporteerd in Hoofdstuk 3. Een case-control studie in een primair cohort (een 
uitgebreid bestudeerd en gepubliceerd cohort van hysterectomie patiënten, 
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n=330) en replicatie cohort (een cohort van patiënten die buik of knie operaties 
zijn ondergaan, n=203) waarbij patiënten met en zonder CPOP worden 
vergeleken. Deze studie leidde niet tot een genoom-wijd significante locus die 
geassocieerd wordt met CPOP. Echter, een meta-analyse wees wel een potentiële 
risico locus aan voor CPSP (IQGAP1 en CRTC3, p=2.26x10-6). De genen in deze 
locus (IQGAP1 en CRTC3) zijn beiden geassocieerd met het functioneren van het 
immuun systeem en neurologische processen. Deze studie zorgde voor het eerste 
bewijs van genoom-wijde genetische risicofactoren in CPOP en verzorgde 
aanknopingspunten voor verder onderzoek. 
Hoofdstuk 4 beschrijft de functionele effecten van single nucleotide 
polymorfismes (SNPs), een vorm van genetische variatie, op gen expressie en 
potentiële causale effecten in CPOP. Meta-analyse van de beschikbare cohorten 
leidde tot de eerste genoom-wijd significante associatie (rs17882261) met CPOP. 
De transcriptoom-wijde mendeliaanse randomisatie (TWMR) analyse 
identificeerde twee genen (SNAP29 en VSP8) die mogelijk causaal geassocieerd 
zijn met CPOP in meerdere weefsels. Beide genen zijn geassocieerd met het 
functioneren van het immuun systeem en neuronale morfologie. Dit toont aan 
dat de TWMR methode zowel weefsel specifieke als globaal potentieel causale 
gene kan identificeren en associëren met CPOP. De geïdentificeerde loci en genen 
moeten verder onderzocht worden door middel van functionele studies om de 
onderliggende biologische mechanismen op te ontdekken en het causale verband 
te bevestigen.  
Het vaststellen van een snijpunt of overlap tussen genetische netwerken van 
verschillende chronische pijnsyndromen kan helpen bij het identificeren van 
gemeenschappelijke mechanismen en zorgt voor aanknopingspunten voor 
functionele en interventionele studies. Polygene risico scores maken het mogelijk 
om de genetische correlatie (m.a.w. overlap) tussen verschillende fenotypes te 
testen. De genetische overlap tussen verschillende chronische perifere 
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pijnsyndromen en CPOP is beschreven in Hoofdstuk 5. Gebruikmakende van 
polygene risico scores hebben we een genetische overlap tussen ischias, 
fibromyalgie pijn, en reumatoïde artritis en CPOP vastgesteld. De gen ontologie 
analyse suggereert betrokkenheid van neurologische processen , specifiek de 
betrokkenheid van natrium kanalen, en inflammatoire reacties. In conclusie, deze 
studie heeft genetische overlap aangetoond tussen regulerende processen 
betrokken bij CPOP en chronische perifere pijnsyndromen. De genen betrokken 
bij de genetische overlap zijn betrokken bij de regulatie van neurologische 
signalen en de inflammatoire reacties. Betere kennis van de onderliggende 
mechanismes van chronificatie van pijn zal bijdragen aan het ontwikkelen van 
nieuwe preventieve behandelingen voor CPOP.  
Om de impact en rol van genetische variaties in de dopaminerge neurotransmissie 
in relatie tot CPOP verder te onderzoeken, hebben we een klinisch fenotype van 
verlaagde dopamine D2 receptor expressie gemodelleerd in zebravissen in 
Hoofdstuk 6 en de effectiviteit van een farmacologische behandeling gericht op 
de dopamine receptor 2 getest. De experimenten tonen aan dat een afname in de 
drd2a expressie geassocieerd word met een toename in beweging als reactie op een 
nociceptieve hitte stimulus als maat voor een toegenomen pijn reacte. Om de anti-
nociceptieve werking van drd2a te verifiëren, hebbe we een farmacologische 
behandeling toegepast middels de drd2a agonist Quinpirole. Activatie van de 
drd2a receptor leidde tot een daling in beweging als reactie op de nociceptieve 
hitte stimulus en bevestigde daarmee de eerdere resultaten. Het opgezette model 
is geschikt voor het verdere screenen en testen van genetische variaties en 
farmacologische behandelingen die betrokken zijn bij nociceptie en pijn. 
Valorisation
APPENDIX
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Academic research should aim to reach further than solely contributing to 
scientific knowledge and be beneficial to society as much as possible. For this 
reason, the current chapter will focus on the societal perspective and valorisation 
of the research on genetic risk factors in prediction and treatment of Chronic Post-
Surgical Pain (CPSP) as presented in this dissertation. Valorisation is defined as 
follows: Valorisation is the process of creating value from knowledge by making 
knowledge suitable and available for societal and/or economic application and by 
transforming it into products, services, processes and new business. This definition will 
be used to address the valorisation of the research in this dissertation specified to 
the following topics: 
 Impact of research: What is the social and economic impact of the results 
of the research as described in this dissertation? 
 Audience of research: Which stakeholders could benefit from the results 
of the experiments relevant outside of the academic community? 
 Product of research: What value (as defined earlier) can be created from 
the research in this dissertation? 
Impact of research 
Annually, an estimated 313 million surgeries take place around the globe [1]. Of 
all patients undergoing surgery, 5-85% develops chronic postsurgical pain (CPSP), 
varying with the type of surgery and with an average incidence of 18% [2]. CPSP 
negatively affects the quality of life (QoL) of the patients as well as their relatives. 
Furthermore, patients with CPSP report higher incidences of sleep disturbances, 
depressive symptoms and comorbid disorders [3]. CPSP and its comorbid 
disorders (depression, stress, anxiety) have a large impact on the daily functioning 
of the patients affected. CPSP patients are less able to participate in private 
activities and at work, the degree of which is correlated with the pain intensity [3]. 
Due to the chronic pain and its comorbidities, some patients enter a vicious cycle 
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wherein the different problems including pain further worsen their quality of life 
[3]. The QoL can be measured by the use of questionnaires and these have shown 
QoL to be significantly decreased in patients affected by CPSP [3]. The majority 
of CPSP patients are prescribed multiple medications against the pain and the 
comorbidities (including opioids and NSAIDs) and on average visit a medical 
professional 12 times per year [3]. The economic costs associated with the 
decreased daily functioning and QoL has been estimated to be $41.463,- per year 
per patient in the United States of America alone, leading to a huge loss for the 
world economy [3]. Combining the incidence of CPSP, volume of surgery and 
estimated cost make clear that CPSP is a major problem with immense societal 
impact. CPSP has a tremendous impact on the economic status of the patients and 
their families.  
Next to the group of surgical patients who develop CPSP each year, there is also a 
substantial group of patients exposed to the same surgeries, but who do not 
develop CPSP. It is important to study these patients as well. Prediction of which 
patients have a higher risk of developing CPSP is important, as it provides the 
opportunity to employ preventive strategies (e.g. alternative surgical approach, 
additional counselling) or to personalize the medication regime before, during 
and after surgery. Research has shown that for a cohort of hysterectomy patients, 
a combination of demographic and clinical factors explains 78% of the variance in 
the incidence of CPSP [4]. Nevertheless this implies still 22% of the incidence 
remains unexplained. Here, genetics might contribute to the solution. Part of the 
unexplained variance could be related to genetic variations and differential 
distributions of these variations between the patients with and without CPSP. 
Data from this dissertation shows that combining genetic data related to multiple 
surgeries can lead to the identification of genetic risk factors of CPSP and finally 
may lead to personalized treatment of the patient undergoing surgery. An example 
of successful personalized medicine has been reported in genetic mutations within 
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the cytochrome p450 enzyme, which alter the metabolism of opioid medication, 
thereby leading to a higher or lower dosage requirement for a similar effect [5].  
To further increase understanding of genetic factors involved in CPSP, an increase 
in sample size is needed. Increasing the sample sizes of genetic studies is expected 
to lead to the identification of more genetic risk factors of CPSP in general as well 
as specific genetic risk factors related to specific surgeries. Interestingly, this 
dissertation has shown that the genetic profile underlying CPSP is not unique, as 
there is a genetic overlap with multiple chronic peripheral pain syndromes. This 
suggests that inclusion of other pain syndromes might be very beneficial in the 
development of new prevention and treatment strategies for chronic pain 
syndromes. Finally, studying the genetics of CPSP will help to develop 
personalized medicine and this should increase the responder rate to treatments, 
thereby lifting a burden from society by decreasing the associated costs and 
increasing QoL of many patients. 
Audience of the research 
The main beneficiaries of the research on genetic risk factors of CPSP are the 313 
million patients who undergo surgery every year and their families. Studying the 
genetic factors of CPSP will lead to new developments in individual 
characterization and possible prediction and prevention of CPSP, but can also lead 
to personalized treatment after establishment of CPSP. Unravelling the individual 
genetic risk for each CPSP patient is an initial and important step towards 
personalized medicine. This will lead to an increase in QoL for the patients and 
their families. Moreover, research in this dissertation shows that there is genetic 
overlap across chronic peripheral pain syndromes (e.g. chronic widespread pain, 
sciatic pain) and CPSP, indicating a shared biological mechanism. Therefore, 
strategies working for one chronic pain disorder might proof beneficial for 
patients suffering other pain disorders as well. This will be of interest to clinicians 
treating all kinds of chronic pain patients, and researchers on other chronic pain 
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disorders. More knowledge on how chronic pain develops will aid the 
development of novel treatment and prevention strategies, which will ultimately 
aid the clinician in his or her daily practice. CPSP is an ideal chronic pain disorder 
to study the chronification of pain, as it involves a clear defined time-point zero.  
Finally, Major stakeholders in this research are the health insurance companies 
and the local and national governments. CPSP has a tremendous effect on the 
society and the associated costs are very high as explained earlier. Better prediction, 
prevention and treatment of CPSP will be reflected in a reduction in the associated 
costs and have major impact for society.  
Product of the research 
The primary product culminating from the research as described in this 
dissertation is the deeper understanding of the genetic factors and molecular 
processes involved in the development of CPSP. Earlier studies have shown that it 
is possible to integrate genetic risk factors into clinical prediction models [4]. 
Integrating genome-wide identified risk factors will further optimize the clinical 
prediction models currently available. Moreover, the identified risk factors could 
lead to new pharmacological targets for CPSP and other chronic pain disorders. 
The pharmacological targets of interest need to be tested and verified in preclinical 
studies before clinical implementation. 
The second important product from this research is the establishment of a genetic 
and pharmacological screening model. Studies performed in zebrafish have shown 
the possibility of modelling clinical phenotypes and testing the effects on 
morphology, development and nociception [6]. This provides a novel method to 
functionally asses the effects of genetic mutation on organisms. Of all the 
associations between SNPs and phenotypes, roughly 3% has been functionally 
assessed [7]. Research in this dissertation showed that Dopamine D2 receptor 
might be a viable candidate in modulating pain and prevention of chronification 
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of pain but more research is necessary [8]. This screening model can aid in this 
development. 
Preclinical studies in zebrafish has several advantages for animal studies; they 
provide a fast screening of the targets due to a high replication rate; the genome is 
fully sequenced and easily manipulated; the associated costs for maintenance are 
low; and they have less ethical restrictions compared to rodents. Ultimately, 
research in zebrafish will decrease the numbers of rodents necessary by 
prioritizing the most likely candidates first. 
Next to the pharmacological treatment strategies, non-pharmacological 
intervention could also aid in the prevention of CPSP. Improving physical health 
(e.g. Better in Better out concept) and/or mental health pre-surgery, focussed on 
individual risk factors of CPSP, can minimize the risk of developing CPSP. 
Finally, through extensive research, the gap between prediction and treatment of 
CPSP might decrease in the future. Extensive prediction models including genetic 
information will provide clear indications of the postsurgical recovery trajectory 
while simultaneously providing options on prevention and treatment of CPSP. 
The research presented in this dissertation is a first contribution to study genome 
wide genetic associations in CPSP. The approach presented, combined with 
further analysis, will be necessary to ensure implementation into the clinical 
practice to aid a vulnerable population of chronic pain patients. 
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Een promotietraject vraagt zowel fysiek als mentaal uithoudingsvermogen van een 
promovendus maar ook van zijn naasten. Tien jaar geleden toen ik voor het eerst 
de universiteit binnenstapte had ik nooit gedacht aan een promoveren. Het zijn 
tien turbulente jaren geweest met vele hoogte- en enkele dieptepunten waarbij ik 
gelukkig altijd heb kunnen vertrouwen op de mensen om mij heen, in zowel de 
privé- als de werksfeer. Wat begon als een ambitieus en abstract idee tijdens mijn 
masterstage is uitgegroeid tot een fantastisch project dat de basis legt voor nog 
jaren aan vervolgonderzoek. Dit idee had meer nodig dan mijn handen om uit te 
groeien tot het proefschrift dat nu voor u ligt. Daarom neem ik nu het podium 
om alle mensen te bedanken die bijgedragen hebben in welke mate dan ook. 
Mocht ik je onverhoopt zijn vergeten te benoemen, bedankt voor je bijdrage! 
 
Ten eerste wil ik mijn promotieteam, prof. dr. Bert Joosten en dr. Nynke van den 
Hoogen, bedanken voor hun steun bij het “vullen” van het proefschrift en bij de 
vorming van mij als zelfstandig onderzoeker.  
Beste prof. Joosten, beste Bert, we hebben van meet af aan een duidelijke klik 
gehad waardoor we al snel een vertrouwensband hadden. Je pusht me om beter te 
worden en zonder jouw kritische noten zou het proefschrift nooit geworden zijn 
wat het nu is. Tijdens overleggen “kalle ver plat” en we vergeten nog wel eens terug 
naar ABN te gaan als Nynke of iemand anders aanschoof bij het overleg. In de 
afgelopen 3,5 jaar zijn we het maar over één ding nooit eens geworden: Ajax of 
PSV blijft een heikel punt. Gelukkig heeft dit ons onderzoek nooit in de weg 
gestaan en hoop ik nog lang met je samen te werken. 
Beste dr. Van den Hoogen, beste Nynke, we go way back. Dat is ook wat we 
vertellen als mensen vragen hoe lang we elkaar nu al kennen. We hebben elkaar 
leren kennen tijdens de bachelor bij Helix (studievereniging Biomedische 
wetenschappen) en ook toen al stond je altijd klaar met advies voor iedereen. Jouw 
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advies aan mij om voor mezelf en mijn interesses te kiezen tijdens een van de 
zware periodes uit mijn leven hebben aan de basis gestaan van het hele 
promotietraject. Ook professioneel kunnen we heel goed samenwerken en zorgen 
we er samen voor dat er mooie projecten van de grond komen. Nog steeds 
waardeer ik je adviezen en ondersteuning en ik wens je al het goeds toe. 
During my PhD training I was lucky enough to do a foreign research training 
twice. My first steps in the genetic analysis and data science were done at the 
University Clinic of Bonn under supervision of dr. Alfredo Ramirez. Together 
with dr. Markus Leber, dr. Leonie Weinhold, dr. Michael Knapp and prof. dr. 
Matthias Schmid you have taught me the principles of genetic research and guided 
me through my first genome-wide association study. Thank you for welcoming 
and teaching me and most of all being patient with me and answering my 
multitude of questions. 
My second research visit was to the Human Pain Genetics lab of McGill university 
led by prof. dr. Diatchenko. Dear prof. Diatchenko, dear Luda, thank you for 
welcoming me into your lab and into your team. I learned a lot during my visit, 
adapted my scientific perspective accordingly and fell in love with the beautiful 
city of Montreal. You have a wonderful and dedicated team who accomplish great 
things. Thank you Francesca, Gillian, Audrey, Niko, Adam, Ryan, Xiang, Katerina, 
Kelly, Marc and Samar for accepting me in your group, guiding me and for joining 
this silly dutchman with his lunch ordeals (2 sandwiches a day). Marc and Samar 
you were my go to people at the lab and I learned so much from you. The level of 
expertise the both of you have enabled me to become a better researcher and I 
cherish our work together. A special word of thanks for Katerina Zorina-
Lichtenwalter and Kelly Cool, both of you have made sure I would see more of 
Montreal than a regular tourist. Dear Katerina, from the moment I arrived you 
have made sure I was up to speed of all the lectures and events happening on 
campus, showed me the best place for an afterwork drink and convinced me that 
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going climbing was a good idea. Dear Kelly, each Monday you requested an 
update on the places in Montreal I had visited, made sure I would go to the Festival 
of Light and you have drilled me that I have to come back to Montreal in summer 
because in summer the city would be even better you said. No worries, I will come 
back to Montreal when there is no snow (apparently I had something to do with 
the early snow storm). I hope to see you all again in the future. 
Daarnaast zijn er twee mensen die letterlijk achter mij staan tijdens de 
verdediging, mijn paranymfen Dean en Daan. We hebben elkaar leren kennen 
tijdens de studie en hadden al snel een klik. Ieder van ons heeft via zijn eigen weg 
een mooi onderzoeksproject zich eigen gemaakt en ik ben super trots op jullie en 
op wat wij bereikt hebben. Dean, altijd vrolijk en in “vuur un teske koffie”. Daan, 
altijd behulpzaam en gezellig. Zonder jullie was het organiseren van mijn grote 
dag niet gelukt en zeker niet zo leuk geweest. Tijdens de stapavonden gedurende 
studie zijn er al enkele oneliners ontstaan (“one with the jacket on”) en ik hoop 
dat we nog vele mooie momenten mogen meemaken. 
Onderzoek doe je samen en de afgelopen jaren heb ik met heel veel leuke en 
verschillende mensen mogen werken in zowel klinische als preklinische 
projecten. Ten eerste het Pijn-team bij mij op kantoor: Glenn, je staat altijd klaar 
voor een gesprek of het nu over onderzoek of flat earth gaat, je kunt er altijd iets 
over kwijt. Rose, altijd vrolijk en betrokken, je staat voor mensen klaar of het nu 
tijdens een experiment is of met koffie. Perla, de enige met wie ik dialect kan 
praten op kantoor en dat hoeft niet altijd over werk te gaan. Daarnaast bestaat ons 
team nog uit Lonne, Martijn en Thomas verdeeld over de hele gang. Aan allen, 
hartelijk dank voor de koffie, de gesprekken en de ondersteuning waar nodig. 
Naast het preklinisch team heb ik ook nog intensief samen gewerkt met 
verschillende clinici. Daisy, samen zijn we het genetica- en CPSP-project gestart 
en zonder jouw invloed was het niet op deze manier van de grond gekomen. 
Vergaderen deden we met goede koffie en onze kennis over het onderzoek was 
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complementair zodat we perfect konden samenwerken. Ik hoop dit in de 
toekomst vaker te doen. Daarnaast ben ik in verschillende projecten betrokken 
geweest bij onderzoek samen met prof. Buhre, prof. Van Kleef, prof. Van Zundert, 
Nelleke, Mischa, Sander, Dianne, Maurice, Anne, Brigitte, Andrea, Philma, 
Carine, Veerle en Jose, hartelijk dank voor de fijne samenwerking.  
Verder wil ik alle collegae binnen MHeNS bedanken, zoals gezegd onderzoek doe 
je samen en jullie maken het zeker aangenamer. Wouter, je was mijn partner-in-
crime wat betreft de tosti’s, bedankt ook voor de curry! Christian, druk bezig met 
het oog te onderzoeken maar daarnaast ook spindoctor op het gebied van kebab. 
Chris, “Lunch?” Manon en Alix, jullie hadden altijd tijd voor een koffie als het mij 
te veel werd en even afstand nodig had, zelfs tijdens de Coronacrisis. Iedereen 
bedankt voor de adviezen, aanwezigheid bij presentaties en momentjes bij het 
koffiezetapparaat: Clara, Katherine, Roman, Jeroen, Margot, Ralph, Ellis, Sylvana, 
An, Jana, Fred, Artemis, Magda, Janou, Renzo, Philippos, Caterina, Marina, 
Shenghua, Nikita, Tanya, Jackson, Govert, Michiel, Mario, Pilar, Jos, Daniel, 
Ehsan, Gunter, Lars, Roy, Laurence, Tim, Christian, Sarah, Ali, Rachelle, Marjan, 
Helen, Denise, Barbie, Wiel, Marie-Thérèse, Nicole, Ankie, Tom, David, Bart en 
iedereen ik die onverhoopt nog vergeet te noemen. 
Ik heb het geluk gehad om tijdens mijn PhD ook betrokken te raken bij de 
zebravisgroep. Jo, toen Bert en ik bij jou op kantoor binnenstapten met ons 
projectidee was je direct enthousiast en hebben we samen een heel mooi 
interessant project opgezet. Ivo, direct een klik dankzij onze gedeelde passie voor 
Star Wars, was er. Me alles geleerd wat jij wist over de vissen, heb je. Het niet 
zonder jou gekund, had ik! Janine en Ellen, jullie hebben de afgelopen jaren altijd 
klaar gestaan om te helpen en vragen te beantwoorden met betrekking tot de 
vissen. Jullie kunde en toewijding maakt het makkelijk om deel te worden van 
een team en om onderzoek te doen. 
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Tijdens mijn PhD-periode heb ik enkele studenten mogen begeleidden tijdens 
hun stages en zij hebben mooie bijdrage geleverd aan dit proefschrift. Maud, jouw 
bijdrage aan de farmacologie tijdens het zebravisexperiment is van onschatbare 
waarde geweest. Antonio, you have accepted a challenging internship project and 
so far have excelled. At the start of your internship I was still in Canada and it did 
not stop you. You have an amazing future ahead of you. 
Naast de mensen op het werk wil ik ook alle mensen buiten het werk bedanken 
en dan met name mijn vrienden en mijn familie. Dit wil ich geire in t dialect doen 
zoe es zich dat huurt.  
Es ierste wil ich de vrun van de Koninklijke Oude Harmonie van Eijsden oftewel 
de Blôw bedanken. Ten ierste Bob, er is gein probleem wat ver neet hebbe kinnen 
oplossen mit Fifa en unne pot beer. Veul geknoeterd en veul gelachen doer dik en 
dun. Het miest verassende van de aofgelaope jaore is dat se mich aon ‘t sporten 
hebs gekreige en ich bliek ‘t aog nog leuk te vinden. Dennis, Daisy en Davey, 
saome zien ver menig pretpark in Europa aofgegange en dao bie genog verteld en 
gelachen. Daoneive staot ger altied klaor mit raod en gezelligheid. Mun vrun van 
Blow hebben er altied vuur gezurg dat ich un oetlaotklep haw, d’r unne pot beer 
of sterker veirdig stond en ich mit beide beentjes op de grond bleef stoen. Lars, 
Hanke, Simone, Guyon, Joep, Celine, Jim, Elke, Bo, Harm, Mark, Dayenne, Tom, 
Tessa, Raoul, Bjorn, Martine en Philippe dankjewel vuur de aw kloete vuur, nao 
en tiedens de repetities en in de café. 
Ich wil aog ming femilie bedanke, ger beet altied geïnteresseerd geweis en heb 
regelmaotig ming verhaole beloesterd uuver ming onderzeuk. Alle neifkes, 
nichekes, nonkes en tantes dankjewel. Opa en oma van Reij, ger beet mit van ming 
groetste supporters. Ger beet altied geïnteresseerd in wat ich doon en ich kaom 
altied geire bie uch langs um te kalle onder t genot van un gleiske wien. Ger geneet 
van t leive en moedigt mich aon um dat zieker aog te blieve doen. Opa en oma 
van den Boorn, al van jongs af aon heb ger os gepusht um mer vuural good te 
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liere, zieker umdat oma dat vreuger zelf neet heit kinne doen. Oma, uche breef 
dee ger sjreef vuur ming middelbare sjaol diploma hink nog altied op en is ming 
inspiratie um doer te blieve goen. Ich been noe klaor mit liere oma, mer nog neet 
klaor op de uni. Es klein jungske heb ich ’t geluk gehad um un derde “opa en 
oma” te hebben, ming oppas awwers Jean & Jessy. Jean & Jessy, ondanks dat unne 
babysit al efkes niemie nuudig is, kaom ich nog altied geire bie uch, zieker es Jessy 
vlaoi heit gebakken. Ger heb mich un paor kier gevraog of ger bie de verdediging 
mocht zien, en ich wil uch hiebie nogmaols op t hart drukken dat ger van harte 
welkom beet. Ger huurt vuur mich er bie. 
Fred & Sylvia en Philippe, es awwers en broor van Nadine beet aog gier nauw 
betrokken geweis bie ming traject op de uni. Onder t genot van un wijntje 
loesterde ger nao ming onderzeuk en huurde ger mich oet uuver wie t noe precies 
zaot. Zoe es ger gemirk heb zurgde de wien ervuur dat ich bleef kalle. Dat is nooit 
un probleem geweis gelukkig en steunt ger mich in keuzes. 
Un speciaol plekske in ming dankwoerd is er vuur mam. Mam, weurd kinne neet 
umsjrieve wie ’t veult um dadelijk te verdedigen op “de Berg”. Lange tied waors 
dich synoniem vuur mich mit de universiteit, en waor de Berg de plaots oe se 
wirkdes en ich af en tow gewoen binnenwandelde. 10 jaor naodat ig zelf op de uni 
begonnen been staon ig dalijk bie dich op de Berg zonder dich, mer blief de uni 
vuur mich nog altied verbonden mit dich. De hebs mich un stamp onder die vot 
geigeve es t mos mer mich vuural aog aofgeremd es ig teveul tiegeliek wow. Ver 
geun der unne sjoene doag van maoke, unne Grimbergen op drinke en noets mie 
vergeite! Mam, tot eng van dies daog… 
G wil aog mun broor, pap & Eveline en de hun bedanke. Ingo en Funske, gier 
kint dit neet leize mer toch wil ich uch numme want wandele mit uch is de biste 
meneer um de kop leig te maoke en ger beet altied doer ’t dolle zoe blij es ich 
binne koam. Henk, mit dich kin ich altied uuver onderzeuk kalle want ver kalle 
de zelfde taol op dat gebied. Soms geit t hèl tiege hèl mer wat wils se es se alletwie 
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geliek hebs. Es awwer broor lits se nog altied op mich, zieker es ich te fanatiek 
vuur Ajax juich mer stimuleers se mich aog um t biste eroet te hoele. Eveline, de 
bis de definitie van un powervrouw. De menier oe op stich projecten op paks en 
ien ’t leive steis, is un inspiratie en ich maok geire gebruuk van ding ervaring en 
advies. De brings kleur mit dich mit en un bitje hoegnuudige chaos. Pap, Peter, ’t 
is gelukt. Dinge steun waor oneindig de aofgelaope paor jaor, hebs mich altied 
gevraog wie ’t ging en vuural gepusht um doer te goen. Toen ich besloet vuur un 
paor maond nao Canada te goen waors se de ierste dee dinger ging oetzeuke vuur 
mich ondanks dat se ’t toch un bitje lestig vons. Ver lieke qua karakter veul op 
elkaar en ’t doorzettingsvermogen heit mich geholpen um de PhD op dis meneer 
in elkaar te kinne zitte. Pap, Eveline, Henk, Ingo en Funske, dankjewel! 
Leeve Nadine, de aofgelaope jaore tiedens de promotie bis dich ming steun en 
toeverlaat geweis. ’t Promotietraject vergt veul en dich hebs er altied vuur gezurg 
dat ich t positieve er van ien zaog, neet teveul aon michzelf twiefelde en mich 
eekere kier oetgehuurd uuver wie ’t noe precies zaot mit ming onderzeuk. De 
aofgelaope jaore bis zelf druk bezig geweis mit ding eigen studie rechten mer de 
bis ondertussen ongetwiefeld de miest biologisch onderlagde jurist gewoere! ‘t 
lestigste vons se de boetelandse reizen die ich gemak heb vuur ’t onderzeuk mer 
praktisch es se bis hebs se van de nood een deugd gemak en mich achternao gereis 
vuur vekansie es dat meugelijk woar. Nadine, ’t is vuur mich un groete 
geruststelling geweis um te weite dat stig er altied vuur mich bis. Ich haw ’t neet 
zonder dich gewild of gekind.  
 
 
